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Abstract
The work presented in this thesis demonstrates that triarylphosphoniopropyl- 
thiosulfate zwitterions and cjj-thioacetylpropyl(triphenyl)phosphonium salts can 
be used to prepare cationic, water-soluble gold nanoparticles with mean core 
sizes in the range of 2.5-5 nm. Phosphonium-functionalised gold nanoparticles 
have been characterised by a number of techniques including NMR, LDI-MS, 
SIMS, XPS, TGA, ICP-MS, MALDI-MS and TEM.
Cytotoxicity studies illustrated that phosphonium ligands are relatively non-toxic 
to human prostate cancer cells and therefore can be used as a delivery vector 
to delivery gold nanoparticles specifically to the site of the mitochondria for 
other therapeutic applications such as photothermal therapy. Cellular uptake 
studies of phosphonium ligands by MALDI-MS showed that they are rapidly 
taken-up by cells within ten minutes.
Phosphonium-functionalised gold nanoparticles are soluble in biological media 
which is of great importance for cell biology studies. Initial photothermal therapy 
studies demonstrated that the gold nanoparticles responds specifically to a 
green light excitation source (510-550 nm) which overlaps the surface plasmon 
resonance band of the phosphonium-functionalised gold nanoparticles at 525 
nm. Preliminary data also showed that phosphonium-functionalised gold 
nanoparticles can selectively induce apoptosis in cells followed by irradiation, 
this was confirmed by Hoechst and caspase-3 staining.
Quantification studies of phosphonium-functionalised gold nanoparticles by ICP- 
MS illustrated that these nanoparticle have good uptake in cells (above 75%). 
TEM data confirmed that phosphonium-functionalised gold nanoparticles are 
taken-up by human prostate cancer cells and are localised in the mitochondria.
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Chapter 1.
Introduction
1
1.1 Nanoscience
Nanoscience is a multidisciplinary subject incorporating chemistry, physics, 
biology, engineering and medicine. Mainstream research has focused on 
synthesising novel nanomaterials and exploring new applications. 
Nanomaterials can be synthesised from a diverse range of materials including 
noble metals, metal oxides, semiconductors, polymers, magnetic compounds, 
liposomes, carbon and silica-based materials. The field of nanotechnology is 
rapidly advancing discipline and is continuously attracting immense interest 
from researchers worldwide across a wide array of industries including, 
electronics, catalysis, environmental remediation, textiles, cosmetics and 
pharmaceuticals (Daniel and Astruc, 2004). Amongst the most widely studied 
nanomaterials are gold nanoparticles.
1.1.1 Gold Nanoparticles
The production, characterisation and properties of gold nanoparticles (AuNPs) 
has gained momentum in recent years, particularly with a view to their 
applications in the field of biotechnology and biomedical science (Boisselier and 
Astruc, 2009, Cobley et a/., 2011, Sperling et a/., 2008). This interest stems not 
least because of their apparent non-toxicity, inertness, biocompatibility, ease of 
synthesis and, most remarkably, their tuneable optical properties.
1.1.2 Synthesis of Gold Nanoparticles
Since Faraday published the first report on the preparation of colloidal gold in 
1857 (Faraday, 1857) a plethora of books, research and review articles have 
been published on this topic. The most well-known methods for synthesising 
gold nanoparticles include the Turkevich method (Turkevich et al., 1953), using 
sodium citrate to reduce AuCI4' salts in boiling water producing AuNPs ~20nm; 
the Frens method (Frens, 1973) which is modified from the Turkevich method to 
produce AuNPs size between 16-147nm by varying the ratio between trisodium 
citrate and gold, and the Brust-Schiffrin two-phase method (Brust et al., 1994, 
Brust et al., 1995) to produce monolayer protected clusters (MPCs) with smaller 
gold core size between 1.5-6nm. AuCU' salts are reduced by sodium 
borohydride (NaBH4) in the presence of a thiol capping ligand, in a biphasic 
system (water-toluene) using tetraoctylammonium bromide as a phase transfer 
reagent to transfer AuCI4" to the organic phase. Different core sizes can be
achieved by fine-tuning the thiol to gold ratio, the larger thiol/gold mole ratios 
leads to smaller average core sizes. Mixed monolayer protected clusters can be 
synthesised either directly or by post-functionalisation of MPCs using the 
Murray place-exchange method (Templeton eta!., 2000).
Interestingly not only gold nanospheres can be synthesised, other geometries of 
gold nanoparticles can also be synthesised using appropriate methods, these 
include nanorods (Huang et al., 2009, Vigderman et al., 2012), nanocages 
(Chen et al., 2005, Skrabalak et al., 2008), nanoshells (Hirsch et al., 2003) 
nanoprisms (Shankar et al., 2004) and nanostars (Barbosa et al., 2010, Khoury 
and Vo-Dinh, 2008). Extensive research in this area has enabled scientists to 
synthesis AuNPs with precise shapes and sizes and narrow size distributions. 
The reason for the synthesis of different shapes of gold nanomaterials is that 
their morphology is strongly related to their properties which will influence the 
end application (Kanaras et al., 2011).
1.1.3 Surface Functionality and Gold Nanoparticles’ Cytotoxicity
Surface properties of AuNPs play a significant role in dictating their interactions
with biological systems, these interactions determine the efficacy and 
cytotoxicity of AuNPs (Kim et al., 2013). The surface charge is a crucial factor; 
Goodman and colleagues have investigated the cytotoxicity of AuNPs 
functionalised with anionic and cationic side chains in monkey kidney cells 
(COS-1), the results indicated that cationic AuNPs were moderately toxic 
compared to anionic AuNPs (Goodman et al., 2004). Surface hydrophobicity is 
another important parameter to consider, Chompoosor and colleagues have 
examined the cytotoxicity of AuNPs functionalised with quaternary ammonium 
group with varied hydrophobic alkyl chains in HeLa cells and the results showed 
that an increase in the hydrophobicity of the surface ligands induces higher 
cytotoxicity in cells (Chompoosor et al., 2010).
1.1.3.1 Surface Ligands
Common strategies for synthesising AuNPs involve a surface coating of some 
form, usually a ligand, surfactant or polymer to encapsulate the growing particle, 
providing stability, preventing uncontrolled aggregation and imparting 
functionality for specific applications; suitable receptor groups for sensor or
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diagnostic purposes and appropriate targeting moieties for delivery applications 
(Wang and Ma, 2009, Agasti etal., 2010, Ghosh etal., 2008).
The surface of AuNP is very versatile and can be coated with a variety of 
organic ligands such as thiols, sulfate, phosphine, phosphine oxide, ammonium, 
amine, carboxylate, selenide and isocyanide; among all ligands organic 
thiolates derived from thiols or disfuldies are most widely used (Daniel and 
Astruc, 2004, Love et al., 2005). Furthermore thiol-protected AuNPs can 
undergo biological modification; various biological cargoes including nucleic 
acids, amphiphilic polymers, short peptide sequences, proteins, lipids, 
antibodies and drugs have been successfully attached to the surface of 
nanoparticles via the strong Au-S bond (Giljohann et al., 2010, Shan and Tenhu, 
2007, Ghosh et al., 2008, Giljohann et al., 2009, Rana et al., 2012, Wang and 
Ma, 2009, Pissuwan etal., 2011).
1.1.3.2 Neutral Gold Nanoparticles
AuNPs can be coated with neutral species such as polyethylene glycol (PEG) to 
minimise protein adsorption and prevent uptake by macrophages through the 
protection of AuNPs from the mononuclear phagocyte system (Wang and 
Thanou, 2010, Larson et al., 2012, Walkey et al., 2012). However PEGylation 
can also diminish cellular interaction, however it can be highly desirable to 
produce AuNPs that do not interact with cells for certain applications such as 
negative control experiments (Arnida et al., 2010, Larson et al., 2012). An 
alternative way for producing uncharged AuNPs is by coating the nanoparticles 
with zwitterionic ligands which are electrically neutral as the ligands incorporate 
both a positive and negative charge (Rouhana etal., 2007).
1.1.3.3 Negatively Charged Gold Nanoparticles
There is evidence in the literature suggesting that negatively charged AuNPs 
are taken-up by cells despite their unfavourable interaction with the negatively 
charged cell membrane. Cho and co-workers (Cho et al., 2009) have 
demonstrated that citrate coated gold nanospheres are taken up slightly more 
by breast cancer cells (SK-BR-3) compared to neutral AuNPs, but are taken up 
significantly less compared to positively charged AuNPs. Arvizo and colleagues 
(Arvizo et al., 2010) have shown that the intracellular uptake of AuNPs is
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influenced by the cellular membrane potential, and the perturbation of the 
membrane potential is dependent on the surface charge of the nanoparticles. 
While negatively charged and neutral AuNPs have negligible effect on the 
membrane potential, positively charged AuNPs depolarize the membrane 
considerably. Overall, negatively charged AuNPs are not readily taken up by 
cells and have little cellular interaction, as the negatively charged membrane 
repelling each other would prevent the AuNPs from entering the cells (Chithrani 
et al., 2006, Verma and Stellacci, 2010).
1.1.3.4 Positively Charged Gold Nanoparticles
In comparison to the low level of cellular uptake and interaction by neutral and 
negatively charged AuNPs, positively charged AuNPs have a higher affinity for 
negatively charged species on the cell surface resulting in higher level of 
cellular interaction and uptake efficiencies (Verma and Stellacci, 2010). Zhu and 
co-workers have used mass spectrometry (LDI-MS and ICP-MS) to quantify 
uptake of AuNPs in monkey kidney cells (COS-1 cells). The results showed that 
all cationic AuNPs (secondary amine species with different alkyl chains) were 
readily taken up compared to neutral AuNPs, however all four cationic AuNPs 
exhibited different uptake efficiencies (Zhu et al., 2008). It is well known that 
positively charged AuNPs are capable of binding to negatively charged groups 
on the cell surface and translocate cross the cellular membrane thus making 
positively charged AuNPs attractive scaffold for drug and gene delivery 
(Bilensoy, 2010).
1.1.4 Phosphonium Functionalised Nanoparticles
While there have been many reports on the use of organophosphorus ligands, 
notably phosphines Figure 1.1 (a) (Shem et al., 2009) and phosphine oxides (e) 
(Green and O'Brien, 2000) for passivating the surface of metal nanoparticles, 
there have been far fewer studies on the use of phosphorus ligands to impart 
functionality to nanoparticles. The phosphonium ionic liquid 
trihexyl(tetradecyl)phosphonium bis(2,4,4-trimethylpentyl phosphinate) (d) has 
been used in the production of luminescent cadmium selenide quantum dots 
(Green etal., 2007). Phosphinophosphonic acids (b) have been used to prepare 
water soluble rhodium and platinum nanoparticles (Richter et al., 2012, Glockler 
et al., 2007). Tris(hydroxymethyl)phosphine capped AuNPs have been formed
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through the reduction of HAuC14 with tetrakis(hydroxymethyl)phosphonium 
chloride (c) (Harnack et a/., 2002).
d)
ONa
,— P— ONa/  n
e)
HO'
HO
OH
Cl
.OH
f)
P—(CH2)n— S-------SO;
9)
Figure 1.1 Chemical structure of phosphonium ligands used for the synthesis of 
functionalised nanoparticles: a) triphenylphosphine, b) tri-n-octylphosphine 
oxide, c) trihexyl(tetradecyl)phosphonium bis(2,4,4-trimethylpentyl phosphonate, 
d) tetrakis(hydroxymethyl)phosphonium chloride, e) diethyl(3,3,3-triphenylpropyl) 
phosphonate, f) phosphonioalkylthiosulfate zwitterions and g) uj -  
thioacetylalkylphosphonium salts.
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Previously, Bricklebank and co-workers have investigated the use of an 
alternative system based on the phosphonium moiety; they have successfully 
synthesised a family of novel cationic phosphonium thiol precursor ligands (f 
and g) which can be used to produce phosphonium-functionalised AuNPs (P- 
AuNPs) (Ju-Nam et al., 2008, Ju-Nam etal., 2006).
1.1.5 The Surface Plasmon Resonance of Gold Nanoparticles
One of the exciting properties of AuNPs is their unique optical property which is 
due to the phenomenon of the surface plasmon resonance (SPR) effect; 
according to Mie theory, free electrons on the surface of a spherical 
nanoparticles (if smaller than the light wavelength) oscillate in response to an 
electromagnetic frequency (Moores and Goettmann, 2006). This localised SPR 
enhances the electromagnetic field at the AuNP surface which results in AuNPs 
having a high-scattering cross section with astonishing high extinction co­
efficient of the SPR bands up to 1011 M'1 cm'1 (which is several orders of 
magnitude higher compared to organic dyes) (Jain etal., 2006, Du etal., 1998).
The SPR band of nanoparticles is very sensitive to the particle size, shape, 
composition and the surrounding environment (dielectric environment) (Dreaden 
et ai, 2011, Jain et al., 2008, Kelly et al., 2003, Liz-Marzan, 2004). Therefore 
this property can be selectively fine-tuned to engineer AuNPs with the desired 
properties for specific purposes. For example spherical AuNPs of 5 nm have an 
SPR band located at 520 nm, an simple increase in size to 99 nm induces a 
slight shift in the SPR band from 520 nm to -560 nm, whereas with a change in 
the shape from sphere to rod the SPR band shifts significantly from the visible 
to the near-infrared (NIR) region (Chen etal., 2008, Link and El-Sayed, 1999).
1.1.6 Biomedical Applications of Gold Nanoparticles
Tailorable surface chemistry for biological modification along with tuneable 
optical properties has made AuNPs attractive candidates for biomedical 
applications. As mentioned above, the SPR effect is sensitive to the dielectric 
environment, therefore any changes to the environment such as aggregation, 
refractive index of the medium and surface modification can all result in a shift 
in the SPR band and this property has been exploited for a range of biomedical 
applications ranging from diagnostic through to therapeutics (Rosi and Mirkin,
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2005, Cobley et al., 2011, Sperling et al., 2008, Kumar et al., 2013b). 
Immunostaining was the first biomedical application of AuNPs which began in 
the early 1970s when Faulk and Taylor discovered immunogold labeling (Faulk 
and Taylor, 1971) and since then the use of AuNPs in this field has expanded.
1.1.6.1 Biosensing
The SPR band changes when the mean distance between gold particles are 
reduced forming small aggregates, a visual colour change can be observed and 
this property has been utilised in colorimetric sensor applications. One of the 
most renowned gold-based sensors was developed by Mirkin and co-workers 
which was used to detect DNA, the colloidal solution changed from red to blue 
in the presence of DNA (Mirkin et al., 1996, Elghanian et al., 1997). AuNPs 
have been used as biosensors to detect analytes such as microalbumin in 
urine (Wiwanitkit et al., 2007), glucose (Zeng et al., 2012) and human chorionic 
gonadotropin for pregnancy tests (Rojanathanes et al., 2008) which all rely on 
the change of colour due to aggregation of particles. Infectious pathogens 
(gonorrhoea, syphilis, malaria parasite and hepatitis B have been detected with 
the use of custom made MNAzyme-linker-AuNPs, for example MNAzymeMai 
containing substrate arms specific to LinkerMai has been used to detect the 
malaria parasite (Zagorovsky and Chan, 2013).
Raman spectroscopy enables the detection and identification of molecules, 
however the signals are relatively weak and a high analyte concentration is 
required for a decent signal. The SPR can dramatically improve the Raman 
signals of molecules near the surface of AuNPs by several orders of magnitude 
with a technique known as surface-enhanced Raman spectroscopy (SERS) 
allowing ultrasensitive detection of analytes. SERS has been applied to the 
detection of DNA and RNA in fingerprints (Cao et al., 2002), DNA in cells 
(Kneipp etal., 2002) and two-photon excitation (Kneipp etal., 2010).
1.1.6.2 Imaging and Visualising
AuNPs unusual high-scattering cross section (4-5 orders of magnitude more 
intensive compared to the most efficient Rhodamine 6G dye molecule) (Jain et 
al., 2006, Du etal., 1998) in conjugation with their superior photostability, unlike 
organic dyes AuNPs do not suffer from photobleaching, has resulted in the
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utilisation of the light-scattering properties of AuNPs for cellular imaging, 
particularly cancer imaging which has advanced in recent years (Sokolov et al., 
2003a, Sokolov etal., 2003b, El-Sayed etal., 2005, Huang etal., 2006).
Single particle tracking has been achieved by conjugating AuNPs with 
antibodies against the molecules on the cell surface; the binding of the 
molecules to the antibodies on the surface of AuNPs induces a change in the 
SPR frequency, since AuNPs absorb and scatter light intensively this change 
can be observed by dark-field microscopy (Khlebtsov and Dykman, 2010, Anker 
et al., 2008, Eustis and El-Sayed, 2006, Wilson, 2008, Raschke et al., 2003). 
AuNPs have also been investigated as contrast agents for in vivo X-ray imaging, 
since the gold core provides a strong X-ray absorption thereby facilitating 
computed tomography imaging (Alric et al., 2008, Hainfeld et al., 2006).
1.1.6.3 Delivering of Biomolecules
A common trait of all nanomaterials is their high surface-area-to-volume ratio 
which enables the attachment of copious drug molecules onto the surface for 
drug delivery applications, for example AuNPs with a core diameter of 2nm can 
be loaded with approximately 100 ligands per particle (Kim et al., 2009). 
Nanocarriers provide a novel platform for site-specific delivery of therapeutic 
agents into cells. Different strategies have been utilised for the intracellular 
delivery of nanomaterials, these include 1) the use of cationic coatings for 
strong interaction with the negatively charged cellular membrane, 2) attachment 
of ligands onto the surface of nanoparticles for ligand-mediated internalisation 
and 3) cell-penetrating peptides to facilitate the translocation of nanocarriers 
across the membrane and to target specific organelles (Chou et al., 2011).
A variety of nano-scale vehicles have been employed including dendrimers, 
liposomes and AuNPs (Ghosh et al., 2008, Wang et al., 2012), the latter has 
been extensively studied due to their apparent non-toxicity, easy of synthesis 
and versatility for further functionalisation through thiol-linkages. Furthermore, 
functionalised or tagged AuNPs are readily taken-up by cells making them an 
ideal carrier system for transporting drugs, biomolecules or other therapeutic 
agents into cells. A variety of biological cargoes including oligonucleotides, 
amphiphilic polymers, short peptide sequences, proteins, lipids, carbohydrates,
antibodies and drugs have been successfully attached to the surface of GNPs 
(Giljohann etal., 2010, Rana etal., 2012).
1.1.6.4 Photothermal Therapy
For metal nanoparticles such as AuNPs with size much smaller than the 
wavelength of the incident light, the free electrons on the surface will oscillate in 
respond to an electromagnetic field at a specific wavelength, also known as the 
SPR effect. As a result of the SPR effect, the particle absorbs and scatters the 
electromagnetic radiation intensely to a high degree (Li and Gu, 2010).
AuNPs have the unique ability to convert absorbed light into heat on a 
picosecond time-domain, the strong SPR absorption followed by rapid energy 
conversion and dissipation has been exploited for the heating of local 
environments by using a light source with a frequency that overlaps the SPR 
band of the AuNPs (Huang et al., 2007). This unique property has resulted in 
AuNPs being promising candidates for photothermal therapy (PTT) applications 
(Huang etal., 2008, Vauthier et al., 2011, Cherukuri et al., 2010, Dreaden etal., 
2011).
The first use of AuNPs for PTT was reported by Pitsillides and co-workers, who 
treated peripheral blood lymphocyte cells with spherical AuNPs (d = 20 nm) 
conjugated to IgG antibodies that target CD8 receptor on lymphocytes and 
irradiated with the short laser pulses at 565 nm (Pitsillides et al., 2003). Since 
then the use AuNPs in this field has been widely investigated and has the 
potential in revolutionising cancer therapeutics in the future (Kennedy et al., 
2011, Dreaden etal., 2011, Akhter etal., 2012).
1.2 Cancer
Cancer is a collective term for a group of diseases characterised by invasive 
abnormal cell growth, and is a common terminology for describing a malignant 
tumour (Hesketh, 2013). While the origin of the word cancer is credited to the 
Greek physician Hippocrates who described tumours as karkinos and karklnona, 
it was Galen who described the appearance of a tumour as similar to the legs of 
a crab, and this resemblance lead to the name of the disease - karkinos (cancer) 
which means crab in Greek (Papavramidou etal., 2010).
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Cancer is the major cause of death in economically developed countries; this is 
predominantly driven by increasing average life-span, in addition to unhealthy 
lifestyle choices including smoking, lack of physical activity and adopting 
westernised diets. In 2008 approximately 12.7 million cancer cases were 
diagnosed with 7.6 million deaths globally, however more than half the cases 
and deaths (56% and 64% respectively) occurred in economically developing 
countries, despite being the second leading cause of death in developing 
countries (Jemal et al., 2011). In the UK alone, 325,000 people were diagnosed 
with cancer in 2010 and someone is diagnosed with cancer every two minutes 
(CancerResearch UK).
1.2.1 Causes of Cancer
Cancer is perceived as a genetic disease involving a series of irreversible 
genetic changes, encompassing single point mutations, gene amplification and 
the loss of large regions of the genome (Tlsty and Coussens, 2006). The 
concept of cancer being a genetic disease of somatic cells was proposed in 
1914 by Theodor Boveri (Knudson, 2001). Alterations in genetics may result in 
the gene no longer functioning normally and can acquire new cellular 
phenotypes that are beneficial to the cells such as resistance to cell death and 
many others which are also known as the hallmarks of cancer (Hanahan and 
Weinberg, 2011). The transition of normal cell into malignant phenotype is 
facilitated through the accumulation of genetic mutation, which can be induced 
by a variety of chemical, physical and biological agents.
1.2.1.1 Chemical Carcinogens
Chemical carcinogens refers to a group of chemicals that are generally 
genotoxic and are able to induce DNA damage either through deletions, 
amplifications, single point mutations or re-arrangements. To date a large 
number of chemical carcinogens that lead to cancer have been identified 
(Wogan et al., 2004, Cohen and Arnold, 2011). However not all cancer causing 
agents result in DNA damage; phorbol esters are a class of tumour promoters 
which induce cellular proliferation but are not mutagenic themselves (Goel et al.,
2007).
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The role of cigarette smoking as a cause of cancer is unquestionable, with more 
than 60 carcinogens from cigarette smoke having been verified to be 
carcinogenic in either animals or humans, nevertheless the majority of tobacco 
carcinogens requires metabolic activation in order to trigger their carcinogenic 
effects. (Pfeifer et al., 2002, Peto et al., 2000). Among all tobacco carcinogens 
tobacco-specific nitrosamine 4-(methylnitrosamino)-1 -(3-pyridyl)-1 -butanone 
(NNK) and polycyclic aromatic hydrocarbons (PAH) have shown to be 
predominately involved in the induction of lung cancer (Hecht, 1999).
Within the PAH family benzo[a]pyrene (BaP) has been the most extensively 
studied compound (Pfeifer et al., 2002). BaP is activated by cytochrome P450 
enzymes by oxidising BaP into an epoxide (BaP-7,8-epoxide) followed by 
detoxification by epoxide hydrolase converting the epoxide into a dihydrodiol 
(BaP-7,8-dihydrodiol). This intermediate is further metabolised to BaP-7,8- 
dihydrodiol-9,10-epoxide (BPDE) a highly reactive species which can interact 
with DNA, forming adducts favourably at guanine residues inducing double 
strand breakages (Moserova etal., 2009, Kim etal., 1998, Schwarz etal., 2001).
It is widely accepted that the main cause of colon cancer is associated to 
dietary carcinogens; heterocyclic amines (HCA) are a group of carcinogens 
which are formed as pyrolysis products when protein-rich food is cooked above 
180°C for long periods of time, these chemicals are commonly found when 
meat or fish have been over-cooked or flame-grilled (Layton et al., 1995, 
Sugimura et al., 2004). Similar to other chemical carcinogens, HCA needs to be 
metabolic activated by cytochrome P450 enzymes to chemically reactive 
electrophiles before reacting with DNA to exert their genotoxicity (Wogan et al., 
2004).
One of the most abundant chemicals found in cooked meats, 2-amino-1-methyl- 
6-phenylimidazo[4,5-b]pyridine (PhIP) is readily activated by the cytochrome 
P450 enzymes, particularly CYP1A2 producing a mutagenic and non-mutagenic 
product (Crofts et al., 1998). The mutagenic metabolite 2-hydroxy-amino-PhlP 
can be further activated by undergoing acetylation or sulfation to form highly 
mutagenic products mainly at the C8 position of guanines (Schut and 
Snyderwine, 1999, Turesky etal., 1991, Sugimura etal., 2004).
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1.2.1.2 Viruses
It has been estimated that 15% of all human cancers are caused by viruses, 
contributing to a substantial proportion of the cancer burden worldwide (Liao, 
2006). Retroviruses cover a diverse class of ribonucleic acid (RNA) viruses 
which are small viruses containing only RNA in their genome, they are 
associated with an array of immunodeficiencies, neurological disorders and 
malignancies (D'Souza and Summers, 2005). Human T lymphotrophic virus 
type 1 and hepatitis C virus are two RNA viruses that have shown to contribute 
towards the development of cancers (Liao, 2006).
Retroviruses can either be non-transforming or transforming, depending on the 
absence or presence of an oncogene in their viral genome (Uren et al., 2005). 
Although no human retroviruses have this ability, many viruses in other species 
do and these viruses produce an enzyme called reverse transcriptase enabling 
the host cell to make a replica of the viral genome and integrate into the host 
cell genome (Weinberg, 2013).
Other virus families such as DNA viruses are also linked to the development of 
a variety of malignancies; these include hepatitis B virus, Epstein-Barr virus, 
human herpes virus 8 and the human papilloma virus (HPVs) (Liao, 2006). HPV 
of the parpova family is the most common cause of certain skin cancers 
(Dubina and Goldenberg, 2009) and cervical cancers (zur Hausen, 2002). 
Currently more than 100 types of HPV have been discovered, type 16 and 18 
being the most important as they cause the majority of cancers of the cervix, 
contributing for 12% of all cancers in women (zur Hausen, 2002). They encode 
for proteins (E6 and E7) that target p53 and retinoblastoma protein (RB) which 
regulates apoptosis (p53) and cell cycle (RB and p53) and thereby ablating two 
essential tumour suppressors (Liao, 2006, Narisawa-Saito and Kiyono, 2007).
1.2.1.3 Radiation
Acute or prolonged exposure to high doses of ionising radiation can lead to 
damaging consequences in humans including but not limited to cancer, in 
contrast at very low levels of radiation the after effects are unclear (Brenner et 
al., 2003). The carcinogenic effect of radiation has been well documented and is 
undisputable; radiation exposure in Hiroshima and Nagasaki in Japan has been
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associated with a number of different cancers predominately leukaemia, 
underground miners exposed to radon sources were prone to develop lung 
cancer and luminous dial painters exposed to radium have been linked with 
bone cancer (Gilbert, 2009).
DNA damage from ionising radiation can occur from either a direct interaction 
between DNA and radiation or via the creation of free radicals, which can result 
in cell death or non-lethal DNA modification including DNA cross-linking, 
mutations, chromosomal loss, single and double strand breaks (Wakeford, 2004, 
Cwikel et al., 2010). It is well known that UV radiation (UVR) present in sunlight 
is a potent carcinogen and chronic repeated exposure of UVR is the main cause 
of skin cancers. Both ultraviolet A radiation (UVA) (320-400 nm) and ultraviolet 
B radiation (UVB) (280-320nm) have important biological significances to the 
skin; UVA has a crucial role in the carcinogenesis of stem cells of the skin while 
UVB produces DNA damage and subsequently gene mutations, oxidative stress, 
immunosuppression and tumourigenesis (Narayanan et al., 2010). UVB induces 
DNA damage by forming dimeric photoproducts at "hot spots" of UV-induced 
mutations between adjacent pyrimidine bases on the same strand; pyrimidine- 
pyrimidone (6-4) photoproducts and cyclobutane dimers (CPDs) are the two 
most prevalent adducts formed (Ichihashi et al., 2003).
Although both lesions are potentially mutagenic, the latter is the major 
contributor to mutations in humans; CPDs are produced three times more often 
and has a slower repair rate compared to (6-4) photoproducts (Matsumura and 
Ananthaswamy, 2004). Furthermore, UVR creates mutations to p53 tumour 
suppressor genes which have critical roles in DNA repair and controlling 
apoptosis of cells with DNA damage. Therefore cells with mutated p53 genes 
no longer have the ability to repair DNA and result in dysregulation of apoptosis, 
therefore mutated keratinocytes increase and initiate skin cancer (Narayanan et 
al., 2010).
Xeroderma pigmentosum is a condition whereby individuals are unable to repair 
DNA damage as a result of UVR; it is an autosomal recessive defect with 100% 
penetrance and can be triggered from mutations in any one of the eight genes. 
Seven out of the eight genes (XP-A through to G) are critically involved in the
nucleotide excision repair (NER) mechanism which repair UV induced 
photoproducts in DNA. Therefore a defect in any one of those seven genes 
results in defective NER and the accumulation of mutations (Lehmann et al., 
2011).
1.2.2 Classification of Tumours
Tumours is a collective term for a group of disease characterised by excessive 
cell proliferation, the naming of tumours based on their cell type and tissue of 
origin is reasonable since tumours exhibit a wide spectrum of characteristics. 
Tumours can be categorised in a number of ways including tissue of origin, cell 
type, aetiology and biological behaviour (Weinberg, 2013, Underwood and 
Cross, 2009).
1.2.2.1 Biological Behaviour
An abnormal cell that grows and proliferates out of control will give rise to a 
tumour or neoplasm which can either be benign or malignant. (Hesketh, 2013). 
At the initial stages of primary tumour expansion the cells are neither invasive 
nor metastatic and are referred to as benign tumours, only tumours capable of 
invading surrounding tissues enabling the tumour to metastasise are defined as 
malignant cells (Yokota, 2000).
Metastases represent the outcome of the multistep invasion metastasis 
cascade, which involves the dissemination of cancer cells to distant organ sites, 
and is the central problem of malignant disease (Valastyan and Weinberg, 
2011). The cascade comprises a long series of sequential, interconnected steps 
which all play a critical role, failure at any one of the steps can lead to the entire 
process being halted (Fidler, 2003). Since every event is driven by the 
recruitment of genetic and/or epigenetic alterations within tumour cells 
(Valastyan and Weinberg, 2011), it isn’t surprising that highly metastatic cells 
accumulate more gene alterations compared to non-metastatic cells (Yokota, 
2000). Although only a limited fraction of the cells in the primary neoplasm are 
highly metastatic (Yokota, 2000) they have an important impact on mortality 
rates associated with cancer, and is accountable for a staggering 90% of deaths 
from solid tumours (Gupta and Massague, 2006). Primary tumours can be 
treated surgically or by radiotherapy or chemotherapy, however once becoming
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metastatic they become surgically unresectable and it is uncommon for long­
term control of the disease by radio- or chemotherapy (Bogenrieder and Herlyn,
2003).
1.2.2.2 Nomenclature
Solid tumours are primarily categorised into benign and malignant type, benign 
tumours have the suffix of "oma" and malignant tumours have the suffix of 
carcinoma, epithelial or sarcoma if mesenchymal. Tumours are further 
categorised to their cell of origin and the tissue in which they arise. Carcinomas 
rising from epithelial tissues are by far the most common cancers in humans, 
accountable for more than 80% of cancer related deaths in the western world 
(King and Robins, 2006, Underwood and Cross, 2009).
For example a benign and malignant epithelial tumour with squamous cell 
organisation is termed squamous cell papilloma and squamous cell carcinoma 
respectively. Cells originated from mesenchymal tissues also follow the same 
pattern, for example benign and malignant tumour of smooth muscle is called 
leiomyoma and leiomyosarcoma respectively, benign and malignant tumour of 
the bone is called osteoma and osteosarcoma respectively. Neuroectodermal 
tumours refer to cells derived from the central and peripheral nervous system 
including gliboblastomas, neutroblastomas, schwannomas and 
medulloblastomas. There are exceptions where tumours do not fit into the major 
classifications these include melanomas, leukaemias and lymphomas (King and 
Robins, 2006, Underwood and Cross, 2009).
1.2.3 Cancer Genes
Normal human cells are continuously exposed to DNA damage by mutagens 
however they have efficient repair mechanisms to protect them against the 
potentially dangerous effects of cancer gene mutations and thus only a small 
proportion become somatically acquired mutations (Vogelstein and Kinzler,
2004). A substantial number of genes mutated in human cancers have the 
capacity to interrupt cellular homeostatic mechanisms causing additional 
mutations and/or alterations in gene expression, it has been established that 
individual tumours can contain up to 40 alterations (Bielas and Loeb, 2005).
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Alterations in oncogenes, tumour suppressors and caretaker genes all 
contribute towards tumourigenesis; while oncogenes and tumour suppressor 
genes both behave similarly in driving the neoplasm process by increasing cell 
numbers through promoting cell birth, inhibiting cell-cycle arrest or cell death. 
Caretakers or DNA stability genes including the nucleotide-excision repair, 
base-excision repair and mismatch repair genes stimulate tumourigenesis 
differently when mutated, since stability genes keep genetic alterations to a 
minimum, when they become inactivated it causes higher mutation rates in 
other genes (Vogelstein and Kinzler, 2004).
1.2.3.1 Oncogenes
Proto-oncogenes encode for proteins that control cell proliferation, apoptosis, or 
both, and become oncogenes when mutated in a style that renders the gene 
constitutively active or active under circumstances in which the wild-type gene 
is not (Vogelstein and Kinzler, 2004).
Activation can occur through chromosomal translocations, gene amplifications 
or fusion gene, an active somatic mutation in one allele of an oncogene is 
sufficient to promote cell growth. For instance, the most widely activated 
mutation of BRAF in human cancers is at codon 600 where valine changes to a 
glutamate, which in turns activates BRAF kinase, which subsequently 
phosphorylates downstream targets such as extracellular signal regulated 
kinases and induces aberrant growth (Vogelstein and Kinzler, 2004). The major 
oncogenes can be classified into six broad groups: transcription factors, 
chromatin remodelers, growth factors, growth factor receptors, signal 
transducers, and apoptosis regulators (Croce, 2008).
1.2.3.2 Tumour Suppressor Genes
In contrast to oncogenes, tumour suppressor genes target the opposite 
direction by reducing the activity of the gene production via mutations, among 
all the regulators disrupted in malignant cells are the two tumour suppressors: 
retinoblastoma protein (pRb) and p53 transcription factor (Sherr and McCormick,
2002). RB has been regarded as the guardian of the restriction point (R-point) 
and can interact with many proteins particularly with E2F transcription factors 
which are key players in controlling the cell division cycle.
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Under normal conditions E2Fs are sequestered by pRb in early Gi phase, 
providing pRb remains hyophosphorylated the cell will not pass the R-point and 
remain in Gi. The interaction between pRb and E2F is regulated by 
phosphorylation and primarily by D-type cyclin-dependent kinases (Cyclin D); 
Cyclin D/cdk4 phosphorylate pRb to release E2Fs and alter its function and thus 
initiate cells to progress from Gi into the S-phase (Nevins, 2001). pRb has been 
identified as a regulator of cell proliferation; it is a significant target of 
oncoproteins that are expressed by DNA tumour viruses including adenovirus 
E1A protein, SV40 T antigen and human papillomavirus E7 protein. Cells with 
overexpression of pRb undergo Gi arrest while cells deficient in pRb leads to 
acceleration in Gi transition (Classon and Harlow, 2002).
p53 is the guardian protein that preserves genomic stability in response to a 
variety of trauma including hypoxia, metabolic stress, DNA damage and 
oncogene activation response to DNA damage. p53 act as the defence 
mechanism against tumourigenesis by activating the following pathways: cell 
cycle arrest, DNA repair and apoptosis (Whibley et al., 2009). The levels of p53 
in cells are tightly regulated, under normal conditions murine double minute 
clone 2 (MDM2) is a key negative regulator of p53, which binds to p53 and 
ubiquitylates the protein and ultimately degrades by the 26S proteasome.
This negative feedback maintain low levels of unphosphorylated p53 in normal 
cells, however in response to DNA damage p53 becomes active followed by 
phosphorylation and can no longer bind to MDM2 thus preventing MDM2- 
medaited degradation, resulting in p53 level rises leading to expression of p53- 
responsive genes (Momand et al., 2000). pRb and p53 pathways are disrupted 
in virtually all human tumours, and are found to be simultaneously inactivated in 
various types of cancer including small-cell lung carcinoma and osteosarcoma 
(Yokota and Sugimura, 1993).
1.2.4 Multistep Tumour Development
While various hypotheses have been proposed for the development of cancer, 
the majority of evidence indicates that carcinogenesis is a complex, multistep 
process also referred to as “somatic evolution”. Carcinogenesis models are 
usually based on the Darwinian theory that new phenotypes are generated
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through the evolution of genetic and/or epigenetic changes (Gatenby and Gillies, 
2008, Vogelstein and Kinzler, 1993). A single mutation is inadequate for the 
development of cancer, cells requires sequential alterations in a number of 
different genes (oncogenes, tumour-suppressors or microRNA genes), usually 
5-7 mutations are required for the transformation to carcinoma (Croce, 2008, 
Yokota and Sugimura, 1993).
Vogelstein and co-workers reported the first model (Vogelstein’s model) 
depicting the sequence of genetic events leading to colorectal cancer (Fearon 
and Vogelstein, 1990) (Figure 1.2), other tumours follow a similar pathway but 
with different genes.
LossofAPC DNA hyForrothytaten Los*o?pS3
Activation of K-ras Lcsson&qTSO
Normal
epithelium
Hyperplastic
epithelium Early-> intermediate -> late adenomas
Invasion &  
metastasis
Figure 1.2 Vogelstein’s multi-hit model showing the sequence of events how 
colorectal cancer developed from normal epithelium, this involved the 
alterations of tumour suppressor genes including adenomatous polyposis coli 
gene (APC), p53 and oncogenes such as K-ras. Diagram adapted from Fearon 
and Vogelstein 1990.
1.2.5 Hallmarks of Cancer
Hanahan and Weinberg summarised that cancer cell genotypes are a 
manifestation of several key alterations in cell physiology that influence 
malignant growth, which are also known as the hallmarks of cancer Figure 1.3. 
In 2000 they reported the six common traits that normal cells must acquire; 
each of these novel capabilities gained during the tumour development stage 
indicate the successful breaching of an anti-cancer defence mechanism present 
in cells (Hanahan and Weinberg, 2000). In 2011 the authors updated the 
hallmarks of cancer and incorporated four new emerging hallmarks (Hanahan 
and Weinberg, 2011), Figure 1.3.
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Figure 1.3 This diagram encompasses the six hallmark capabilities (pale grey) 
proposed by Hanahan and Weinberg in 2000 (evading growth suppressors, 
enabling replicative immortality, activating invasion and metastasis, inducing 
angiogenesis, resisting cell death and sustaining proliferative signals) and the 
emerging of new hallmarks updated by the same authors in 2011 as highlighted 
in green (avoiding immune destruction, tumour promoting inflammation, 
genome instability and mutation and deregulating cellular energetics) (diagram 
adapted from Hanahan and Weinberg 2000 and 2011).
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1.2.5.1 Sustain Proliferative Signals
The ultimate trait of malignant cells is perhaps their ability to maintain chronic 
proliferation; in normal cells the production and release of growth factor (GF) 
signals for initiating the cell division cycle is vigilantly controlled ensuring tissue 
homeostasis for maintaining normal tissue architecture and function. Growth 
signals are a necessity for cells to transit from a quiescent state into an active 
proliferative state, no normal cells can proliferate in the absence of these 
stimulatory signals. Since the majority of oncogenes behave by mimicking 
normal growth signal by some means, tumour cells are not dependent on 
growth stimulation from their normal tissue microenvironment. Cancer cells can 
obtain the ability to sustain proliferative signalling either by producing GF 
themselves or sending signals to stimulate normal cells within the supporting 
tumour-associated stroma. For example glioblastomas and sarcomas both 
produce their own GF: platelet-derived growth factor and tumour growth factor a 
respectively (Witsch etal., 2010, Perona, 2006).
The majority of GF receptors consist of tyrosine kinase activities in their 
domains are overexpressed in many cancers, overexpression of receptors on 
cancer cells could result in the cells becoming hyper-responsive to ambient 
levels of GF that would usually not trigger a proliferation response. For instance 
epidermal growth factor receptor is up-regulated in stomach, brain and breast 
cancer (Witsch et al., 2010, Normanno et al., 2006, Cheng et al., 2008, 
Bhowmick et al., 2004).
1.2.5.2 Evade Growth Suppressors
Numerous anti-proliferative signals are active within normal tissue to sustain 
cellular quiescence and tissue homeostasis. These signals can block 
proliferation by either forcing the cells out of the active proliferation state into the 
quiescent (Go) state or prompting the cells to enter into post-mitotic states. Anti­
proliferative signals are controlled by the tumour suppressor gene pRb 
(described previously) which inhibits proliferation by sequestering and altering 
the function of E2Fs that drives cells progression from Gi into S-phase. 
Dysfunction in the pRb pathway make cells become insensitive to anti-growth 
signals, therefore cancer cells with defects in the pRb pathway are missing the 
crucial gatekeeper of cell-cycle progression thus enabling malignant cells to
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flourish by evading anti-proliferative signals (Weinberg, 1995, Burkhart and 
Sage, 2008, Sherr and McCormick, 2002).
1.2.5.3 Tissue Invasion and Metastasis
The process of invasion and metastasis is very complicated and can be 
described as a sequence of events often termed the invasion-metastasis 
cascade (Talmadge and Fidler, 2010). For metastasis to occur in human 
cancers, primary tumour mass must spawn pioneer cells with the capacity to 
move and invade adjacent tissues and travel to distant sites forming new 
colonies, metastasis remains the majority cause of deaths from solid tumours. 
When cells possess invasive or metastatic capabilities their ability to adhere to 
one another decreases and an alteration in their shape, attachment to other 
cells and to the extracellular matrix (ECM) can be observed (Berx and van Roy, 
2009). One of the key changes exhibited by carcinoma cells is the loss of cell­
cell adhesion molecule notably the immunoglobulin and calcium-dependent 
cadherin families, both of which facilitate cell to cell interactions and integrins, 
which are involved in interactions between cells of the ECM. E-cadherin is a key 
player in cell-to-cell interactions, forming adherens junctions with adjacent 
epithelial cells aiding the assembly of epithelial sheets, as well as maintaining 
the quiescence of cells within the epithelial sheets. It has been well established 
that E-cadherin is a key suppressor for this hallmark; down-regulation of E- 
cadherin is frequently observed in human epithelial cancers, while up-regulation 
of E-cadherin inhibits tumour invasion (Cavallaro and Christofori, 2004, Gupta 
and Massague, 2006).
The degradation of the extra-cellular matrix and basement membranes is 
another important factor associated with cancer-cell invasion and metastasis; in 
general the activity of matrix metalloproteinases (MMPs) are tightly controlled 
through specific localization, autoinhibition, and secreted tissue inhibitors 
(Gupta and Massague, 2006) and there is usually an increase in expression 
and activity of MMPs in human cancers (Egeblad and Werb, 2002). MMPs are 
proteolytic enzymes that degrade the basement membrane which is a vital step 
during the metastatic cascade. MMPs (such as MMP7) originate from cancer 
cells, however in human tumours they are not the only source, other MMP 
(including MMP2 and MMP9) are predominantly synthesised by stromal cells
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(Egeblad and Werb, 2002). An epithelial-mesenchymal transition (EMT) is a 
biological process that allows epithelial cells to undergo a series of multiple 
biochemical changes and behave as a mesenchymal cell phenotype, which 
comprises improved migratory ability, invasiveness, elevated resilience to 
apoptosis and increased production of ECM components (Kalluri and Weinberg, 
2009). The EMT model has been perceived to transform epithelial cells to 
acquire the abilities to invade, to resist apoptosis and to disseminate, features 
of EMT have been observed in many different cancer models including colon, 
oesophageal, ovarian and breast. In general, EMT is characterised by a down- 
regulation of epithelial markers, predominantly E-cadherin and an up-regulation 
of mesenchymal markers particularly vimentin or fibronectin, complemented by 
an increase in cell migration and invasion (Micalizzi etal., 2010).
1.2.5.4 Resisting Cell Death
Apoptosis is a form of programmed cell death and exists in latent form in almost 
all cell types through the body. Apoptosis is a highly regulated mechanism, 
when triggered by physiologic signals, cells undergo a precise sequence of 
events; disruption of cellular membrane, breakdown of cytoplasmic and nuclear 
skeletons, extrusion of the cytosol, degradation of the chromosomes and the 
fragmentation of nucleus, all in a time of 30-120 min. The apoptotic bodies are 
engulfed by nearby cells within 24 hours (Wyllie et al., 1980).
The two main apoptotic pathways are the death receptor-mediated pathway 
(extrinsic) and the mitochondrial-mediated pathway (intrinsic) (Figure 1.4), 
though their initial method of activation differs, both cascades are mediated by a 
family of proteins called cysteinyl-aspartate-specific proteases (caspases) 
(Samali et al., 1999, Wang and Lenardo, 2000). Caspases are synthesised as 
inactive pro-caspases and are generally classified into two groups: initiator (or 
apical) caspase (caspases-2, -8, -9 and -10) and executioner (or effector) 
caspase (caspases-3,-6 and -7) (Thornberry and Lazebnik, 1998, Bao and Shi, 
2007, Gupta et al., 2009). While the initiator caspases are different in the two 
apoptotic pathways; caspase-9 for the intrinsic pathway and caspase -8 and -10 
for the extrinsic pathway, both pathways share the same executioner caspases 
(caspase-3, -6 and -7) which cleave cellular substrates and induce apoptotic 
cell death (Chen and Wang, 2002, Wyllie, 2010).
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The extrinsic pathway is engaged when death receptors on the exterior plasma 
membrane (such as TNFR, death receptor 4 and 5 (DR4 and DR5) TRAIL and 
Fas receptors) are bounded to their cognate ligands TNFa, TRAIL and FasL 
(which can be decoy or soluble decoy receptors). This results in the 
oligomerisation of the adapter molecule Fas associated death domain (FADD) 
within the death-inducing signalling complex, the oligomerised FADD then binds 
to pro-caspases-8 and -10, causing their homodimerisation and activation 
thereby resulting in apoptosis (Gupta et al., 2009, Parsons and Green, 2010, 
Igney and Krammer, 2002).
The intrinsic apoptotic pathway in which the mitochondria act as an intermediate 
gate keeper is activated by cellular stresses including radiation, 
chemotherapeutic drugs, oxidative and genotoxic stress. The mitochondria 
pathway is regulated by pro and anti-apoptotic proteins, when pro-apoptotic 
level increases, apoptogenic factors such as cytochrome c are released from 
the mitochondrial intermembrane space into the cytosol. It recruits pro-caspase- 
9 and Apaf-1 forming a multiprotein complex termed apoptosome, which 
cleaves and activates the executor caspase-3 and induces apoptosis (Fulda 
and Debatin, 2006, Riedl and Salvesen, 2007).
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Figure 1.4 Apoptosis signalling pathways. The apoptosis pathway can be 
initiated through different entry sites; at the plasma membrane by death 
receptor ligation (extrinsic pathway) or at the mitochondria (intrinsic pathway). 
Diagram reprinted with permission from Sayers and Cross (Sayers and Cross, 
2014).
The “apoptotic switch” is regulated by counterbalancing pro- and anti-apoptotic 
members of the Bcl-2 family of regulatory proteins; Bcl-2, Bcl-xL, Bcl-w, Mcl-1 
and A1 are anti-apoptotic proteins suppressing the two pro-apoptotic triggering 
proteins (Bax and Bak) (Adams and Cory, 2007, Kuwana and Newmeyer, 2003). 
Tumour cells evolve strategies to limit or avoid apoptosis; the loss of p53 
tumour suppressor function is most common which removes this critical 
damage sensor from the apoptosis-inducing cycle. Alternatively, tumour cells 
down regulate pro-apoptotic factors (Bax, Bim and Puma) which enable them to 
escape the induction of cell death or by short-circuiting the extrinsic ligand- 
induced death pathway (Lowe and Lin, 2000, Fulda, 2009, Townson et al.,
2003).
1.2.5.5 Enabling Replicate Immortality
It has been established that normal cultured cells have a limited replicative 
potential meaning that when cells divide a finite number of times they stop 
growing (senescence) a phenomenon also known as the “Hayflick limit” (Shay 
and Wright, 2000). This restriction has been linked with senescence and crisis 
which involves cell death and are both distinct proliferation barriers, normally 
when cells undergo repeated cycles of cell division it leads to senescence, 
subsequently cells progressing pass this stage will reach a crisis phase where 
the majority of cells in the population dies. Cells that escape crisis will have 
acquired the capability to divide without limit, a transition termed immortalisation 
and is a widely accepted characteristic of cancer cells (Hayflick, 2000, Olaussen 
et al., 2006). The ends of chromosomes are protected by specialised structures 
called telomeres; human telomeres consist of multiple tandem hexanucleotide 
repeats - TTAGGG. Evidence in the literature indicates that telomeres 
protecting chromosomal ends are centrally involved in enabling replicate 
immortality (Shay and Wright, 2006, Shay and Wright, 2002).
1.2.5.6 Inducing Angiogenesis
Oxygen and nutrients are essential for cells to survive and are thereby located 
within the diffusion limit of oxygen (100-200 pm) from blood vessels. Growing 
tumours must recruit new blood vessels by vasculogenesis and angiogenesis in 
order to sustain the growth (Carmeliet and Jain, 2000). In normal tissue once 
formed the angiogenesis process is carefully monitored; under certain
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physiologic processes including wound healing and the female productive 
cycling, angiogenesis is transiently turned on while during tumour progression 
the "angiogenic switch" is usually on and active and thus enabling normal 
quiescent vasculature to continuously grow new blood vessels (Hanahan and 
Weinberg, 2011).
Angiogenic activators can be broadly classified into 6 groups: growth factors, 
cytokines, oncogenes, trace elements, endogenous modulators, proteases and 
protease inhibitors. Particularly the vascular endothelial growth factor (VEGF) 
family has been extensively studied and is one of the most well-known 
angiogenesis inducer (Nishida et al., 2006).
VEGF expression is up-regulated by a number of factors including tumour 
necrosis factor, fibroblast growth factor, epidermal growth factor, transforming 
growth factor-p, interleukin-1 and hypoxia (Carmeliet, 2005, Kerbel, 2008). 
Angiogenesis is balanced by inducers and inhibitors; thrombospondin-1 (TSP-1) 
is a key inhibitor which counteracts the angiogenic switch by binding to CD36 
on the endothelial cell membrane which mediates suppressive signals that can 
counterbalance proangiogenic stimuli. It has been shown in melanoma, bladder 
and colon cancer that a decrease in TSP-1 has been linked with p53 mutations 
(Lawler, 2002).
1.2.6 Emerging Hallmarks
A handful of other properties of cancer cells have been proposed to have 
important roles in the development of cancer and have been added to the core 
list of hallmarks by Weinberg and co-worker (Hanahan and Weinberg, 2011), 
these emerging hallmarks will be described individually below.
1.2.6.1 Deregulating Cellular Energetics
In order for cancer cells to fuel cell growth and division, they must adjust their 
energy metabolism. In the 1920s Otto Warburg made the ground breaking 
discovery that even in the presence of oxygen cancer cells reprogram their 
glucose metabolism to favour aerobic glycolysis, a phenomenon known as the 
“Warburg effect" (Hsu and Sabatini, 2008). This metabolic switch seems 
counterintuitive since cancer cells must overcome the lower efficiency offered
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by glycolysis in relation to mitochondrial oxidative phosphorylation. This occurs 
by the up-regulation of glucose transporters, specifically GLUT1, which 
dramatically increases glucose import into the cytoplasm (DeBerardinis et al., 
2008, Jones and Thompson, 2009). It has been demonstrated that glycolytic 
fuelling is associated with mutant tumour suppressors such as P53 and 
activated oncogenes including RAS and c-Myc (Osthus et al., 2000). This 
dependence on glycolysis can be emphasised under hypoxia conditions 
observed in almost all cancers; responses to hypoxia is mediated by the 
hypoxia-inducible factor 1 (HIF-1) transcription factor complex. Both RAS and 
hypoxia can increase levels of HIF1a and HIF2a and subsequently up-regulate 
glycolysis (Semenza, 2010, Gordan and Simon, 2007).
1.2.6.2 Avoiding Immune Destruction
Immune surveillance is necessary to prevent tumour formations in humans and 
thus immune escape is a vital pathway to malignancy; this field of research is 
still in its infancy with the interconnections between signalling pathways that 
control immune escape and those that control proliferation, senescence, 
apoptosis, angiogenesis, invasion and metastasis (Prendergast, 2008). 
Evidence in the literature indicated that the immune system can promote the 
emergence of primary tumours with reduced immunogenicity with the ability to 
escape immune recognition and destruction (Prendergast, 2008). This lead to 
the development of the cancer immunoediting hypothesis, which is now an 
emerging Hallmark of cancer and encompasses three phases: elimination, 
equilibrium and escape.
The first phase is elimination which involves eliminating cancer cells thereby 
inhibiting tumour development and/or growth, tumour cells not killed by the 
immune system in the elimination phase will advance forward to the second 
phase -  equilibrium, where the remaining tumour persists in the 
immunocompetent host but is prevented from growing by immune pressure. 
Cancer cells that develop the ability to bypass immunological suppression of 
tumours enter the final stage of immunoediting -  escape phase and will 
continue to divide and grow (Dunn et al., 2006, Dunn et al., 2004).
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1.2.6.3 Genome Instability and Mutation
Almost all human cancers has the common trait of genomic instability; there are 
several forms of genomic instability including increased frequencies of base pair 
mutations, the expansion or contraction of the number of oligonucleotide 
repeats in microsatellite sequences also known as microsatellite instability and 
chromosomal instability. The latter is the most common, characterised by high 
alteration rates where chromosome number and structure changes over time 
(Negrini et al., 2010). The high replication accuracy along with the remarkable 
ability of the genome maintenance mechanism to detect and repair defects in 
the DNA ensures mutation rates are kept to a minimum during cell cycle.
The majority of cancer cells have a higher mutation rate due to the 
accumulation of mutant genes required for tumorigenesis (Salk et al., 2010). In 
hereditary cancers, genomic instability has been associated with mutations in 
DNA repair genes and thus driving cancer development. The most well-known 
example is hereditary nonpolyposis colon cancer also termed Lynch syndrome, 
where mutations in DNA mismatch repair genes result in microsatellite 
instability and a high mutation rate (Liu et al., 1996, Lynch and Smyrk, 1996).
1.2.6.4 Tumour Promoting Inflammation
While the relationship between inflammation and cancer is not new and it dates 
back to the late 18th Century, it is only during the last decade where there has 
been an increase of evidence in the literature indicating that inflammation has 
pivotal roles throughout the different stages of tumour development, from 
initiation through to invasion and metastasis (Coussens and Werb, 2002, 
Grivennikov et al., 2010).
Nowadays it is widely accepted that inflammation plays an important role in 
tumorigenesis with the majority of cancers (up to 95%) closely associated with 
chronic inflammation caused by environmental and lifestyle choices. 
Approximately 35% of all cancers can be attributed to dietary factors (up to 20% 
by obesity), 30% to tobacco smoke, 18% to infections and 7% to radiation and 
inhalation of environmental pollutants (Aggarwal etal., 2009).
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1.2.7 Cancer Therapeutics
To date the most common types of cancer treatment includes surgery, 
radiotherapy and chemotherapy. Surgery is most effective for the treatment of 
localised primary tumour and associated metastases in regional lymphatics, 
with advances in technology radical mastectomy has been replaced by partial 
mastectomy for breast cancer to minimise surgical trauma to tissues and organs 
and to retain as much of its function as possible (Urruticoechea et al., 2010).
Radiotherapy utilises high energy radiation sources to cause damage to the 
DNA of cancer cells hence blocking their cell division cycle. Radiotherapy is an 
effective treatment; early cancers including prostate, lung, cervix, head and 
neck, lymphomas (Hodgkin’s and low grade Non-Hodgkin’s) and skin cancers 
(squamous and basal cell) are curable with radiation therapy alone. 
Furthermore radiotherapy is commonly used in conjunction with surgery and 
chemotherapy, around 50% of all patients will receive radiotherapy in due 
course of their illness contributing towards 40% of curative treatment of cancer. 
Even with high success rates, radiotherapy is highly cost effective and is only 
accountable for 5% of the total cancer care cost (Baskar et al., 2012).
The first use of chemotherapy to treat cancer dates back to the early 20th 
Century with the first use of nitrogen mustards and antifolate drugs, since then 
cancer drugs have become one of the most researched areas and have evolved 
into a multi-billion dollar industry (Chabner and Roberts, 2005, DeVita and Chu,
2008). Chemotherapy involves the use of cytotoxic drugs that disrupt the cell 
cycle; alkylating agents such as cisplatin, cyclophosphamide forms adduct with 
DNA bases primarily at the guanine sites and interfere with DNA replication 
(Emadi et al., 2009, Zamble and Lippard, 1995). Antimetabolites including 
methotrexate and 5-fluorouracil inhibit vital enzymes in metabolic processes 
thus halting cell growth (Kaye, 1998).
Conventional treatments possess several drawbacks; surgery is limited to large 
accessible tumours, radiation therapy is non-specific and kills both normal and 
abnormal cells in the radiated pathway, chemotherapeutic drugs have a narrow 
therapeutic index, it causes immuno-suppression and are highly expensive. 
Consequently, research has focused on the development of new, novel
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therapies to decrease drug toxicity in healthy cells and increase efficacy, this 
has led to the development of targeted therapies (Arruebo et al., 2011).
One approach is to use monoclonal antibodies to target receptors 
overexpressed on the surface of cancer cells, antibody-based therapy has 
become established over the past 15 years and is now often the preferred 
choice in the treatment of haematological malignancies and solid tumours (Scott 
et al., 2012). Over the years several fully human monoclonal antibodies (e.g. 
Herceptin) have been approved by regulatory agencies and many more are at 
the clinical trial stages (Arruebo et al., 2011). Alternative methods include 
targeting specific cellular signalling pathways with the use of tyrosine kinase 
inhibitors (e.g. Imatinib) (Arora and Scholar, 2005), triggering the extrinsic 
apoptotic pathway via the use of apoptosis-inducing ligand (e.g. TRAIL) 
(Mahmood and Shukla, 2010, Wang, 2010) and targeting the p53 gene therapy 
pathway to reactivate the p53 apoptosis pathway (Bykov and Wiman, 2003). 
Nanotechnology has arrived on the scene and the use of nanomaterials for 
novel applications in the field of oncology has emerged as hot topics, with 
plethora of publications in this area, selected reviews include Akhter et al., 2012, 
Bilensoy 2010, Davis et al., 2008, Dreaden et al., 2011, Wang and Thanou 
2010, Wesselinova 2011, Thanh and Green 2010, (Bertrand et al., 2014, 
Biswas and Torchilin, 2014, Sanna et al., 2014).
1.2.8 Cancer Nanotechnology
At present, there is a strong focus on the application of nanotechnology in 
cancer research; cancer nanotechnology is new field of interdisciplinary 
research cutting across chemistry, engineering, biology and medicine and is 
anticipated to revolutionised the detection, diagnosis and treatment of cancer 
(Llevot and Astruc, 2012, Portney and Ozkan, 2006, Srinivas et al., 2002, 
Ferrari, 2005, Davis etal., 2008).
Fluorescence techniques have many important biomedical applications 
including cell labelling, cell tracking, cellular and molecular imaging. Standard 
fluorescent labels such as organic dyes suffers from limitations particularly in 
multicolour experiments due to issues associated with signal intensity strength, 
narrow excitation ranges, broad emission spectra and relatively short lifetimes.
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To overcome the limitations of organic dyes, new reporter species have been 
developed. Semiconductor nano-crystals also known as quantum dots (QDs) 
has been developed and they exhibit improved optical qualities that are 
desirable for biological applications and overcome the limitations of organic 
dyes (Walling et al., 2009).
The utilisation of nanomaterials for imaging applications has been widely 
investigated; cellular labelling using QDs has advanced the most and they are a 
promising new class of fluorescent probe for in vivo biomolecular and cellular 
imaging (Walling et al., 2009, Gao et al., 2004, Li et al., 2009a, Bentolila et al.,
2009). Furthermore QDs have been used in cell tracking for the study of tumour 
metastasis (Voura et al., 2004) and the binding of EGF to EGFR (Lidke et al.,
2004), magnetic nanoparticles have been exploited for magnetic resonance 
imaging and cell tracking (Arbab et al., 2006, Pankhurst et al., 2003, Singh, 
2001, McCarthy and Weissleder, 2008).
The application of nanosize devices for drug delivery has blossomed over the 
years, with several nanomedicine products already available on the market (e.g. 
Doxil) and many more in the clinical trial stages (Wagner et al., 2006, Kumar et 
al., 2013a). A range of nanometric delivery vehicles have been showcased 
these include polymeric micelles, dendrimers, liposomes, QDs, carbon 
nanotubes and inorganic NPs (Rivera Gil et al., 2010, Bawarski et al., 2008, 
Elhissi et al., 2012, Riggio et al., 2011). Among the inorganic NPs, AuNPs have 
emerged as promising drug delivery carriers (Akhter et al., 2012, Ahmad et al., 
2013, Han etal., 2007).
1.2.8.1 Nanoparticles as Drug Delivery Carriers
As mentioned above, the majority of current anti-cancer agents are not specific 
and lack the ability to differentiate between normal and cancerous cells leading 
to systemic toxicity. Furthermore, because of the rapid elimination and wide 
spread distribution of agents into non-targeted organs and tissues, higher 
dosages are required which not economical and often result in adverse side 
effects due to non-specific toxicity (Nie et al., 2007). The use of nanomaterials 
to delivery anti-cancer drugs to tumour sites is a promising platform, and can be 
achieved by either passive or active targeting.
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1.2.8.1.1 Passive Targeting
Passive targeting refers to the accumulation of drug or drug delivery system at a 
desired site due to physico-chemical or pharmacological factors; the use of 
AuNPs takes advantage of its inherent size in the nature of the tumour 
microenvironment. Tumour vasculature differs dramatically compared to normal 
tissue; blood vessel walls in tumours are generally more porous and leaky 
owing to the formation of new blood vessel from existing ones, a process also 
known angiogenesis (Carmeliet and Jain, 2000, Nishida et al., 2006). 
Angiogenic blood vessels in tumour tissues have gaps as large as 600-800 nm 
between adjacent endothelial cells.
Furthermore tumours have a dysfunctional lymphatic drainage resulting in 
AuNPs being retained longer at the tumour site. Together these effects induce a 
phenomenon called the enhanced permeability and retention (EPR) effect, 
enabling nanoparticles to extravasate through these large gaps into 
extravascular spaces and accumulate inside tumour tissues (Misra et al., 2010, 
Ghosh etal., 2008, Nie eta!., 2007).
A significant increase in tumour drug concentration can be achieved when the 
drug is delivered by a nanoparticle in comparison to the free drug form, however 
passive targeting does suffer from several limitations. It is not always feasible to 
target all cells within a tumour as some drugs cannot diffuse efficiently, in 
addition the random nature of passive targeting makes it difficult to control the 
process and could lead to multiple-drug resistance (Peer et al., 2007). To 
complicate matters further the permeability of vessels may not be identical 
throughout the tumour and certain tumours do not exhibit the EPR effect, 
nanocarriers may potentially suffer from non-specific uptake and degradation in 
macrophages, therefore targeting is critical for achieving maximum drug efficacy 
with minimal size effects (Ghosh etal., 2008).
1.2.8.1.2 Active Targeting
The development of nanocarriers with the capability of binding to specific 
cells/tumour sites of interest is an attractive proposition, this can be achieved by 
attaching targeting moieties of interest onto the nanoparticle scaffold to enable 
their selective uptake by specific interactions such as ligand-receptor, antibody-
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antigen and lectin-carbohydrate (Allen, 2002). Lectin-carbohydrate binding is 
very specific, delivery based on this system have been developed to target 
organs as a whole (Yamazaki et al., 2000, Kannagi et al., 2004). The fact that 
receptors or antigens are usually over expressed in human cancer cells has 
been exploited, as receptor-ligand binding facilitates internalisation via receptor- 
mediated endocytosis. The strength of NP interactions with antigens or 
membrane receptors can be controlled by the property of the ligand (e.g. affinity) 
and by changing the ligand density (e.g. avidity) attached to the surface of the 
particle (Chou et al., 2011).
Surface functionalisation of nanoparticles plays a major role in active targeting 
enabling scientists to engineer specific AuNPs with active targeting capabilities 
via specific surface modifications. These targeting groups can be broadly 
classified as proteins (antibodies and their fragments), nucleic acids or other 
receptor ligands (small molecules, peptides, vitamins and carbohydrates). 
Targeting agents developed to-date has been predominately for cancer 
applications (Chou et al., 2011, Scheinberg et al., 2010).
Folate receptors are overexpressed on the surfaces of many tumour cells and 
have been explored as a target; Dixit and co-workers (Dixit et al., 2006) have 
shown that AuNPs (d = 10 nm) conjugated to folic acid were selectively taken 
up by folate receptor positive KB cells, with minimal uptake in cells that do not 
overexpress the folate receptor. Chen and colleagues (Chen etal., 2007b) have 
demonstrated that AuNPs (d = 13 nm) (MTX-AuNPs) conjugated to 
methotrexate (a dihydrofolate reductase inhibitor that destroys folate 
metabolism) are rapidly taken-up and are more cytotoxic compared to 
methotrexate alone. Furthermore MTX-AuNPs have shown to suppress tumour 
growth in Lewis lung carcinoma cell line (LL2).
Transferrin (TF) interacts specifically with TF receptors which are actively 
expressed on the surface of a variety of tumour cells, as a result, the transferrin- 
receptor interaction has been investigated as a potential target for drug delivery. 
Yang and co-workers (Yang et al., 2005) have shown that AuNPs (d = 20 nm) 
conjugated to transferrin were taken-up by human nasopharyngeal carcinoma 
cells (NPC, SUNE1). Tumour necrosis factor (TNF) is a potent cytokine with
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anti-tumor properties, however the practical dosage is restricted due to its 
severe toxicity, this toxicity can be reduced by conjugation to AuNPs. PEG- 
AuNPs (d = 32 nm) conjugated TNF (PEG-cAu-TNF) have been injected in mice 
and the results illustrated that PEG-cAu-TNF were specifically accumulated in 
MC-38 colon carcinoma tumours and no accumulation were observed in the 
liver, spleens nor other healthy organs (Paciotti et al., 2004).
Antibody based targeting is an alternative approach; in the 1950s the use of 
antibodies binded AuNPs for staining cellular components for electron 
microscopy was published, since then antibodies conjugated to AuNPs have 
been explored for cancer therapeutics (Huang et al., 2008). Single chain 
antibody scFv has been conjugated to gold and iron oxide hybrid nanoparticles 
to target A33 antigens which is expressed in 95% of primary and metastatic 
human colorectal tumor cells for targeted phototherapy and cancer imaging 
(Kirui et al., 2010). Several research groups have conjugated anti-human 
epidermal growth factor receptor 2 (anti-HER2) to a variety of AuNPs to take 
advantage of the overexpression of EGFR on the surface of breast cancer cells 
for imaging and therapeutic applications (Lee et al., 2009, Loo et al., 2005, 
Chen et al., 2007a). El-Sayed’s group have conjugated AuNPs (d = 35 nm) to 
monoclonal anti-epidermal growth factor receptor (anti-EGFR) antibodies to 
target overexpression EGFR on epithelial carcinoma cells for diagnosis and 
laser photothermal therapy (El-Sayed etal., 2005, El-Sayed etal., 2006).
There has been a growing interest in attaching chemotherapeutic drugs to 
AuNPs as an attempt to improve drug delivery to the tumour site; paclitaxel is a 
popular chemotherapeutic drug for the treatment of a variety of cancers 
however it suffers from lack of tumour specificity and low solubility in water, an 
approach to overcome these limitations is by conjugating paclitaxel to 
nanocarriers (Gibson et al., 2007, Hwu et al., 2009). AuNPs (d = 25 nm) 
conjugated to tamoxifen exhibited selective uptake by estrogen receptor 
positive breast cancer cells and an increase in drug potency of up to 2.7 fold 
was observed compared to the free drug (Dreaden et al., 2009). Doxorubicin 
conjugated to AuNPs (d = 2.8 nm) are up to 5-fold more cytotoxic to B16 
melanoma cells compared to the equivalent concentration of doxorubicin alone 
(Nadeau et al., 2010).
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The application of AuNPs for active targeting are not limited only for cell-specific 
targeting it can also be used for the localisation into desired organelles; a 
peptide sequence derived from the HIV-1 Tat peptide has been coupled to 
AuNPs for nucleus targeting (De La Fuente and Berry, 2005).
1.3 Mitochondria
The integrity of mitochondrial function is essential to cell life since many critical 
cellular parameters are controlled by mitochondria; these include energy 
production, modulation of redox status, generation of reactive oxygen species, 
maintenance of calcium homeostasis, involvement in a number of metabolic 
and biosynthetic pathways and the regulation of programmed cell death 
(apoptosis). Mitochondrial dysfunction contributes to a spectrum of human 
disorders such as neurodegenerative diseases (e.g. Parkinsons’ and 
Alzheimers’), ischemia-reperfusion injury, diabetes and cancer (Gupta et al., 
2009, Wallace, 2005, Weissig et al., 2004).
In the past few years mitochondrial research has become one of the fastest 
growing disciplines in biomedicine (Singh, 2001), current research activities 
includes targeting the mitochondrial apoptotic mechanism (D'Souza et al., 2011, 
Fulda, 2010, Fulda et al., 2010, Wallace, 2012, Wang, 2001), protecting 
mitochondria from oxidative stress (Kelso et al., 2002, James et al., 2004, 
Coulter et al., 2000, Sheu et al., 2006) and diseases caused by mutated 
mitochondrial DNA (mtDNA) (Pulkes and Hanna, 2001, Tuppen et al., 2010, 
D'Souza and Weissig, 2004).
1.3.1 Role of Mitochondria in Cell Death
At the centre of the intrinsic apoptotic pathway is the mitochondria (as 
mentioned briefly in chapter 1.2.5.4), it is the cell’s reservoir of pro-apoptotic 
factors which reside in the mitochondrial intermembrane space (IMS). Following 
an apoptotic stimuli, pores are formed in the outer mitochondrial membrane 
(OMM) of the mitochondria in a process termed mitochondrial outer membrane 
permeabilisation (MOMP) this is a crucial event and is also referred to as the 
“point of no return” of cell death. Subsequently IMS proteins are released into 
the cytosol; while some of these proteins are considered to be “innocent 
bystanders” and do not cause any cellular response, cytochrome c and
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Smac/DIABLO (Second mitochondria-derived activator of caspase/direct 
inhibitor of apoptosis-binding protein with low pi) promotes cell death via the 
activation of caspases (Parsons and Green, 2010, Gupta etal., 2009).
Caspases are key players in the apoptotic response, to date 11 human caspase 
proteins have been identified, among them all only 7 of these are thought to 
have functions in apoptosis including the initiator caspases (caspase-2, -8, -9 
and -10) and effector caspases (caspases-3, -6 and -7). In normal cells, 
caspases exist as zymogens (catalytically inactive) and must undergo 
proteolytic activity to become active. Following an apoptotic stimuli, initiator 
caspase (i.e. caspase-9) is auto-activated which activates the effector caspase 
(i.e. caspase-3) via the cleavage at specific aspartate residues between the 
small (~p10) and the large (~p20) subunits, the two subunits are closely 
associated with each other forming a caspase monomer (Riedl and Shi, 2004).
The activation of the caspase cascade is well regulated and requires the 
assembly of a multi-component complex; following the release of cytochrome c 
into the cyotosol, it forms a multimeric complex called an apoptosome (~1.4- 
MDa) with dATP, APAF1 (apoptotic-protease-activating factor-1) and the 
initiator caspase-9 which act as an activating platform for caspase-9 (Adams 
and Cory, 2002). Once activated, the effector caspases proteolytically cleaves 
regulatory and structural proteins within the cell and result in the physical and 
morphological characteristics of apoptosis including membrane blebbing, 
phosphatidylserine externalisation and chromatin condensation (Thornberry and 
Lazebnik, 1998).
The release of cytochrome c is a must for the formation of the apoptosome and 
the activation of caspase-9, hence without MOMP and the subsequent release 
of cytochrome c from the IMS, caspase-9 and the caspase cascade would not 
be activated. The integrity of MOMP is controlled by the B-cell lymphoma-2 
(Bcl-2) family of proteins, which are further classified into one of three functional 
groups: anti-apoptotic proteins, pro-apoptotic effectors and BH3-only proteins. 
The Bcl-2 proteins share similar sequences of the Bcl-2 homology (BH) 
domains; anti-apoptotic proteins contain 4 BH domains, pro-apoptotic effectors
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contains 3 BH domains and BH3-only proteins only contain the third BH domain 
(Wong and Puthalakath, 2008).
The anti-apoptotic family members (e.g. Bcl-2, BcI-Xl, Bcl-w and Mcl-1) are 
potent anti-apoptotic molecules that inhibit MOMP and the subsequent release 
of cytochrome c and are found tethered to the OMM (Chipuk and Green, 2008). 
The pro-apoptotic family members (e.g. Bak and Bax) and BH3 only proteins 
(e.g. Bid, Bim, Bad, Bik and BIK) which are regarded as the essential initiators 
of the mitochondrial apoptotic pathway, all execute pro-death functions via 
different approaches. The majority of pro-apoptotic proteins are located in the 
cytosol with the exception of Bak which is located on the OMM (Wong and 
Puthalakath, 2008, Parsons and Green, 2010).
Beside the release of cytochrome c, other apoptogenic molecules including 
Smac/DIABLO, Htra2/Omi, apoptosis inducing factors (AIF) and endonuclease 
G (EndoG) are also released from the intermembrane and result in cell death 
via different ways. The release of cytochrome c triggers the caspase cascade 
and induces apoptosis, Smac/Diablo and Htra2/Omi inactivates the inhibitors of 
apoptosis, AIF and EndoG enter the nucleus and degrade nuclear DNA 
(Breckenridge and Xue, 2004, Wang, 2001).
1.3.2 Targeting Mitochondria for Cancer Therapy
Mitochondria have emerged as an attractive novel pharmacological target for 
cancer therapeutics (Gupta et al., 2009, Frantz and Wipf, 2010, Modica- 
Napolitano and Singh, 2002, Costantini et al., 2000, Weissig, 2003). 
Interestingly cancer cell mitochondria are structurally and functionally different 
in comparison to their normal counterparts (Gogvadze et al., 2008, Modica- 
Napolitano and Singh, 2004). These notable differences have been exploited as 
potential targets for anti-cancer therapy (Figure 1.5) by using agents that either 
interact directly at the site of mitochondria or target metabolic alterations caused 
by mitochondrial dysfunction.
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Figure 1.5 Summary of possible sites and functions of mitochondria as potential 
targets for anti-cancer therapyDiagram adapted from Wang et al. (2010).
The first approach is to target mtDNA, which encodes for 13 crucial proteins of 
the respiratory chain and are more vulnerable to damage than DNA due to the 
unique structure of lacking histone protection and having a weak repair 
capability (Carew et al., 2003). Cisplatin is an alkylating agent and has been 
shown to preferentially bind to mtDNA 50 times more than DNA leading to the 
inhibition of NADH-ubiquinone reductase and the reduction in ATP generation 
(Murata et al., 1990).
The second method is to target altered metabolisms associated with 
mitochondrial dysfunction; in cancer cells an important change is the increase in 
aerobic glycolysis also known as the “Warburg phenomenon” which is 
necessary for cancer cells to survive and proliferate. Altered expression and 
activities of enzymes involved in glycolysis and the tricarboxylic acid cycle have 
been observed in various cancer types (Kroemer and Pouyssegur, 2008). 3-
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bromopyruvate, dichloroacetate, lonidamine and oxamate have all been shown 
to be effective in targeting cancer cells with high glycolytic profiles (Wang et al.,
2010).
The third tactic is to focus on the cancer mitochondrial respiration; evidence 
suggested that cancer cells have increased levels of reactive oxygen species 
(ROS) compared to their normal counterparts, the manipulation of ROS levels 
by redox modulation is a feasible approach to selectively kill cancer cells 
without causing significant toxicity to normal cells. ROS modulating agents 
include arsenic trioxide, buthionine sulphoximine, phenylethyl isothiocyanate 
and 2-methoxyestradiol (Trachootham etal., 2009).
The fourth route is to target the mitochondrial membrane permeability; the 
permeability transition pore complex (PTPC) is a highly dynamic supra- 
molecular complex, its exact structural identity is not yet fully understood (Fulda 
et al., 2010). In response to pro-apoptotic stimuli such as Ca2+ overload and 
ROS the PTPC enables the deregulated entry of small solutes into the 
mitochondrial matrix along their electrochemical gradient a process also known 
as the mitochondrial permeability transition pore (MPTP) which result in the 
immediate dissipation of the mitochondrial membrane potential and osmotic 
swelling of the mitochondrial matrix leading to MOMP (Kim et al., 2003, 
Lemasters etal., 1998, Fulda etal., 2010).
Despite extensive research over the years, the exact mechanisms regulating 
mitochondrial permeability and the release of cytochrome c during apoptosis is 
not fully understood; the most accepted theory is that in response to an 
apoptotic stimulus pro-apoptotic proteins such as Bax and Bak undergo 
conformational changes, oligomerise and form pores on the outer mitochondrial 
membrane to facilitate the release of proteins into the cytosol (Antignani and 
Youle, 2006). Agents used to target the MPTP includes Bcl-2 inhibitors such as 
Gossypol which inhibits anti-apoptotic Bcl-2 proteins (e.g. Bcl-2, Bcl-XL and 
Mcl-1) (Kang and Reynolds, 2009) and ABT-737 that induces mitochondrial 
inner membrane permeabilisation and subsequently matrix swelling and 
rupturing of the outer mitochondrial membrane in leukemia and lymphoma cells 
(Vogler et al., 2008).
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The final approach is to target the mitochondrial transmembrane potential 
(A^m); it is known that the A'+’m in cancer cells is significantly higher than in 
normal cells (Johnson et al., 1980, Summerhayes et al., 1982, Davis et al., 
1985, Modica-Napolitano and Aprille, 1987) and this biological difference has 
been exploited as a target. Delocalised lipophilic cations (DLCs) are able to 
selectively accumulate in the mitochondria of tumour cells due to the highly 
negatively-charged microenvironment inside the mitochondrial matrix and this 
specific accumulation has been demonstrated both in vitro (Sehy et al., 1993, 
Rideout et al., 1989, Steichen et al., 1991, Manetta et al., 1996, Patel et al., 
1994, Rideout etal., 1994) and in vivo (Manetta etal., 1996, Madar etal., 2002, 
Li etal., 2009b, Min etal., 2004).
1.3.3 Strategies for Mitochondrial Pharmacology
With mitochondria emerging as a novel pharmacological target, there has been 
a growing interest in delivering biologically active molecules including proteins, 
enzyme and drugs to the site of mitochondria for therapeutic effects (Smith et 
al., 2012, Malhi and Murthy, 2012).The main strategy employed in mitochondrial 
pharmacology for site specific delivery involves the conjugation of small 
molecules to a lipophilic cation which has been reviewed extensively elsewhere 
(Murphy, 1997, Murphy and Smith, 2007, Murphy and Smith, 2000, Ross et al.,
2005), other strategies include mitochondria targeted peptides (Yousif et al., 
2009a, Yousif et al., 2009b, Jacotot et al., 2006, Cai et al., 2010) and making 
use of the high affinity mitochondria-specific binding sites (Smith et al., 2011).
1.3.3.1 Conjugation to Lipophilic Cations
The term “lipophilic cations” refer to molecular cations in which the charge is 
“delocalised” by organic substituents, also referred to as delocalised lipophilic 
cations (DLCs) examples include rhodamine 123 (Rh 123) (a) dequalinium, 
Victoria Blue BO (b) choride (DECA) (c) MKT-077 (d) safranine O (e) and a 
family of compounds called lipophilic phosphonium compounds (LPCs) (Cooper 
et al., 2001, Rideout et al., 1989, Murphy, 2008, Pathania et al., 2009), 
structures are shown in Figure 1.6.
Among all DLCs, LPCs have been extensively investigated for mitochondria 
specific targeting; whilst the ability of LPCs to permeate artificial phospholipids
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bilayers has been known for some time, its first application in mitochondrial 
biology wasn’t reported until the late 1960’s when Skulachev and colleagues 
demonstrated that derivatives of triphenylphosphonium (Ph3P+R) (f) such as 
tetraphenylphosphonium (tetraPP) (g) and methytriphenylphosphonium (TPMP) 
(h) were able to cross the mitochondrial inner membrane without the facilitation 
from ionophores or carrier proteins and accumulate inside the mitochondria 
matrix due to the phenomenon of the mitochondrial transmembrane potential 
(Liberman etal., 1969).
The mitochondrial transmembrane potential arises as a result of protons being 
pumped out of the mitochondrial matrix which creates a negative potential 
(Henry-Mowatt et al., 2004). The mitochondrial transmembrane potential within 
cells can be determine by the distribution of phosphonium cations, as the 
plasma membrane potential drives the uptake of phosphonium cations into the 
cytoplasm, which they are further accumulated in mitochondria by the 
mitochondrial transmembrane potential (Brand and Felber, 1984, Brand, 1995).
The finding that lipophilic cations were taken up by mitochondria made sense of 
the fact that several vital stains used since the 20th Century such as Janus 
Green and more recently Rh 123, JC-1 and Mitotracker have been widely used 
for visualising mitochondria in cells are in fact all lipophilic cations (Ross et al., 
2005). Since the ground breaking discovery of the accumulation of LPCs in the 
mitochondria by Skulachev’s group (Liberman et al., 1969), the TPP moiety has 
become the fundamental building blocks in the design of novel probes for 
investigating mitochondria function and treating mitochondria dysfunction.
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Figure 1.6 Chemical structures of DLCs: a) Rh 123, b) Victoria Blue BO, c) 
DECA, d) MKT-077, e) Safranin O, f) Ph3P+R, g) tetra PP and h) TPMP.
1.3.3.2 Mitochondrial Accumulation of Lipophilic Phosphonium Cations
LPCs such as tetra PP and TPMP are cationic in nature and are attracted to the 
negative energy potentials of the membrane bilayer, because their positive 
charge is delocalised over a large surface area the activation energy required to 
be taken-up by cells is lowered. Despite their net positive charge, LPCs have 
the unusual properties of being relatively lipid-soluble, enabling their passage 
through the lipid bilayers and accumulate specifically inside the mitochondria 
matrix, thereby making them ideal candidates for mitochondria-targeted 
diagnostics and therapeutics (Weissig, 2005, Yousif etal., 2009b, Murphy, 1997, 
Porteous et al., 2010, Ross etal., 2008).
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The uptake of LPCs into mitochondria is primarily governed by the large 
membrane potential across the mitochondrial inner membrane of up to 150-160 
mV (negative inside) (Figure 1.7). The plasma membrane potential (usually 30- 
60 mV, negative inside) also drives the uptake of cations into the cell where 
they are further accumulated inside the mitochondria, with majority of the 
intracellular cation (90-95%) localising in the mitochondria (Burns and Murphy, 
1997).
30-60 mV
5-10 fold x
Nucleus
150-180 mV
Matri:
MitochondrionPlasma
membrane
h h h h n m
Figure 1.7 Uptake of LPCs by mitochondria within cells. This diagram shows a 
TPP moiety attached to a moiety (x) is taken-up 5-10 fold into the cytoplasm 
from the extracellular environment driven by the plasma transmembrane 
potential (A’+’p). From the cytoplasm, the compound is further accumulated 100- 
500 fold into the mitochondria driven by the mitochondrial transmembrane 
potential (A'+’m). (Diagram adapted from Ross et al. 2005).
The fact that lipophilic cations are taken-up by the mitochondria in cells, it was 
natural to consider linking molecules of interest to a lipophilic cation for targeted 
delivery to mitochondria in vivo (Murphy, 1997, Smith et al., 2003, Weissig, 
2005), this was first utilised by Chen who attached cisplatin to Rh 123 (Chen, 
1988). In general alkyltriphenylphosphonium cations are better candidates for
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targeted delivery to the site of mitochondria as they accumulate to a greater 
extent within the mitochondria.
Furthermore, the synthesis of alkyltriphenylphosphonium cations from the 
reaction of triphenylphosphine with an appropriate precursor (Smith et al., 2004, 
Kelso et al., 2001, Smith et al., 1999) or by conjugation of a pre-formed 
alkyltriphenylphosphonium cation to a molecule is relatively simple (Murphy et 
al., 2003, James et al., 2003). This property has been exploited to direct a 
broad range of potential probe or therapeutic agents to the site of mitochondria 
and some are these are outlined below.
1.3.3.3 Mitochondria Targeted Anti-Cancer Agents
It has been demonstrated that the mitochondria transmembrane potential in 
cancerous cells is significantly higher compared to non-cancerous cells (-163 
mV and -104 mV respectively) (Modica-Napolitano and Aprille, 1987) and this 
difference has a dramatic effect on the uptake of LPCs. The Nernst equation 
predicts a difference of 61.5 mV in trans-membrane potential at 37°C will result 
in a ten-fold increase in accumulation, therefore the concentration of LPCs in 
the mitochondrial matrix should then be several hundred- to a few thousand-fold 
greater in comparison to the extracellular environment (Ross et al., 2005).
The Nernst equation describes the concentration of the free, unbound cations. 
In the presence of the mitochondrial transmembrane potential, the distribution of 
singly charged lipophilic cations such as TPMP (Figure 1.6 h) across the 
membrane will equilibrate with the mitochondrial transmembrane potential 
which will result in the extensive accumulation of the cation in the mitochondrial 
matrix to extent described by the Nernst equation (Ross et al., 2005):
The idea of utilising LPCs as a delivery vector to take advantage of the elevated 
mitochondrial transmembrane potential observed in cancer cells has been 
investigated over the years; tetra PP has been administered at concentrations 
high enough to cause cell death in cancer cells due to non-specific disruption to 
mitochondrial function, but is non-toxic to control cells (Rideout et al., 1989).
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This approach has been extended to conjugate protein alkylating agents to the 
TPP moiety and thus increasing the concentration of these compounds within 
cancer cells to selectively promote cell death (Manetta et al., 1996, Rideout et 
al., 1989, Patel et al., 1994).
1.3.3.4 Mitochondria Targeted Photodynamic Therapy
Photodynamic therapy (PDT) is novel treatment modality for several types of 
cancer; it involves photoreactions mediated by three key elements: 
photosensitisers, light and oxygen to generate ROS such as singlet oxygen, 
superoxide anion radical and hydroxyl radical. PDT benefit from the cytotoxic 
effects generated from the ROS to induce apoptosis or necrosis in cancerous 
cells (Lei et al., 2010). The photosensitiser mesochlorine e6 (Mcee) has been 
conjugated to the TPP group (P-SS-TPP-lysince-Mce6), while both 
unconjugated and conjugated photosensitiser displayed a time dependent 
cytotoxicity effect in ovarian carcinoma cells (SKOV-3) the conjugated, (Mcee) 
exhibited greater cytotoxicity (Cuchelkar et al., 2008).
Meso-tetraphenylporphyrin derivatives incorporating a TPP ion terminated 
alkoxy group at either para- or meta- position of one meso-phenyl group have 
shown to be phototoxic in human breast cancer (MCF-7) (Lei et al., 2010). More 
recently, a core modified porphyrin-mono-triphenylphosphonium cation (CMP- 
tPP) has shown improvement in cellular uptake and photodynamic activity 
compared to the monohydroxy core modified porphyrin alone (Rajaputra et al., 
2013).
1.3.3.5 Mitochondria Targeted Radiotracers for Tumour Imaging
Conventional cationic radiotracers such as " mTc-Tetrofosrnin and " mTc- 
Sestamibi have been used for the diagnosis of cancer by single-photon 
emission computed tomography (SPECT) and the monitor of the multidrug 
resistance transport function in tumours of different origin, however they suffer 
from low tumour selectivity and insufficient tumour localization and thus limiting 
their diagnostic and prognostic values in a clinical setting (Zhou and Liu, 2011).
Nearly 30 years ago, radiolabeled quaternary phosphonium cations were first 
investigated as perfusion radiotracers for myocardial perfusion imaging
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(Srivastava et al., 1985), since then several groups have proposed the use of 
radiolabeled triphenylphosphonium cations as PET radiotracers. These include 
18F labelled probes as mentioned previously in chapter 3.1 and 64Cu labelled 
phosphonium cations including 64Cu-labeled 2-(diphenylphosphoryl)- 
ethyldiphenylphosphonium cations (Yang et al., 2008, Liu et al., 2009, Yang et 
al., 2007). 64Cu-labeled phosphonium cations have emerged as a promising 
new class of PET radiotracers with high tumour selectivity and uptake (Wang et 
al., 2007, Zhou and Liu, 2011).
1.3.3.6 Mitochondria Targeted Antioxidants
In contrast to sending drugs to the site of mitochondria to kill cells, therapeutic 
agents may also be used to protect the cell; the mitochondrial respiratory chain 
is a major source of ROS within the cell and the accumulation of these oxidative 
species contribute to a number of degenerative diseases (Raha and Robinson, 
2000, Finkel and Holbrook, 2000). Protecting the mitochondria from oxidative 
damage is an attractive proposition, however the use of antioxidants to halt the 
progression of oxidative damage related disease has had limited success, one 
reason could be due to the non-specific targeting of the antioxidants which 
means that only a small fraction of the given dose is actually taken up by the 
mitochondria, consequently there has been considerable interest in developing 
mitochondria-specificantioxidants (Smith etal., 1999, Sheu etal., 2006, Murphy 
and Smith, 2007).
Researchers have taken advantage of the fact that LPCs are specifically 
accumulated in the mitochondria; the first mitochondria-targeted antioxidant 
MitoE2, which consists of the a-tocopherol moiety of vitamin E conjugated to a 
TPP cation by a two-carbon chain was reported by Smith and colleagues (Smith 
et al., 1999). To date, a number of mitochondria-targeted antioxidants have 
been published, these include mitochondria-targeted nitroxide (Mito-carboxy 
proxy) which consist of a carboxy proxy conjugated to TPP (Dhanasekaran et 
al., 2005), MitoPeroxidase which contains an ebselen moiety covalently linked 
to a TPP cation (Filipovska et al., 2005), MitoPBN a derivate of spin trap a- 
phenyl-A/-ferf-butylnitrone incorporating the TPP moiety (Murphy et al., 2003) 
and MitoQ (ubiquinone conjugated to TPP) (Kelso et al., 2001, James et al., 
2005, Cocheme et al., 2007).
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1.3.3.7 Mitochondria Targeted Peptides
Recently, peptides have been conjugated to the TPP cation to facilitate delivery 
to the site of mitochondria; Abu-Gosh and colleagues (Abu-Gosh et al., 2009) 
have covalently linked a hydrophilic peptide Hemagglutinin A (HA) to a varied 
number of TPPs (0-3), data showed that increasing the number of TPP cations 
in the HA-TPP conjugates result in significant improvement in cellular uptake 
and mitochondrial localisation. Kolevzon and co-workers (Kolevzon etal., 2011) 
have conjugated a pro-apoptotic peptide D-(KLAKLAK)2 that induces 
mitochondria-dependent apoptosis but suffers from poor uptake in the cells to 
multiple TPPs (0-3), the biological activity of the peptide as a pro-apoptotic 
agent was dramatically increased with the attachment of three TPPs.
1.3.4 Mitochondria-Specific Nanocarriers
Several types of nanosystems have been developed for mitochondrial targeting: 
including DQAsomes (DeQuAlinium based liposome-like vesicles) (D'Souza et 
al., 2003b), liposomes (nanolipid vesicles) (Boddapati et al., 2005) and solid 
nanoparticles (Weissig and Torchilin, 2000) each system will be described in 
more detail below.
1.3.4.1 DQAsomes
DQAsomes were proposed as the first nanoscale mitochondria-specific drug- 
delivery system in the late 1990s; these drug carriers have been designed 
based on the basis that amphiphilic cations with a delocalised centre were able 
to accumulate inside the mitochondria of living cells in response to the 
mitochondrial transmembrane potential. (Weissig et al., 1998). DQAsomes 
were the first delivery vector capable of selectively delivering plasmid DNA to 
mitochondria within living mammalian cells and thus opening doors to 
mitochondrial gene therapy (D'Souza etal., 2007, D'Souza etal., 2003a).
Weissig’s group have also investigated the use of DQAsomes as mitochondria 
specific drug carriers for low-molecular-weight compounds; in vitro and in vivo 
data from on-going investigation in Weissig’s lab strongly suggest that 
encapsulating paclitaxel into this delivery system increases the bioavailability of 
this drug in the mitochondria and subsequently improve the drugs’ therapeutic 
efficiency (Cheng etal., 2005).
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1.3.4.2 Liposomes
The application of phospholipid vesicles (liposomes) as drug delivery vehicles 
were developed during the 1970s and 1980s and were available on the market 
from the mid 1990’s. The first liposomal formulation Doxil® (doxorubicin stealth 
liposomes) was approved by the food and drug administration (FDA) in 1995, 
since then other liposomal formulations including Daunome® (daunorobicin), 
AmBiosome® (amphotericin) and DepoCyte® (cytarabine) have also entered 
the market (Durazo and Kompella, 2012).
With several products approved by the FDA, liposomes have become the most 
investigated class of nanovehicles for mitochondrial-targeted therapeutics. The 
advancement of liposomes in targeted mitochondrial research is essentially 
attributed to Professor Volkmar Weissig's research group (Boddapati et al., 
2005, Boddapati et al., 2008, Boddapati et al., 2010, Patel et al., 2010, Weissig 
et al., 2006). On-going research in Weissig’s group is exploring the feasibility of 
utilising mitochondria-specific liposomes for the targeted delivery of pro- 
apoptotic agents to enhance the drug’s bioavailability and therapeutic efficiency 
(Weissig et al., 2007).
1.3.4.3 Solid Nanoparticles
In theory, membrane probes could enter mitochondria through a number of 
mechanisms including PT pores, mitochondrial apoptosis related channels, 
apoptosis-related ceramide pores, damage to the outer mitochondrial 
membrane, translocase of the outer membrane 40 (TOM40) and voltage- 
dependent anion channel (VDAC) (Mannella, 1998, Guo etal., 2004, Crompton, 
1999, Siskind et al., 2006, Halestrap, 2005). However only the latter two are 
relevant to normal mitochondrial function, while the others are related to 
apoptosis or PT related mitochondrial swelling. The internal diameter of TOM 
has been determined to be between 2.0-2.6 nm using nanogold clusters 
conjugated to precursor proteins, this eliminated TOM40 as a possible entry 
route for nanoparticles > 3 nm in size (Schwartz and Matouschek, 1999).
Salnikov and colleagues investigated the permeability of the OMM using 
calibrated AuNPs of different sizes (d = 3 and 6 nm) (Salnikov et al., 2007, 
Parfenov et al., 2006); the results showed that under control conditions the
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OMM was impermeable to 6 nm AuNPs, in contrast 3 nm AuNPs could enter 
the mitochondrial intermembrane space in mitochondria of both permeabilised 
cells and isolated cardiac mitochondria.
The authors also established that the voltage-dependent anion channel (VDAC) 
was the port of entry for the 3 nm AuNPs; if the AuNPs were entering the 
mitochondria through the VDAC, inhibition of VDAC should therefore prevent 
their entry, because in the closed state the VDAC is only permeable to small 
cations (Rostovtseva et al., 2005). Even in the presence of VDAC inhibitors 3 
nm AuNPs were still able to enter the MIMS, therefore the AuNPs must have 
entered the MIMS through the VDAC. Based on the data obtained, the authors 
were able to assess the physical diameter of the VDAC pore is likely to be > 3 
nm and < 6 nm.
A synthetic strategy for attaching mitochondria targeting moiety (Weissig, 2003) 
to the surface of AuNPs was introduced by Ju-Nam and co-workers (Ju-Nam et 
al., 2006), it will be interesting to compare the mitochondrial accumulation inside 
living cells of plain 3 nm AuNPs reported by Parfenov and colleagues (Parfenov 
et al., 2006) with AuNPs of the same size coated with mitochondria specific 
targeted ligands (Weissig et al., 2007).
1.4 Hypothesis
Functionalised AuNPs are known to passively accumulate around tumours due 
to the phenomenon of the EPR effect (Wang and Thanou, 2010). AuNPs have 
the unique ability to absorb energy from an electromagnetic radiation source, 
causing them to become excited, generating local heating of tumour cells, a 
process known as PTT (Cherukuri et al., 2010). This local heating can be 
enhanced by synthesising AuNPs that can be directed to target tumour cells, or 
to sub-cellular organelles such as mitochondria.
Mitochondria play a crucial role in controlling apoptosis and thus making them 
an attractive pharmacological target for cancer therapeutics (Smith et al., 2012). 
LPCs are readily taken by cells and are preferentially accumulated in the 
mitochondria of tumour cells due to the elevated membrane potential observed 
in cancer cells (Ross et al., 2005). By synthesising AuNPs with diameter in the
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region of 3 nm functionalised with LPCs should result in their specific 
accumulation in the mitochondria, as it has been demonstrated that AuNPs with 
a diameter of 3 nm are able to permeate through both the outer and inner 
mitochondrial membrane (Salnikov et al., 2007). Therefore AuNPs 
functionalised with LPCs should lead to mitochondria specific accumulation 
inside tumour cells,when the cells are irradiated with a light source, the AuNPs 
will become excited, consequently rupturing the mitochondrial membrane, 
releasing cytochrome c into the cytosol and triggering the caspase cascade 
which ultimately induces apoptosis (Figure 1.8).
nucleus
C ~ ^ > Normal Cell Tumour Cell P-AuNPs Mitochondria
Light Source
Heat
Apoptosis
Figure 1.8 Diagram illustrating the hypothesis. TPP conjugated on the surface 
of AuNPs should lead to the specific delivery of AuNPs inside the mitochondria 
of cancer cells. When cells are irradiated with a light source the AuNPs should 
become excited, rupturing the membrane, causing the release of cytochrome c 
from the mitochondrial intermembrane space, triggering the caspase-3 
activation and inducing apoptosis.
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1.5 Scope of Thesis
The main aims of the work reported in this thesis include the synthesis and 
detailed characterisation of phosphonium ligands and phosphonium- 
functionalised AuNPs, the validation of use of these compounds inside cells, 
and to investigate their potential as PTT agents.
Chapter 3 describes the synthesis and the detailed characterisation of 
phosphonium compounds and phosphonium-functionalised AuNPs using a 
variety of techniques.
Chapter 4 presents the cytotoxicity studies of phosphonium ligands and the 
semi-quantification uptake studies of phosphonium compounds in cells using 
mass spectrometry.
Chapter 5 evaluates the possibility of using P-AuNPs as PTT agents, and their 
uptake in cells by electron microscopy.
Chapter 6 summaries the work reported in this thesis and makes some 
conclusions along with recommendations for future studies.
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Chapter 2.
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2.1 Solvents
General solvents including acetonitrile (MeCN), methanol (MeOH), ethanol 
(EtOH), dichloromethane (DCM), diethyl ether were all laboratory grade 
reagents acquired from Fisher Scientific (Loughborough, Leicestershire, UK). 
Deionised water (DIH2O) was purified in house by ELGA PURELAB Maxima 
system (18.2 MQ).
2.2 Thin Layer Chromatography
Analytical thin layer chromatography (TLC) was performed on Alugram, SIL 
G/UV254 plates using 80:20 DCM:MeOH as the mobile phase. All samples 
analysed were dissolved in DCM.
2.3 Nuclear Magnetic Resonance
1H and 31P nuclear magnetic resonance (NMR) spectra were obtained in 
deuterated chloroform (CDCI3) or deuterated DCM (CD2CI2) on a Brucker 
AVANCE III (400 MHz) NMR spectrometer (Brucker, Coventry, West Midlands, 
UK). NMR proton and 31P spectra were interpreted by using NMR interpretation 
tables (Sorensen, 2006, Duus, 2002).
2.4 Fourier Transform Infrared Spectroscopy
Fourier transform infrared (FTIR) spectra were recorded on a PerkinElmer 
spectrum 100 FTIR spectrometer (PerkinElmer, Waltham, Massachusetts, USA). 
FTIR spectra were interpreted using interpretation tables (Giinzler and 
Gremlich, 2002, Larkin, 2011).
2.5 Elemental Analysis
All samples submitted for elemental analysis were dried in an oven at 60°C. 
Carbon and Hydrogen analysis were carried out by MEDAC Ltd (Chobham, 
Surrey, UK). Values obtained are compared to the calculated therotically value.
2.6 X-Ray Crystallography
The compounds dissolved in DCM, were placed in a sealed container 
containing diethyl ether which was left to slowly diffuse into the DCM solution. 
Samples were than submitted for analysis by the UK National Crystallography
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Service at the University of Southampton (School of Chemistry, Highfield, 
Southampton, UK).
2.7 Ultraviolet-Visible Spectroscopy
Ultraviolet-visible (UV-vis) absorption spectra of aqueous colloidal solutions 
were recorded at room temperature on a Jenway 6715 UV/Vis 
spectrophotometer (Bibby Scientific Limited, Stone, Staffordshire, UK) with UV- 
quartz cuvettes (1 mm optical path). Spectra obtained were compared to 
spectra reported in the literature for gold nanoparticles of similar size (Daniel 
and Astruc, 2004).
2.8 Electrospray Ionization Mass Spectrometry
Samples were dissolved in EtOH: DIH20  (50:50) to a concentration of 
approximately 1 mg/mL for molecular ion determination. Electrospray mass 
spectra were recorded using a Thermo Finnigan MAT LCQ classic electrospray 
ionisation mass spectrometer (ESI-MS) (Thermo Scientific, Sanjose, California, 
USA) in positive ion mode. Samples were introduced by direct infusion using 
the syringe pump on the instrument at a flow rate of 5 pL/min with an acquisition 
time of one minute. Spectra obtained are compared to the expected value of the 
compounds and calculating the possibility of cleaved peak, to confirm the 
correct compound has been synthesised.
2.9 Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry
Matrix-assisted laser desorption ionisation mass spectrometry (MALDI-MS)) 
and laser desorption ionisation mass spectrometry (LDI-MS) experiments were 
performed in positive ion mode on an applied Biosystems/MDS Sciex hybrid 
quadrupole time-of-flight mass spectrometer (Q-Star Pulsar-/) with an 
orthogonal MALDI ion source (Applied Biosystems, Foster City, California, USA) 
and a high repetition Neodymium-doped yttrium vandate (Nd: YVO4 laser (5 
KHz)) (Elforlight Ltd, Daventry, Northamptonshire, UK). Spectrum were 
collected with an acquisition time of one minute.
In MALDI experiments, the compound analysed was dissolved in a solution of 
small organic molecules in a solvent called the matrix. Prior to analysis, this
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mixture is dried so the solvent is removed, and result in a “solid solution” 
deposit of analyte-doped matrix crystals. A matrix is incorporated into the 
sample preparation stage to provide efficient desorption and soft ionisation, 
hence the name matrix assisted laser desorption ionisation. CHCA is the most 
common matrix used for the analysis of small molecules and is also known as 
the universal matrix (Hoffmann and Stroobant, 2007). MALDI matrices were 
made to a concentration of 10 mg/mL in 70:30 MeCN: water with 0.1% TFA.
MALDI analysis of AuNPs were conducted using an Applied Biosystems MALDI 
TOF Voyager De-STR mass spectrometer (Applied Biosystems, Foster City, 
California, USA) equipped with a 355 nm Nd-YAG solid state laser operating at 
a repetition rate of 60 Hz. 100 shots were accumulated per spectrum, the 
accelerating voltage was set at 93% and the delay time was 150 ns.
For analysis, the peak area of the analyte was divided by the peak area of the 
internal standard to give an analyte to internal standard ratio. The standard 
curve for PPTA and FPPTA are plotted by plotting the concentration of the 
compound with the respective analyte to internal standard ratio.
2.10 Inductively Coupled Plasma Optical Emission Spectrometry
Inductively coupled plasma optical emission spectrometry (ICP-OES) analyses 
were performed on a HORIBA Jobin Yvon ACTIVA (HORIBA Scientific, 
Stanmore, Middlesex, UK). Calibration curves were generated from ICP- 
standard solutions purchased from Sigma Aldrich (Gillingham, Dorset, UK).
2.11 Thermogravimetric Analysis
Thermogravimetric analyses (TGA) were carried out on a Mettler Toledo 
(Beaumont Leys, Leicester, UK) TGA/DSC (Materials and Engineering 
Research Institute, Sheffield Hallam University, Sheffield, UK). 5mg of AuNPs 
were initially held at 35°C for 15 minutes and then heated to 800°C at 20°C/min 
with a gas flow rate of 40 mL/min under nitrogen atmosphere.
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2.12 X-Ray Photoelectron Spectroscopy
Freeze-dried P-AuNPs were sent to the Experimental Techniques Centre (ETC) 
at Brunei University for analysis. X-ray photoelectron spectroscopy (XPS) 
measurements were made on a VG Escalab 210 Photoelectron Spectrometer 
(ETC, Brunei University, Middlesex, UK). The X-ray source was a non- 
monochromated Al Ka source (1486.6 eV), operated with an X-ray emission 
current of 20 mA and an anode high tension (acceleration voltage) of 12 kV. 
Freeze-dried sample was placed on a standard sample stud using double sided 
adhesive tape with a take-off angle fixed at 90° relative to the sample plane. 
The area of each acquisition was 0.79 mm2.
Each analysis consisted of a wide survey scan (pass energy 50 eV, 1.0 eV step 
size) and high-resolution scans (pass energy 50 eV, 0.05 eV step size) for 
component speciation. The binding energy scale of the instrument was 
calibrated using the Au 4 f5/2 (83.9 eV), Cu 2 p3/2 (932.7 eV) and Ag 3 ds/2 (368.27 
eV) lines of cleaned gold, copper and silver standards obtained from the 
National Physical Laboratory, UK. CasaXPS 2.3.15 software was used to fit the 
XPS spectra peaks, and the binding energies obtained in the XPS spectra were 
corrected for specimen charging by referencing the C 1s to 284.6 eV.
2.13 Secondary Ion Mass Spectrometry
Freeze-dried P-AuNPs were sent to the Experimental Techniques Centre (ETC) 
at Brunei University for analysis. Secondary ion mapping studies were 
performed with a Kore Technology Ltd. time-of-flight secondary ion mass 
spectrometry (TOF-SIMS) instrument (ETC, Brunei University, Middlesex, UK). 
Using a 25 keV Indium primary ion source 9FEI Liquid Metal Ion Gun operating 
at 1 pA current. Secondary ions were analysed in a reflectron mass 
spectrometry and detected with a dual microchannel plate assembly. Flight 
times were recorded with a 0.5 ns time-to-digital converter. Spectra were taken 
from an area of approximately 250 x 250 pm. Freeze-dried AuNPs was placed 
on a standard sample stud using double-sided adhesive tape. Calibration of the 
mass spectra was established by defining a common series of CxHy peaks with 
a known mass using the mass calibration function in the instrument’s software.
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2.14 Transmission Electron Microscopy
For particle size distribution analysis, freeze-dried P-AuNPs were sent to the 
Experimental Techniques Centre (ETC) at Brunei University for analysis. 
Freeze-dried P-AuNP samples were re-suspended in ethanol, and placed on a 
Holey coated copper grid, and the grids were left to dry in air at room 
temperature. The grid was then examined using a Jeol 2000 FX transmission 
electron microscope (TEM) (ETC, Brunei University, Middlesex, UK), set at 200 
KV. A few images were acquired under bright field mode and particle size 
distribution was obtained over 1000 AuNPs using Abel imaging software.
PC3 cells treated with P-AuNPs were fixed in 2% aqueous osmium tetroxide 
and embedded in epoxy resin. The samples were taken to ETC at Brunei 
University for sectioning using a PowerTome XL Ultramicrotome (Boeckeler, 
Tuscon, Arizona, USA). The sections 100nm in thickness were placed on a 
Holey coated copper grid, the grid was then examined using a Joel JEM-21 OOF 
TEM, set at 100 KV.
2.15 Cell Culture
Human prostate cancer cells (PC3) obtained from ATTC were maintained in 
complete media (cDMEM) which contains Dulbecco’s modified Eagle medium 
with GlutaMAX, 4.5 g/L D-Glucose and sodium puruvate (Invitrogen Life 
Technologies, Paisley, Renfrewshire, UK) containing 10% heat-inactivated fetal 
bovine serum (Biosera, East Sussex, Sussex, UK) and 1% penicillin- 
streptomycin (Invitrogen Life Technologies, Paisley, Renfrewshire, UK) at 37°C 
in 5% CO2 and 95% air. Cells were sub-cultured every 3 days and routinely 
screened for mycoplasma.
2.16 Cytotoxicity Assay
Cytotoxicity was assessed using CellTiter-Glo luminescent cell viability assay kit 
(Promega Corporation, Southampton, Hampshire, UK). Cell viability was 
measured according to the manufacturer’s instructions. In brief plates were 
equilibrated at room temperature for 30 minutes, 100 pL of assay reagent was 
added to each well, placed on an orbital shaker for 2  minutes, left to stand at 
room temperature for 10 minutes and read on a Wallac Victor2 1420 multilabel
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counter (PerkinElmer, Cambridge, Cambridgeshire, UK). For detailed 
experimental procedure refer to chapter 4.2.2.
Data obtained are expressed as a percentage of live cells normalised to control. 
The average, standard deviation and IC50 values were plotted and calculated 
using GraphPad Prism (GraphPad software, La Jolla, California, USA). 
Staistical analyses were then conducted using the method described below in 
chapter 2.16.
2.17 Statistical Analysis
Cell viability and microscopy data obtained in this project were found to be non- 
parametric in distribution, thereby the Kruskall-Wallis with Conver Inman post 
hoc analysis test was used to identify sinficant differences between treatments 
(P < 0.05). All statistical analyses were performed on StatsDirect statistics 
software (StatsDirect Ltd, Cheshire, UK).
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Chapter 3.
The synthesis and characterisation of
phosphonium ligands and phosphonium- 
functionalised gold nanoparticles
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3.1 Introduction
Functionalised or tagged AuNPs are readily taken-up by cells making them an 
attractive delivery platform for transporting drugs, biomolecules and other 
therapeutic agents into the cells (Giljohann et al., 2010, Thanh and Green, 
2010). The surface of AuNPs can be coated with a diverse range of ligands; the 
most widely used ligands for protecting AuNPs are organic thiolates derived 
from thiols (Ulman, 1996, Shon et al., 2000) or disulfides (Heister et al., 1999, 
Biebuyck and Whitesides, 1993).
Thiolate-protected AuNPs offer great stability, can easily be isolated, re­
suspended in a range of solvents, and most importantly they can be 
manipulated and functionalised further with a diverse range of organic and 
biological compounds to enhance selectivity, sensitivity and practicality for 
specific applications (Daniel and Astruc, 2004). Other ligands commonly used 
include citrate (Turkevich et al., 1951, Frens, 1973) and tertiary phosphines 
(Shem et al., 2009).
Incorporating ionic ligands to the surface of AuNPs is an attractive proposition 
for improving the aqueous solubility of the AuNPs thereby facilitating cellular 
uptake and biomolecular recognition through non-covalent interactions (Verma 
and Stellacci, 2010). Thiolate derivatives of carboxylic acids have been used to 
produce anionic charged AuNPs (Cho et al., 2009, Song et al., 2003), thiolates 
incorporating ammonium groups (McIntosh et al., 2001, Sandhu et al., 2002) 
including tetraoctylammonium thiosulfate (Isaacs et al., 2005) and cetyl 
trimethylammonium bromide (Vigderman et al., 2012) or other cationic nitrogen 
systems such as ethidium (Wang et al., 2002) have been used to synthesise 
cationic charged AuNPs. Zwitterionic ligands for example a thiolate 
incorporating an ammonium alkyl sulfonate head group (Rouhana et al., 2007) 
and phosphorylcholine thiolate (Jin et al., 2008), have been employed to 
generate neutral AuNPs.
While there have been many reports on the use of organophosphorous ligands, 
particularly phosphines (Shem et al., 2009) and phosphine oxides (Green and 
O'Brien, 2000) to produce functionalised AuNPs, there have been fewer studies
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on the use of organophosphorus ligands to impart functionality. Examples 
include tris(hydroxymethyl)phosphine which has been used to synthesise 
AuNPs that form conjugates with DNA (Harnack et al., 2002) and cadmium 
selenide nanoparticles have been prepared using phosphonium ionic liquid 
trihexyl(tetradecyl)phosphonium bis(2,4,4-trimethylpentylphosphinate) to 
enhance surface passivation (Green et al., 2007).
Organic phosphonium salts are an important class of lipophilic cations that are 
readily taken-up by cells and are preferentially accumulated in the mitochondria; 
this has resulted in the use of phosphonium compounds as agents for tumour 
imaging, cancer therapeutics and as intra-cellular transport vectors (Ross et al.,
2005). With this in mind Bricklebank and co-workers have previously published 
the synthesis of a series of phosphonioalkylthiosulfate zwitterions (Ju-Nam etal.,
2006) and ca-thioacetylalkylphosphonium salts (Ju-Nam et al., 2008) that 
behave as "masked thiolate" ligands, in which the thiolate group is protected as 
a thiosulfate or thioacetate. Under reducing conditions or in contact with the 
surface of Au, the sulfur-sulfur or sulfur-carbon bond cleaves respectively to 
yield cationic-functionalised AuNPs.
It has been demonstrated that the rate and extent of uptake of phosphonium 
compounds in vitro are affected by the hydrophobicity of the compound (Ross et 
al., 2008). The addition of fluorine has been routinely applied in medicinal 
chemistry to modify the physiochemical properties of drugs; fluorine has been 
incorporated into compounds to improve metabolic stability, lipophilicity and 
binding affinity with an overall target to increase the bioavailability of the product 
(Bohm et al., 2004, Filler and Saha, 2009). Fluorinated drugs have been used to 
treat a range of human disorders including the central nervous system, 
cardiovascular diseases, obesity (Kirk, 2006) and cancer (Isanbor and O’Hagan, 
2006).
Furthermore phosphonium compounds labelled with radioactive 18F have been 
developed as a new class of lipophilic positron emission tomography (PET) 
radiotracers. There is an increasing demand in a clinical setting for PET 
myocardial perfusion imaging, however conventional single photon emission
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tomography (SPECT) suffers from technical limitations including low spatial 
resolution and tracer inhomogeneities. Although PET overcomes the downfalls 
of SPECT, PET tracers currently used for myocardial imaging including [13N]- 
ammonia, 82Rb and [150 ]H2 0 , all of which have short half-lives and require an 
on-site cyclotron or generator thus limiting clinical applications of PET (Kim et 
al., 2 0 1 2 ).
Analogues of TPMP labelled with 18F have been exploited as PET tracers since 
phosphonium cations exhibit similar properties to popular SPECT tracers such 
as [99mTc]-sestarnibi and [99mTc] tetrofosmin in terms of increasing accumulation 
in cardiomyocytes compared to normal cells (Madar et al., 2007). A number of 
18F labelled phosphonium radiotracers have been synthesised, these include (4- 
[18F]fluorophenyl)triphenylphosphonium (a) (Cheng et al., 2005) 3-
[18F]fluoropropyltriphenylphosphonium (b) (Ravert et al., 2004), [18F](2-(2- 
fluoroethoxy)ethyltris(4-methoxyphenyl)phosphonium (d) (Kim et al., 2012) and 
18F-fluorobenzyltriphenylphosphonium (c) (Madar et al., 2006). The latter has 
also been investigated for quantifying time-dependent apoptotic action both in 
vitro and in vivo (Madar et al., 2009).
OM e
Figure 3.1 Chemical structures of phosphonium PET radiotracers; a) (4-[18F] 
fluorophenyl)triphenylphosphonium, b)3[18F]fluoropropyltriphenylphosphonium, 
c) 18F-fluorobenzyltriphenylphosphonium and d) [18F](2-(2- 
fluoroethyoxy)ethyltris(4-methyoxphenyl)phosphonium.
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Recently it has been demonstrated the incorporation of phosphonium groups 
into the lipid bilayer of liposomes or onto the surface of dendrimers or core-shell 
nanoparticles can facilitate their preferential uptake by mitochondria (Weissig, 
2011, Biswas etal., 2012, Weissig etal., 2008, Weissig etal., 2009, Wang etal., 
2013). Thereby the attachment of phosphonium compounds to the surface of 
nanoparticles has emerged as an attractive proposition for mitochondria- 
targeted pharmaceutical nanotechnology.
The work presented in this chapter includes the synthesis of phosphonium 
ligands incorporating fluorine which are used as protecting ligands to produce 
cationic functionalised AuNPs. In addition the detailed characterisation of water- 
soluble phosphonioalkylthiolate-capped AuNPs will also be reported.
3.2 Materials and Methods
3.2.1 Chemicals
All chemicals were used as received: 3(bromopropyl)triphenylphosphonium 
bromide, tris(4-fluorophenyl)phosphine, sodium thiosulfate (Na2S2 0 3 ), 
potassium thioacetate (KSCOCH3), gold(lll) chloride trihydrate (HAuCI4), 
hydrobromic acid (HBr), potassium bromide (KBr), magnesium sulfate (MgSCU) 
were obtained from Sigma-Aldrich (Gillingham, Dorset, UK). Deuterated 
chloroform and dichloromethane NMR solvents and an ICP Au standard were 
purchased from Sigma-Aldrich (Gillingham, Dorset, UK).
3.2.2 Synthesis of Phosphonium Compounds
3-triphenylphosphoniopropylthiosulfate (PPTS) (2) and (3- 
thioacetylpropyl)triphenylphosphonim bromide salt (PPTA) (3) were synthesised 
using methods described by Ju-Nam and colleagues (Ju-Nam et al., 2006, Ju- 
Nam et al., 2008). In brief, both compounds were prepared by either refluxing 
(3-bromopropyl)triphenylphosphonium bromide (1) (1.0 g, 2.15 x 10‘3 mol) with 
Na2S2 0 3  (0.8 g, 3.23 x 10' 3 mol) in aqueous EtOH or stirred overnight under 
nitrogen with KSCOCH3 (0.37 g, 3.23 x 10' 3 mol) to obtained products (2) and (3) 
respectively. The progress of the reaction was monitored by TLC, using 80:20 
DCM:MeOH as the mobile phase; upon completion KBr (20mL, 10% w/w) was 
added prior to isolating the bromide salt (3). Both compounds were obtained by
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solvent extraction with DCM (3x10 mL) and purified by triturating with diethyl 
ether and characterised by FTIR, ESI-MS and NMR.
Na2S20< 
EtOH (aq
3
P.+
(1 ) \
Br
i) KSC(0)CH3 EtOH (aq)
ii) KBr (aq)
SV c h 3o
(3)
Figure 3.2 Synthesis scheme for 3-triphenylphosphoniopropylthiosulfate (PPTS) 
(2) and (3-thioacetylpropyl)triphenylphosphonim bromide salt (PPTA) (3).
3.2.3 Synthesis of Tri(p-fluorophenyl)phosphonium Compounds
Tri(p-fluorophenyl)phosphoniopropyl thiosulfate zwitterion (FPPTS) (7) and w- 
thioacetylpropyl(tri-p-fluorophenyl)phsophonium bromide (FPPTA) (8 ) were 
synthesised following protocols reported by Ju-Nam and co-workers (Ju-Nam et 
al., 2006, Ju-Nam et al., 2008). Both compounds were generated by refluxing 
tris(4-fluorophenyl)phosphine (4) (1.0 g, 3.16 x 10‘3 mol) with 3-bromo-1- 
propanol (1.1 mL, 1.25 x 10‘2 mol) in MeCN (20 mL) overnight to obtain tris(4- 
fluorophenyl)hydroxypropylphosponium salt (5). The salt (5) was then treated 
with HBr (48%, 10 mL) and refluxed overnight to yield the (3-bromopropyl)tris(4- 
fluorophenyl)phosphonium salt (6 ). The salt (6 ) (0.250 g, 5.70 x 10-4 mol) was 
refluxed overnight with Na2S2 0 3  (0.212 g, 8.56 x 10-4 mol) in aqueous EtOH or 
stirred overnight under nitrogen with KSC(0 )CH3 (0.098 g, 8.56 x 10‘4 mol) in 
aqueous EtOH to obtained the zwitterion (7) and the bromide salt (8 ) 
respectively. The progress of the reaction was monitored by TLC, prior to 
isolating the intermediate salt (5) 10 mL of DIH2O was added; all compounds 
were obtained by DCM extraction ( 3X10  mL) and purified by triturating with 
diethyl ether. All intermediates and end products were confirmed by conducting 
ESI-MS, FTIR and NMR analysis.
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Figure 3.3 Synthesis scheme for Tri(p-fluorophenyl)phosphoniopropyl 
thiosulfate zwitterion (FPPTS) (7) and u)-thioacetylpropyl(tri-p- 
fluorophenyl)phsophonium bromide (FPPTA) (8 ).
3.2.4 Synthesis of Phosphonium-Functionalised Gold Nanoparticles
Phosphonium-functionalised AuNPs were synthesised based on methods 
described previously (Ju-Nam et al., 2006, Ju-Nam et al., 2008); in brief a 
solution of the phosphonium compound corresponded to the protecting ligand 
(0.25 mmol) was prepared in HAuCI4 (0.12 mmol) and DCM (15 mL). The 
solution was stirred vigorously under nitrogen for 6  hours, subsequently NaBH4 
(3 mL, 400 mmol L'1) was added drop wise followed by the addition of DIH2O 
(15 mL) and stirred under nitrogen overnight. After 24 hours the colloidal 
solution was purified by DCM extraction (3x10 mL), freeze dried, flushed with 
nitrogen and retained for further analysis.
3.2.5 Characterisation of Phosphonium Ligands
All phosphonium ligands were characterised using a range of techniques 
including 1H and 31P NMR, ESI-MS, FT-IR. FPPTS and FPPTA were further 
characterised by elemental analysis, x-ray crystallography and accurate mass 
analysis by MALDI. Mass spectra from Analyst software were exported in the 
form of text files and imported into mMass, an open source mass spectrometry 
software used for mass spectral processing (Strohalm et al., 2010).
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3.2.6 Characterisation of Phosphonium-Functionalised Gold 
Nanoparticles
Phosphonium-functionalised gold nanoparticles were characterised by 31P NMR, 
UV-Vis, MALDI-MS, ICP, TGA, XPS and TEM as outlined in chapter 2. MALDI 
matrices were made to a concentration of 10 mg/mL in 70:30 MeCN:H2 0 , for 
positive ion mode analysis an additional 0.1% TFA was added to the matrix 
solution.
3.3 Results and Discussion
3.3.1 Synthesis of Phosphonium Ligands
3.3.1.1 3-Triphenylphosphoniopropylthiosulfate (PPTS)
Colourless crystals, 5 31P NMR (CDCI2) = 23.3 ppm, 5 31P NMR (CDCI2) = 2 . 2  
(2H, m), 3.3 (2H, m), 3.6 (2H, m), 7.6-8.0 ppm (15H, m). ESMS 417.1 [M+H]+,
439.1 [M+Na]+. All results obtained supported the successful synthesis of PPTS.
3.3.1.2 (3-Thioacetylpropyl)triphenylphosphonium Bromide Salt (PPTA)
Isolated as a pale yellow powder, 5 31P NMR (CDCI3) = 24.3 ppm, 5 31P NMR 
(CDCI3) = 1.7 (3H, m), 2.0 (2H, m), 3.0 (2H, m), 4.1 (2H, m), 7.5-8.0 ppm (15H, 
m). ESMS 379.2 [M]+, 380.2 [M+H]+. FT-IR = 1680 cm' 1 v(C=0). All results 
obtained supported the successful synthesis of PPTA.
3.3.1.3 Tri(p-fluoropheny)phosphoniopropyl thiosulfate zwitterion (FPPTS)
The chemical structure of FPPTS is shown in Figure 3.4. This compound was 
isolated as colourless crystals and is soluble in polar organic solvents including 
DCM, MeOH and MeCN. All analytical and spectroscopy data support the 
formulation of this compound.
F
F
Figure 3.4 Chemical structure of FPPTS.
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Formula: C21H18F3O3PS2 
ESI-MS: 471 [M+H+], 493 [M+Na+].
NMR: 6  31P NMR (CDCI2) = 23.4 ppm; 5 1H NMR (CDCI2) = 2.2 (2H, m), 3.2 (2H, 
m), 3.6 (2H, m), 7.3-7.9 (12H, m) ppm.
Elemental analysis: found: C, 53.89; H, 3.93; C21H18F3O3PS2 requires: C, 
53.61; H, 3.86.
Accurate mass analysis: found 471.0474 [M]+; cation C21H-18F3O3PS2 requires 
433.471.0465 [M f.
X-ray crystallography: The structure of FPPTS was confirmed by x-ray 
crystallography. Single crystals of FPPTS were grown by slow diffusion of a 
diethyl ether into a DCM solution of FPPTS which gave colourless needles. The 
crystals were sent for full structure analysis at the EPSRC X-ray 
Crystallography Service at the University of Southampton. The molecular 
structure is shown in Figure 3.5, selected bond lengths and bond angles are 
listed in Table 3.1. Crystal data and structure refinement details are presented 
in appendix 1 .
nil
Figure 3.5 An Ortep representation of the molecular structure of FPPTS. 
Thermal ellipsoids are drawn at 50% probability level.
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P1-C11 1.792(5) S1-S2 2.0930(18)
P1-C111 1.784(5) S2-011 1.442(3)
P1-C121 1.791(5) S2-012 1.444(3)
P1-C131 1.788(5) S2-013 1.447(3)
S1-C13 1.824(5)
C121-P1-C11 109.9(2) 011-S2-012 113.9(2)
C131-P1-C121 108.3(2) 01 1-S2-013 114.9(2)
C131-P1-C11 110.4(2) 012-S2-013 1 1 2 .2 (2 )
C111-P1-C121 109.5(2) 01 1-S2-S1 101.24(15)
C111-P1-C11 109.8(2) 012-S2-S1 106.94(15)
C111-P1-C131 108.9(2) 013-S2-S1 106.58(17)
C13-S1-S2 100.27(17)
C116-C13-P1 120.1(4)
C12-C13-S1 111.5(3)
Table 3.1 Selected bond lengths [A] and angles [°] in FPPTS.
Perhaps surprisingly, the structures of few other organic thiosulfate zwitterions 
have been described in the literature. The crystal structures of the triphenyl 
(Figure 3.6a) and tributyl (Figure 3.6b) phosphonium zwitterions have been 
reported previously (Ju-Nam et al., 2006) and the only other example being an 
ammonium zwitterion, S-[4-(trimethylammonio)phenyl]thiosulfate (Figure 3.6c) 
(Chen et al., 2004).
a) b)
eSSOj ‘SS03
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V /
esso.
Figure 3.6 Chemical structures of thiosulfate zwitterions; a) 3- 
triphenylphosphoniopropylthiosulfate, b) 3-tributylphosphoniopropylthiosulfate 
(Ju-Nam etal., 2006) and c) S-[4-(trimethylammonio)phenyl]thiosulfate (Chen et 
al., 2004).
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Zwitterion PPTS (Figure 3.6a) exhibits the expected tetrahedral geometry 
around the phosphorus atoms with a mean C-P-C bond angle of 109.47(2)°. 
The corresponding values for the triphenyl (FPPTS, Figure 3.4) and tributyl 
(Figure 3.6b) analogues are 109.47(11)° and 109.47(17)° respectively. The 
bond lengths and angles in the aryl rings are unremarkable and the C-F bonds 
[mean length 1.359(6) A] are similar to those in the parent phosphine 
(p-FC6H4)3P [mean length 1.366(6) A] (Shawkataly etal., 1996).
The S-0 bonds in the thiosulfate group of compound FPPTS are all similar, with 
a mean length of 1.4478(19) A [c.f. 1.4478(19)A and 1.440(3) A in then phenyl 
analogue and 1.440(3) A in the butyl compound], indicative of multiple bond 
character. The mean S-S bond length [2.1081 (18) A] is slightly shorter than 
that in the phenyl derivative [2.1117(9) A], and longer than that in the butyl 
compound [2.1030(14) A], but are all longer than the established length of a 
single S-S bond [2.05 A].
The ammonium thiosulfate zwitterion (Figure 3.6c) ha an S-S bond length of 
2.1137(7) A, similar to those in FPPTS and related phosphonium zwitterions, 
but are all appreciably shorter than the S-S bond in the monoanion of 
thiosulfuric acid, HSSO3' [2.155 A] (Miaskiewicz and Steudel, 1992). The 
lengthening of the S-0 bond and S-S bonds in the zwitterions is consistent with 
the delocalisation of the negative charge across the entire thiosulfate group. 
Furthermore, the longer and weaker S-S bond of the phosphonium zwitterions 
expedites the dissociation of the thiosulfate group with the concomitant 
formation of the corresponding thiolate ion which is a key step in the application 
of these compounds in the synthesis of metal nanoparticles.
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Figure 3.7 Molecular packing in FPPTS.
The zwitterions are packed fairly loosely within the crystal lattice (Figure 3.7), 
held together in a head-to-tail manner, by hydrogen-bonding interactions 
between the sulfate oxygen’s and the phenyl hydrogen’s. Analysis of the 
supramolecular structure reveals interactions between phenyl groups on 
adjacent molecules (Figure 3.8) (Hunter and Sanders, 1990). The centroid- 
centroid distance between these two rings is 3.65 A which fits well with the 
interplaner spacing observed in stacked arenes which lie in the range between
3.6 -  3.8 A (Cozzi etal., 2008).
The molecules also display intramolecular C-F....H hydrogen bonding 
interactions between adjacent aryl rings. The F...H distance (2.409 A). The 
nature of C-F...H interactions is the subject of debate (Dunitz and Taylor, 1997, 
Reichenbacher et al., 2005). Nonetheless, the distances are shorter than the 
sum of the van der Waals radii for hydrogen and fluorine (2.67 A) and are 
similar in length to those found in other fluorine-containing organic molecules 
(Reichenbacher et al., 2005).
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Figure 3.8 Molecular packing in FPPTS with the interaction between adjacent 
phenyl rings highlighted. The distance between the centres of the phenyl rings 
is 3.65 A.
3.3.1.4 oj-thioacetylpropyl(tri-p-fluorophenyl)phosphonium Bromide
(FPPTA)
The chemical structure of FPPTA is shown in Figure 3.9. This compound was 
isolated as a pale cream powder and is soluble in organic solvents such as 
DCM, EtOH and MeOH. All analytical and spectroscopy data supported the 
formulation of this compound; x-ray crystallography data show the presence of 
a water molecule which is further supported by elemental analysis.
F
F CH.
F
Figure 3.9 Molecular structure of FPPTA.
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Formula: C23H2 iF3SOPBr 
ESI-MS: 433 [M+], 434 [M+H+],
NMR: 5 31P NMR (CDCI3) = 23.9 ppm; 5 1H NMR (CDCI3) = 1.9 (5H, m), 3.2 (2H, 
m), 4.3 (2H, m), 7.3-8.1 (12H, m) ppm.
FT-IR: 1680 cm'1 v(C=0).
Elemental analysis: found: C, 52.47%; H, 4.09%; C23H2iF3SOPBr + H20  
requires: C, 51.97%; H, 4.33%.
Accurate mass analysis: found 433.0976 [M]+; cation C23H21F3SOPBr requires 
433.1003 [M]+.
X-ray crystallography: The structure of FPPTA was confirmed by x-ray 
crystallography. Single crystals of FPPTS were grown by slow diffusion of a 
diethyl ether into a DCM solution of FPPTS which yield colourless needless. 
The crystals were sent for full structure analysis at the EPSRC X-ray 
Crystallography Service at the University of Southampton. The molecular 
structure is shown in Figure 3.10, selected bond lengths and bond angles are 
listed in Table 3.2. Crystal data and structure refinement details are presented 
in appendix 2. This compound is the first example of a 
phosphoniumalkylthioacetate salt to be characterised crystallographically.
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Figure 3.10 An Ortep representation of the asymmetric unit of FPPTA. Thermal 
ellipsoids are drawn at 50% probability level. Hydrogen atoms are omitted for 
the sake of clarity.
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C1-P1 1.783(6) C21-S1 1.783(7)
C7-P1 1.790(6) C22-S1 1.770(7)
C18-P1 1.789(6) C22-C23 1.506(10)
C19-P1 1.810(6) C22-01 1.191(8)
C21-S1 1.783(7) C4-F1 1.363(8)
C10-F2 1.354(8)
C15-F3 1.355(7)
C20-C19-P1 113.8(4) C22-S1-C21 100.4(3)
C20-C21-S1 112.2(5) 01-C22-C23 124.6(7)
C7-P1-C19 111.0(3) C23-C22-S1 112.6(5)
C18-P1-C7 109.3(3) 01-C22-S1 122.7(6)
C18-P1-C19 107.7(3) F1-C4-C5 118.9(7)
C1-P1-C7 109.6(3) F1-C4-C3 117.7(7)
C1-P1-C19 109.9(3) F2-C10-C9 117.0(8)
C1-P1-C18 109.3(3) F2-C10-C11 119.2(8)
F3-C15-C14 118.6(6)
F3-C15-C16 118.4(6)
Table 3.2 Selected bond lengths [A] and angles [°] in FPPTA.
The asymmetric unit contains two crystallographically independent 
phosphonium cations, two bromide anions and two water molecules of 
crystallisation. The compound exhibits the expected tetrahedral geometry 
around the phosphorus atom with a mean bond angle of 109.47(3)° identical to 
the zwitterion (FPPTS). The C-F bonds in the phenyl rings lie in the range
1.354(8)-1.369(2), similar to the zwitterion (FPPTS) and the parent phosphine 
which have an average length of 1.366(6) A (Ju-Nam et al., 2006).
The C-S [1.783(7) A and 1.770(7) A and C-0[1.191(8) A] bond lengths of the 
thioacetate group in FPPTA are similar to the expected distances for C-S single 
and C=0 bonds, c.a. 1.8 A and 1.2 A respectively (Huheey, 1972) and are close 
to the values reported in dimethylmonothiocarbonate, CH3 0 C(S)CH3, which has 
C-S bond lengths of 1.791(2) A, 1.759(1) A and a C=0 bond length of 1.195(2) 
A (Erben et al., 2006). The FPPTA molecules display the expected angular 
geometry around the sulfur atom with bond angles of 100.4(3)° and 101.2(4)° 
for the two cations in the unit cell.
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The molecular packing displays some interesting features (Figure 3.11); the unit 
cell contained eight cations together with eight bromide anions and the water 
molecules are associated with the bromide ions, held together through a 
complex network of hydrogen bonds and intermolecular interactions between 
the different species. The structural parameters for these hydrogen bond 
interactions are presented in Table 3.3. The molecules also display 
intramolecular C-F....H interactions which lie in the range 2.639 - 2.670 A. 
These distances are slightly longer than those observed in the FPPTA 
zwitterion and are close to the sum of the van der Waals radii of fluorine and 
hydrogen (2.67 A) but are comparable with the distances observed in other 
organofluorine compounds (Reichenbacher et al., 2005).
Figure 3.11 Unit cell of the FPPTA salt parallel to c axis.
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D -H -A  d(H-A) d(D-H) d(D-A) Z{DHA)
03-H3A-BM 0.937(18) 2.44(3) 3.347(5) 163(7)
0 3 -H 3 B -B rf 0.84(2) 2.51(2) 3.350(5) 175(7)
04-H4A—Br2ii 0.963(18) 2.35(3) 3.296(6) 165(7)
04-H4B--Br2iii 0.86(2) 2.36(5) 3.141(6) 152(9)
Table 3.3 Hydrogen bonds in FPPTA [A and °], Symmetry transformations used 
to generate equivalent atoms: (i) x,-y+1/2,z-1/2 (ii) x+1,y,z (iii) -x+1,-y+1,-z.
3.3.2 Synthesis of Phosphonium-Functionalised Gold Nanoparticles
The first indication that AuNPs had been successfully prepared was the visually 
observation of the colour change of the solutions during the synthesis; when 
HAuCU was added to the solution of the corresponding protecting ligand PPTS, 
PPTA, FPPTS and FPPTA in DCM the stirring organic solution turned yellow. 
The addition of NaBH4 induced a colour change from yellow to a characteristic 
deep red wine colour which indicated the reduction had taken place (Daniel and 
Astruc, 2004). When the reaction was stopped after 24 hours, the DCM layer 
was colourless and the aqueous phase was a dark red-purple colour for 
protecting ligands: PPTS, PPTA and FPPTS, with no evidence of aggregation 
indicating that functionalised AuNPs were present in the aqueous phase. The 
interface between the organic and aqueous phase for FPPTA, dark blue/black 
particles of aggregated colloidal gold were observed, showing no affinity with 
either the DCM or water layer. Since the use of either FPPTS or FPPTA will 
produce the same functionalised AuNPs (Figure 3.12) it was decided that 
FPPTS would be used for the synthesis of functionalised AuNPs for future 
experiments.
PPTS R=Pn
i i i) HAuCl., H..0FPPTS R= p-FC6H4    R.p
p D+ e ii) NaBH4, DCMr 3p >. CM,
PPTA R=Ph
FPPTA R= p-F C(;H4
Figure 3.12 Synthesis scheme of phoshonium-functionalised AuNPs using 
different phosphonium capping ligands.
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3.3.3 8Characterisation of Phosphonium-Functionalised Gold 
Nanoparticles
Characterisation of AuNPs is challenging but essential for their application; 
chemists rely on a number of techniques to determine the structure and purity of 
NPs synthesised these include NMR, TGA, DLS, MS and TEM (Kim et al., 
2013). Samples of AuNPs functionalised with phosphonioalkyl-thiosulfate and -  
thioacetate ligands were analysed using UV-visible spectroscopy, NMR, TGA, 
LDI, ICP, XPS and TEM.
3.3.3.1 UV-Visible (UV-vis) Spectroscopy
UV-Vis absorption spectroscopy has been widely used to characterise the 
optical properties of nanoparticles, as the absorption bands is governed by a 
number of factors predominantly the size and shape of metal nanoparticles. 
Evidence for the successful formation of AuNPs was supported by UV-vis 
spectroscopy; a broad absorption band in the visible region -520 nm was 
observed for AuNPs prepared from PPTA, PPTS and FPPTA (Figure 3.13). 
This demonstrated that all P-AuNPs synthesised were all similar in size, a peak 
absorption band -520 nm indicated that particle synthesised are between 2-10 
nm in diameter (Daniel and Astruc, 2004)However they are slight differences 
between the P-AuNPs.
The peaks for the thiosulfate species (PPTS and FPPTS) are very similar, 
which suggested that these two particles synthesised are similar in size, this 
observation is in agreement with TEM data reported in section 3.3.3.2. PPTS 
and FPPTS has a mean particle size of 3.0 nm and 2.7 nm respectively. A 
difference of 0.3 nm in size can be observed in the slight difference in the peak 
in their visible spectra shown in Figure 3.13,
Interestingly the peak for PPTS and FPPTS are different compared to the peak 
for PPTA, thereby suggesting that the particle size for PPTA are different to 
PPTS and FPPTS. This observation is in agreement with TEM data reported in 
section 3.3.3.2, PPTA has a mean particle size of 4.9 nm, which is -  2 nm 
larger than PPTS and FPPTS, this difference in size was also observed in the 
UV-vis results (Figure 3.13).
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Figure 3.13 Visible spectra of phosphonium-functionalised AuNPs prepared 
from PPTS, PPTA and FPPTS.
All solutions of phosphonium-functionalised AuNPs were freeze-dried to remove 
water to keep them stable for longer periods; previous studies have shown that 
phosphonioalkylthioacetate functionalised AuNPs are stable for 6 months (Ju- 
Nam et al., 2008). UV-Vis spectra (Figure 3.14) showed no changes in the SPR 
band for the freeze-dried AuNPs re-suspended in water compared to the freshly 
prepared colloidal solution, this demonstrated that P-AuNPs can be stored in 
the freeze-dried form and be re-suspended in solvents at a later date for further 
analyses and experiments.
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Figure 3.14 UV-vis spectra of the fresh solution of AuNPs capped with a) PPTS, 
b) PPTA and C) FPPTS re-suspended in water after freeze-drying.
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3.3.3.2 Transmission Electron Microscopy (TEM)
TEM is routinely used for the characterisation of nanoparticles, which provides a 
photograph of the gold core and size information (Daniel and Astruc, 2004). The 
size and morphology of AuNPs functionalised with different phosphonium 
ligands were investigated by TEM.
300
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Figure 3.15 Typical TEM micrographs and particle size histograms of 
phosphonium-functionalised AuNPs with precursor PPTS ligand. Mean particle 
size 3.0 ± 1.2., in each histogram 1,000 nanoparticles were counted.
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Figure 3.16 Typical TEM micrographs and particle size histograms of 
phosphonium-functionalised AuNPs with precursor PPTA ligand. Mean particle 
size 4.9 ± 1.5, in each histogram 1,000 nanoparticles were counted.
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Figure 3.17 Typical TEM micrographs and particle size histograms of 
phosphonium-functionalised AuNPs with precursor FPPTS ligand. Mean particle 
size 2.7 ± 0.8, in each histogram 1,000 nanoparticles were counted.
TEM studies showed that all the samples are spherical in shape (Figure 3.15- 
3.17), the particle size count revealed that AuNPs prepared from thiosulfate 
species (PPTS and FPPTS) produces particles of similar size and distribution. 
In contrast AuNPs prepared using thioacetate precursor ligand (PPTA) 
produces larger particle sizes and with a broader particle size distribution (Table 
3.4).
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Precursor Phosphonium Ligand Mean Particle Size (nm)
PPTS 3.0 ± 1.2
PPTA 4.9 ± 1.5
FPPTS 2.7 ± 0.8
Table 3.4 Average particle size of phosphonium-functionalised AuNPs prepared 
from different phosphonium ligands. Mean particle size was calculated from 
1000 nanoparticles.
The differences in size between AuNPs derived from the PPTS zwitterion and 
PPTA salt can be explained on the basis of the differing passivation kinetics of 
the two types of ligand (Lohse et al., 2010, Singh et al., 2010, Zhang et al.,
2009). The first stage of the synthesis should be adsorption of the ligand on the 
surface of the growing particles and the thioacetate might be expected to be a 
more weakly binding ligand than the thiosulfate. The next stage involves the 
transformation of the thiosulfate or thioacetate to the thiolate.
The exact mechanism of this step in this system is unclear at present, the 
mechanisms of the formation of self-assembled monolayers on gold using alkyl 
thiosulfates (Bunte Salts) as the precursor ligands has been the subject of 
recent studies (Lohse et al., 2010, Fealy et al., 2011). Recent studies into the 
formation of monolayers on gold surfaces from alkylthiosulfates show hydrolysis 
by the presence of trace amounts of water in the solvent (Fealy et al., 2011, 
Pillai and Freund, 2011).
Phosphonium-functionalised AuNPs reported in this chapter were prepared in a 
two-phase water/DCM system, the possibility of the growing AuNPs and/or the 
reducing agent cannot be excluded being involved in the cleavage of the 
thiosulfate sulfur-sulfur bond (S-S) or thioacetate sulfur-carbon (S-C) bonds. 
The cleavage step for thioacetate bond appears to be slower than the sulfate 
bond and thus result in slower monolayer formation.
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3.3.3.3 Nuclear Magnetic Resonance Spectroscopy (NMR)
NMR is a useful technique in determining the structure of organic materials, 
because the NMR shifts changes depending on the magnetic field at the 
nucleus which is very sensitive to the surrounding electrons. NMR is also 
commonly used to characterise capping ligands on the surface of nanoparticles 
(Liu eta!., 2012).
In this chapter, 31P NMR has been used for the initial characterisation of the 
protecting ligands surrounding the surface of AuNPs. Data are summarised in 
Table 3.5.
Free Ligand Phosphonium-AuNPs
PPTS 23.3 ppm 23.5 ppm
PPTA 24.3 ppm 23.3 ppm
FPPTS 23.4 ppm 23.0 ppm
Table 3.5 Summary of 31P NMR chemical shift for phosphonium precursor 
ligands and the corresponding phosphonium-AuNPs.
Overall no significant changes were observed in the 31P NMR spectra for all free 
ligands (PPTS, PPTA and FPPTS) and the corresponding phosphonium-AuNPs 
(Table 3.5). All free ligands have a 31P chemical shift of approximately 23 ppm 
and the functionalised AuNPs have a 31P chemical shift around 23 ppm. The 
similarity between the 31P chemical shift of the free ligand and its corresponding 
functionalised AuNP, provided evidence that the chemical structure of the ligand 
stabilising the Au core is the same structure of the ligand itself and that the 
phosphonium head group remains unchanged.
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Figure 3.18 The 31P NMR spectra (CD2CI2) of PPTS (insert) and PPTS 
functionalised AuNP: with 31P peak at 23.49 ppm and 23.27 ppm respectively. 
This shows that the phosphorous head group for both the free ligand and the 
functionalised AuNPs form are in similar chemical environments.
The 31P NMR spectra of the free ligand (PPTS) and the corresponding AuNPs 
are shown above in Figure 3.18. The free ligand (PPTS) has a 31P value of 23.5 
ppm and the capped AuNPs has a 31P value of 23.3 ppm, both values are very 
similar with a slight difference of 0.2 ppm. This indicated that the phosphonium 
head group are in a similar chemical environment in both cases, thereby 
confirming that the chemical structure of the ligand stabilising the Au core is the 
same structure of the ligand itself and that the phosphonium head group 
remains unchanged.
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3.3.3.4 X-Ray Photoelectron Spectroscopy (XPS)
XPS has become a useful surface analysis tool for understanding the nature of 
different types of surfaces, particularly nanomaterials as it can provide valuable 
information regarding the atomic composition of the surface ligands as well as 
the chemical state of surfaces and interfaces (5-10 nm depth) which have 
strong influence on the properties of the nanomaterials (Baer and Engelhard, 
2010). XPS has been widely used to study numerous monolayer-protected 
metal cluster and self-assembled monolayer systems (Shon et al.t 2000, Love 
et a/., 2005).
XPS has been employed in this project to determine the elemental composition 
of the phosphonium-AuNPs and the nature of the Au-S linkage, that data are 
summarised in Table 3.6.
Au S
Precursor Ligand
4f 7/2 4f 5/2 2 p  3/2
PPTS 84.0 87.5 162.9
PPTA 84.1 87.8 162.1
FPPTS 83.8 87.5 162.5
Table 3.6 Summary of gold and sulfur XPS binding energies (eV) for 
phosphonium-AuNPs.
Binding energy values reported for S (2p3/2) in Table 3.6 are consistent with a 
system in which the sulfur species is bound to the surface of gold as a thiolate, 
which usually occur in the range between 162.0 to 162.9 eV (Bourg et al., 2000, 
Bain etal., 1989).
Wide scan spectra of AuNPs prepared from thiosulfate precursor ligands (PPTS 
and FPPTS) (Figure 3.17) were very similar, showing signals due to Au, P and 
S. In addition, the XPS spectrum of the AuNP capped with the FPPTS 
compound contained a F(1s) peak (Figure 3.20), with a binding energy of 687.4 
eV this is consistent with the presence of fluorine in this sample.
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Figure 3.19 XPS wide scan spectrum corresponding to the freeze-dried sample 
of AuNPs functionalised with a) PPTS and b) PPTA and. Spectrum showing the 
bonding energies for sulfur (S 2p), phosphorous (P 2p) and gold (Au 4f) peaks 
at 170, 133 and 84 eV respectively for both samples.
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Figure 3.20 XPS wide scan spectrum corresponding to the freeze-dried sample 
of AuNPs functionalised with FPPTS. Spectrum showing the binding energies 
for sulfur (S 2p), phosphorous (P 2p), gold (Au 4f) and fluorine (F 1s) at 170, 
133, 84 and 688 eV respectively. The fluorine peak confirmed the presence of 
fluorine in the sample.
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Figure 3.21 High resolution F(1s) XPS spectra of phosphonium-AuNP capped 
with FPPTS compound showing F 1s peak with a binding energy at 687.4 eV, 
confirming the present of fluorine in the sample.
The high resolution Au (4f) spectra for both samples contain a doublet for Au 
(4f7/2) and Au (4f5/2) with binding energies c.a. 83.8 and 87.5 eV, respectively 
(Figure 3.22). These values are similar to those reported by Brust (83.8 eV and
87.5 eV) (Brust et at., 1994) and Yee and colleagues (84.2 eV and 87.85 eV) 
(Yee etal., 2003) for AuNPs capped with dodecanethiol.
The binding energy of Au(l) in a gold thiolate is 86 eV and AuNPs that are 
reported to contain a fraction of their surface atoms in the Au(l) oxidation state 
show a Au 4f7/2peak with a binding energy of 84.9 eV (McNeillie et al., 1980). 
The Au (4f7/2) observed at 84.0 eV in the phosphonium-AuNPs (Figure 3.22) 
suggested that the bulk of the gold atoms are in the Au(0) oxidation state.
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Figure 3.22 High resolution Au (4f) XPS spectrum of freeze-dried 
phosphonium-AuNPs derived from a) PPTS, b) PPTA and c) FPPTS. All 
spectrum show samples containing a doublet for Au at Au 4f7/2 and Au 4f5/2 with 
binding energies 84.0 and 87.5 eV for PPTS, 84.1 and 87.8 eV for PPTA, 83.8 
and 87.5 eV for FPPTS.
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High resolution S (2p) XPS spectra (Figure 3.23) displayed a peak with a 
binding energy of 162.9 eV corresponding to S (2p3/2) (Bourg et al., 2000), 
providing strong evidence for the cleavage of the sulfur-sulfur bond in the 
phosphoniopropylthiosulfate zwitterions during the synthesis with the 
concomitant expulsion of S 032'(or some other sulfur species derived from it) at 
the ligand/Au interface. There was no evidence for oxidised sulfur which 
appears at -167 eV on gold clusters (Lee et al., 1998, Schoenfisch and 
Pemberton, 1998).
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Figure 3.23 High resolution S (2p) XPS spectrum of freeze-dried phosphonium- 
AuNP derived from PPTS zwitterion. Showing S (2p) has a binding energy of 
162.9 eV confirming the sulfur species is bound to the surface of gold as a 
thiolate.
Overall XPS data have provided valuable information regarding the ligands 
coating the surface of AuNPs. A wide scan spectrum confirmed the presence of 
sulfur, phosphorous and gold in all the samples, in addition fluorine was present 
in FPPTS, which was expected and agrees with the chemical structure. The 
high resolution of Au (4f) spectrum showed a doublet for Au at Au (4f7/2) and Au 
(4f5/2) for all samples in the region of 84 and 88 eV respectively, which are 
similar to the values of gold thiolates reported in the literature (Brust et al., 1994, 
Yee et al., 2003). Furthermore the presence of the peak for Au (4f7/2) shows that 
the bulk of the gold atom are in the Au(0) oxidation state, confirming the 
successful synthesis of gold nanoparticles.
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3.3.3.5 Secondary Ion Mass Spectrometry (SIMS)
The surface chemical analysis is an important part of the characterisation of 
both natural and synthetic nanoparticles; SIMS is a useful surface technique for 
the characterisation of the surfaces of nanoparticles and is predominantly used 
to extract molecular information. Furthermore, SIMS has also shown to be a 
useful tool in determining the basic composition of nanoparticles (Baer et al.,
2010).
In SIMS analysis, a high energy primary beam is directed onto a sample surface 
which penetrates the surface region and induces a collision cascade, and 
releases secondary ions in the form of neutral and charged secondary species. 
Static mode is used to extract surface molecular details, which involved the use 
of low density and low primary ion dose which reduces the interactions of the 
primary ions to the top monolayers of the sample and thus resulting in minimal 
surface damage (Baer et al., 2010, Senoner and Unger, 2012).
The surface sensitivity of SIMS is considerably higher than XPS; SIMS was 
used in this chapter as an attempt to obtain additional data regarding the basic 
composition and the surface coatings on the nanoparticles. Zoomed-in SIMS 
spectra in positive ion mode of P-AuNPs derived from PPTS, PPTS and FPPTS 
(Figure 3.24 and 3.25) shows a peak at 197 Daltons, this corresponded to the 
molecular weight of gold. Along with UV-vis (chapter 3.3.3.1), TEM (chapter
3.3.3.2) and XPS (chapter 3.3.3.4) results reported previously in this thesis, all 
data supports each other and confirmed the successful synthesis of Au 
nanoparticles.
In the case of the AuNPs prepared from phosphonium ligand containing fluorine 
(FPPTS), a peak at 19 dalton corresponding to fluorine was observed (Figure 
3.22b) this results confirmed the presence of fluorine in the sample, and SIMS 
data are agrees with data obtained previously by x-ray crystallography (chapter
3.3.1.3) and XPS (chapter 3.3.3.4).
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Figure 3.24 Zoomed-in SIMS spectrum in positive ion mode of P-AuNPs 
derived from a) PPTS and b) PPTA. Spectrum shows a peak for Au 
corresponding to its molecular weight at 197 and this confirms the present of Au.
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Figure 3.25 Zoomed in SIMS spectrum in positive ion mode of P-AuNPs 
derived from FPPTS. Figure 3.22a shows a peak for Au corresponding to its 
molecular weight at 197 and this confirms the present of Au. Figure 3.22b 
shows a peak corresponding to F, which confirms the presence of fluorine in the 
sample.
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3.3.3.6 Matrix Assisted Laser Desorption/ionization Mass Spectrometry 
(MALDI-MS)
Since it’s invention in the late 1980s, MALDI-MS has become an important 
analytical tool for the analysis of a wide variety of biomolecules including 
proteins and peptides (Karas and Hillenkamp, 1988, Hoffmann and Stroobant, 
2007). MALDI is a soft ionization technique that involves the use of a matrix 
(hence the name matrix assisted) of small, laser absorbing organic molecules to 
minimize damage to the analyte sample from laser irradiation (Chiang et al.,
2011).
MALDI-MS has been successfully used in the quantitative analysis of AuNP 
clusters (Helfrich and Bettmer, 2011, Harkness et al., 2010). The earliest work 
for characterising thiolate-protected AuNPs by mass spectrometry dates back to 
the late 1990s, since then several papers have reported the characterisation of 
Au clusters using a number of different matrices including a-cyano-4- 
hydroxycinnamic acid (CHCA), 2-(4'-Hydroxybenzeneazo)benzoic acid (HABA) 
and sinapinic acid (Pena-Mendez et al., 2008, Schaaff, 2004, Arnold and Reilly, 
1998, Dass et al., 2008a). While the use of common weak organic acid MALDI 
matrices enables the analysis of the core of ligand-protected AuNPs, these 
matrices do not prevent extensive ligand fragmentation (Harkness et al., 2010).
In 2008 Dass and co-workers published the first MALDI spectra of intact ligand- 
protected AuNPs with the use of an alternative matrix -  trans-2-[3-{4-tert- 
butylphenyl)-2-methyl-2-propenylidene] malononitrile (DCTB). The success was 
due to ionisation assisted by electron transfer rather than proton transfer from 
weak organic acid matrices (Dass et al., 2008b). Recently Kouchi and 
colleagues (Kouchi et al., 2012) have successfully demonstrated that a new 
matrix -  a, (3-diphenylfumaronitrile (DPF) can be used to detect intact thiolate- 
protected gold clusters with stronger ion peak intensities compared to DCTB.
While MALDI-TOF-MS can be an invaluable tool in determining the number of 
gold atoms/ligand molecules in thiolated Au clusters, the elucidation of the exact 
formula is not straightforward and remains technically challenging (Kouchi et al.,
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2012). To date, MALDI-MS has been successfully used to identify and quantify 
AuNPs with diameter 2 nm or smaller (Yu and Andriola, 2010).
In this chapter different matrices have been investigated as an attempt to 
determine the exact formula of AuNPs synthesised; due to the nature of looking 
for peaks with m/z greater than 1000, a MALDI-TOF Voyager De-STR mass 
spectrometer was used for the analysis, for instrument details refer to chapter 
2.9. PPTS capped AuNPs were analysed by MALDI-TOF-MS both in positive 
and negative ion modes with CHCA, DCTB and DPF, with m/z up to 10,000 as 
well as varying laser intensity.
When PPTS capped AuNPs were analysed using CHCA as the matrix, peaks 
corresponding to the matrix and the PPTS ligand were detected (Figure 3.26). 
Peaks for CHCA were observed at m/z 191 [M+H]+ and 380 [2M+H]+, peaks for 
the PPTS ligand were observed at m/z 304 [M-S]+ and 338 [M-SCH2]+. All 
peaks detected were 1 dalton higher than expected; CHCA matrix peak were 
expected at m/z 190 [M+H]+ and 379 [2M+H]+, PPTS ligand peaks were 
expected to be at m/z 303 [M-S]+ and 337 [M-SCH2]+. This could be due to 
instrument being calibrated using cytochrome c which was a suitable standard 
to calibrate the instrument to higher mass ranges in the region of m/z 10,000. 
The De-STR is suitable for the analysis of high molecular weight samples such 
as proteins, in contrast the QSTAR (MALDI-QTOF-MS) has greater sensitivity 
for the analysis of samples with smaller molecular weights below m/z 1000. The 
use of the QSTAR for the analysis of PPTS capped AuNPs is reported in the 
next section (chapter 3.3.3.7).
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Figure 3.26 Typical MALDI spectrum of PPTS capped AuNPs with CHCA matrix analysed in positive ion mode. Peaks corresponding to 
CHCA at m/z 191 [M+H]+, 380 [2M+H]+, PPTS ligand at m/z 304 [M-S]+ and 338 [M-SCH2]+.
Figure 3.27 Typical MALDI spectrum of PPTS capped AuNPs with DCTB matrix analysed in negative ion mode. Peak corresponding to 
the matrix at m/z 249.67 [M-H]'.
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Although peaks below m/z of 500 were observed with all the matrices 
investigated, the matrix peaks has been identified, however the expected peaks 
for the sample analysed in negative ion modes (Figure 3.27 and 3.28) were not 
observed. Peaks for PPTA ligand are expected to at m/z 261 [M-S(CH2 )3]', 274 
[M-S(CH2)2]', 288 [M-S(CH2]' and 302 [M-S]', No major peaks corresponding to 
the intact AuNPs were observed above m/z 500 (Figure 3.26 and 3.28).
In general the use of CHCA produces noiser spectra compared to DPF and 
DCTB, this observation is in agreement with the literature; Dass et al. (2008b) 
and Kouchi et al (2012) have both successfully used alternative matrices (DCTB 
and DPF respectively) which assist ionisation by electron transfer to overcome 
the extensive ligand fragmentation observed when using the universal matrix -  
CHCA which assist ionisation by proton transfer. The use of MALDI-MS to 
characterise P-AuNPs synthesised in this project has been investigated; 
different matrices (CHCA, DPF and DCTB) have been employed in this section 
with varying different laser intensities and different mass ranges. Despite 
exploring different matrices and instrumentation settings, intact peak of the 
AuNPs was not observed during the experiments, and due to time restrictions 
the analysis of P-AuNPs by MALDI-MS was not continued.
MALDI-MS analysis of PPTS capped AuNPs with the use of CHCA showed that 
the reaction has gone to completion, with no free ligand of PPTS present, due 
to the absence of the PPTS [M]+ peak at m/z 379. This result is in agreement 
with LDI-MS data obtained in the section 3.3.3.7. This observation is also in 
agreement with the TEM data reported previously in section 3.3.3.2; AuNPs 
prepared from the PPTS precursor produces particles with narrower particle 
size distribution, as the cleavage step for the thiosulfate sulfur-sulfur bond (S-S) 
is faster which result in complete reaction thus produces AuNPs with narrower 
particle size distributions.
For future work, it might be worth investigating further into the unidentified 
peaks in Figure 3.26 and try to identify them, a feasible approach is to analyse 
the peaks of interest by tandem MS-MS to gain more information about a 
specific peak
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MALDI-MS analysis is limited to small AuNPs due to common detectors used 
decreases sensitivity with increase mass, and since the mass of AuNPs 
increases exponentially with diamater size, therefore larger AuNP clusters will 
become unobservable (Harkness et al., 2010). To the best of the authors 
knowledge MS characterisation has only been successfully conducted on 
AuNP’s with diameter size of up to 2 nm (Chaki et al., 2008, Yu and Andriola,
2010). AuNPs synthesised in this project are larger than 2 nm in diameter, 
which may explain why initial experiments using MALDI-MS for the analysis of 
P-AuNPs did not yield positive results, nevertheless the use of MALDI-MS for 
the characterisation of AuNPs is an active area of research being pursued by 
other research groups and further experiments are required in order to obtain 
useful information to aid in the determination of the exact formula.
3.3.3.7 Laser Desorption/Ionization Mass Spectrometry (LDI-MS)
MALDI has become a powerful technique in the analysis of biomolecules. 
Several groups have demonstrated the use of an organic chemical matrix in 
MALDI MS, and the technique is capable of detecting a range of biomolecules 
(peptides, proteins and nucleic aicds) (Wu et al., 2009, Chiang et al., 2011).
AuNPs have been studied as potential inorganic matrices, compared with 
organic chemical matrices, nanomaterial matrices offer the advantages of 
eliminating matrix ion interference and improving the sample homogeneity 
(McLean et al., 2005, Wu et al., 2009). As a result LDI-TOF-MS has become a 
powerful analytical tool for the analysis of functionalised AuNPs since the 
surface ligands can be efficiently ionised due to the ability of the gold particles 
to absorb at wavelengths commonly used by mass spectrometers (Spencer et 
al., 2008, Su and Tseng, 2007).
In this section LDI-TOF-MS has been employed as an additional technique to 
characterise the surface ligands coated on the surface of AuNPs.
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All LDI-MS spectra obtained from AuNPs capped with PPTS, PPTA and FPPTS 
(Figure 3.29-3.31) exhibited cleaved peaks; both PPTS and PPTA showed the 
cleaved phosphoniopropylthiolate ion [Ph3P+(CH2)3S]+ at m/z 377, and FPPTS 
showed the cleaved peak [p-FC6H4P+(CH2)3S]+ at m/z 389.
The molecular ions for the parent PPTS and FPPTS species were absent in 
their LDI-MS spectrum (Figure 3.29 and 3.30), this confirmed the successful 
synthesis of functionalised AuNPs, as all ligands were cleaved at the thiosfulate 
S-S bond and formed strong Au-S bonds to the surface of the nanoparticles. In 
contrast, AuNPs capped with PPTA displayed the molecular ion peak 
corresponding to the parent molecular ion at m/z 379. This observation of the 
molecular ion for the PPTA salt is in accord with the TEM analysis (chapter
3.3.3.2) of this sample with larger diameter than those prepared from the 
corresponding PPTS zwitterion which is consistent with slower, or incomplete, 
reaction.
Furthermore all spectra showed in-source fragmentation peaks with 14 m/z 
which corresponded to the consecutive loss a CH2 group, in total the loss of 3 
CH2 groups were observed in the LDI-MS spectra (Figure 3.29-3.31) which 
further supported the structure of the ligands present on the surface of AuNPs.
Overall LDI-MS analyses have provided valuable information regarding the 
chemical composition of the surface ligands; the spectrum showed that the S-S 
bond of the thiolate (S-SO3) (PPTS and FPPTS) and thioacetate (S-SOCH3 3 ) 
(PPTA) have successfully been cleaved forming strong Au-S bonds, particularly 
the thiolate species (PPTS and FPPTS) had very clean cleavage which was 
confirmed from LDI-MS with the absence of the molecular ion peak. This 
observation is in agreement with TEM data obtained previously in chapter
3.3.3.2 with smaller particle size and distribution produced in comparison to 
AuNPs prepared from the thioacetate precursor ion. Along with the loss of three 
CH2 groups which could clearly be identified from the spectrum, LDI-MS data 
provided strong evidence that the surface ligands coated on the surface of the 
AuNPs were as expected.
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3.3.3.8 Thermogravimetric Analysis (TGA)
TGA is a relatively simple technique that requires no special sample preparation. 
During the analysis samples are heated to elevated temperatures and the mass 
of the sample is recorded giving a decomposition curve. The decomposition 
curve provides information on the temperature at which the bulk of the material 
decomposes and the residual mass of the sample (Mansfield et al., 2014). TGA 
has been used in evaluating the purity of nanomaterials (Mansfield et al., 2010) 
and the determination of the organic weight fraction of Au thiolate-MPCs; MPCs 
decompose thermally leaving elemental gold residue therefore the thiol/Au ratio 
can be determined and thus the average number of sulfur ligands can be 
calculated (Hostetler et al., 1998). In this project, TGA analysis has been 
conducted to obtain additional information on the P-AuNPs synthesised, and 
attempt to deduce the number of sulphur ligands in relation to number of Au 
atoms.
TGA thermograms (Figure 3.32) showed two main thermal events; the first 
weight loss around 50-150°C (~7%) is due to the loss of solvents with the 
majority of solvents lost in this region. The second weight loss starts from 250°C 
until 500°C (-33%), then plateaus and decreases again until 750°C (-0.9%), 
this major weight loss is due to the loss of the organic capping agent. Visual 
inspection of the sample holder showed that the material remaining after 
thermolysis is most likely to be pure Au due to the gold colour of the sample, 
and no other element in the sample other than gold has a decomposition value 
above 750°C.
The loss of organic capping ligands on the gold surface starts around at 250°C, 
this will not have an effect of the end application of utilising these P-AuNPs in 
photothermal therapy applications, which involve increasing the temperature of 
cells between 41-46°C to induce apoptotic cell death (Cherukuri et al., 2010). If 
the loss of organic ligands at low temperatures around 40-50°C this would have 
been an issue, as when the cells get heated up to above this temperature, the 
ligands will begin to detach from the surface of the AuNPs, this will no doubt 
change the functionality of the AuNPs this can induce a change in the 
properties of the AuNPs thus effecting its end application.
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The TGA results showed that there is a large organic fraction ~ 40% which 
suggest the ratio between thiol/Au is nearly 1:1, suggesting that AuNPs 
synthesised are small MPCs, since smaller MPCs have a larger organic weight 
fraction as they have a larger surface area per unit of Au mass. AuNPs (3.7 nm) 
prepared with S-dodecylthiosulfate has shown to have 18.5% of organic 
coverage, while AuNPs (2.2 nm) prepared with dodecanethiol were shown to 
have a higher organic coverage of 41.6% (Shon et al., 2000). Based on the data 
reported in the literature, TGA data suggested that the size of P-AuNPs 
synthesised are between 2.2 and 3.7 nm in size, this size range is in agreement 
with TEM data reported previously in section 3.3.3.2, with a mean particle size 
of 3.0 nm.
TGA data provides the general picture of the sample indicated the presence of 
a large organic fraction, in contrast TEM is capable of providing size data on a 
particle by particle basis, the size distribution showed that not all particles 
synthesised are the same size, which suggest that there is variation between 
the organic fractions on each gold nanoparticle. As the different in the ratio 
between the thiol and Au will result in the formation of AuNPs with different 
sizes (Frenkel et al., 2005)
To further support data obtained from TGA and TEM, future work will be to 
conduct DLS analysis to provide data on the hydrodynamic radius of the P- 
AuNPs. It would be interesting to compare the results obtained DLS with TEM, 
the results obtained can help to calculate the thickness of the capping ligands 
coating the surface of the gold nanoparticles, from this an estimate of the ratio 
of the organic ligand compared to the Au core can be calculated (Jans et al., 
2009).
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3.3.3.9 Inductively Coupled Plasma Mass Spectrometry (ICP-MS)
ICP coupled plasma mass spectrometry (ICP-MS) has emerged as an important 
and useful technique for the analysis of AuNPs; both ICP-OES (Elzey et a/., 
2012) and ICP-MS (Scheffer et al., 2008) have been used for the 
characterisation of AuNPs. ICP-MS has a limit of detection of Au ~1 pg/mL (1 
part per trillion) and is more sensitive than ICP-OES by around 3 orders of 
magnitude. ICP-MS is the method of choice when maximum sensitivity is 
required. Overall ICP offers a fast and reliable method for quantifying AuNPs in 
solution (Scheffer et al., 2008).
ICP has been commonly used to determine the concentration of elemental Au in 
colloidal solutions. It has been demonstrated that AuNP dispersions can be 
analysed directly without previous digestion, excellent spike recovery >90% was 
observed using 1% (v/v) HCI (Allabashi et al., 2009). Recent studies have 
extended the application of ICP for the characterisation of AuNPs to quantify the 
ligand packing density on AuNPs (Elzey et al., 2012, Hinterwirth et al., 2013). In 
this chapter, the use of ICP to determine the Au concentration has been 
investigated.
ICP-MS results indicated that PPTS capped AuNPs have a lower Au 
concentration of 7.54 mg/L when dissolved in DIH2O compared to 9.59 mg/L 
when dissolved in 1% (v/v) HCI. This decrease in Au concentration is consistent 
with the results of Allabashi and colleagues (Allabashi et al., 2009) who 
reported a reduction in Au concentration when AuNP dispersion was diluted by 
DIH20  compared to 1% (v/v) HCI. In addition to analysing gold, phosphorous 
and sulfur have also been quantified using ICP-OES to obtain additional 
information regarding the surface ligands. To confirm the results obtained, 
samples were sent to MEDAC (Chobham, Surrey, UK) for analysis. Both sets of 
results were very similar, data are shown in Table 3.7.
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Element
Concentration (mg/mL)
In house MEDAC
Au 95.9 102.7
P 26.4 28.7
S 75.4 77.2
Table 3.7 Elemental analysis of Au, P and S of PPTS capped AuNPs using 
ICP-MS; ICP-MS data obtained in house and externally (MEDAC) are reported.
Preliminary results suggest that the ratio Au:S is approximately 5:4, this value is 
very similar to TGA data obtained previously (chapter 3.3.3.8) Au and organic 
fraction of 49% and 42% respectively.
The average number of gold atoms per nanoparticle ( N a u /g n p )  can be calculated 
theoretically. Assuming a spherical shape and a uniform structure, the average 
number of gold atoms (A/) can be calculated using Equationl, where p is the 
density for gold (19.3 g/cm3) (Zhang et al., 2004, Cui et al., 2002) and M stands 
for atomic weight of gold (197 g/mol).
With an increase in diameter, the average number of gold atoms per gold 
nanoparticle ( N Au/g n p ) will increase with cube (Liu et al., 2007). Based on TEM 
results reported previously in chapter 3.3.3.2 and substituting in Equation 1, the 
average number of gold atoms calculated to be 1.39x1 O'21.
Nau/gnp = ^ r j f  (Equation 1)
The ligand coverage via the gold-to-sulfur ratio can be calculated based on the 
fact that the gold atoms constitute the particle core with each ligand on the 
nanoparticle surface carrying a single surfur atom only, The number of sulfur 
atoms per gold nanoparticle ( N s /g n p )  will increase to the square of the AuNP 
diameter and is proportional to the maximal coverage factor kmax and can be 
calculated using Equation 2.
Ns/gnp = (Equation 2).
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Combining the two equations (Equation 3), it assumes that spherical 
nanoparticles monodispersed with complete saturation with a monolayer of thiol 
ligands on the particle surface.
npD 3
NAv'crlp=— aL_=fc , x 9 . 8 3  x D (Equation 3).
N s / g n p  K m a x n D 2 m a x  v ^  '
Using equation 3, the calculated theoretical maximum number of PPTA ligands 
on the surface of gold nanoparticles is 8.39 x 10'19. Therefore based on ICP-MS 
(Chapter 3.3.3.9) and TGA (3.3.3.8) data obtained that the ratio of Au:S was 
approximately 5:4, based on this ratio and the calculated values for Au and S 
are 4.66x1 O'19 and 3.73x1 O'19 respectively.
3.4 Conclusion
Results in this chapter, showed that triarylphosphoniopropylthiosulfate 
zwitterions and u)-thioacetylpropyl(triphenyl)phosphonium salts can be used to 
prepared cationic AuNPs with average core sizes between 2.7-5.0 nm. A variety 
of techniques incorporating both qualitative and quantitative analysis have been 
employed throughout this section to characterise phosphonium-AuNPs 
synthesised.
Spectroscopy results (31P NMR, 1H NMR, ESMS, FTIR) all supported the 
successful synthesis of phosphonium ligands (PPTS, PPTA, FPPTS and 
FPPTA). X-ray crystallography further confirmed the expected structure for 
FPPTS and FPPTA.
The first indication for the successful synthesis of P-AuNPs was the visual 
observation of the colour change to the characteristic deep red wine colour of 
colloidal gold. UV-vis results showed SPR band -520 nm for all AuNPs 
prepared, this result is in agreement with AuNPs in the region of 5 nm (Daniel 
and Astruc, 2004). 31P NMR provided evidence that the chemical structure of 
the ligand stabilising the gold core is the same structure of the ligand itself and 
that the phosphonium head group remained intact.
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XPS data provided valuable information about the ligands coating the surface of 
AuNPs, wide scan spectrum confirmed the presence of phosphorous, sulfur and 
gold in all the samples. Furthermore, AuNPs prepared from FPPTS, a fluorine 
peak was observed, which agrees with the chemical structure. High resolution 
of Au (4f) spectrum showed a double for Au at Au (4f7/2) and Au (4fs/2) for all 
samples analysed in the region of 84 and 88 eV respectively, which are similar 
to the values of gold thiolates reported in the literature (Brust et al., 1994, Yee 
et al., 2003). The presence of the peak for Au (4f7/2) shows that the bulk of the 
gold atom are in the Au(0) oxidation state, confirming the successful synthesis 
of AuNPs.
LDI-MS data also provided useful information regarding the chemical 
composition of the surface ligands on the AuNPs. LDI-MS spectrum showed 
that the S-S bond of the thiolate (S-SO3) (PPTS and FPPTS) and thioacetate 
(S-SOCH3 3 ) (PPTA) have successfully been cleaved forming strong Au-S 
bonds, particularly the thiolate species (PPTS and FPPTS) had very clean 
cleavage which was confirmed from LDI-MS with the absence of the molecular 
ion peak.
Preliminary TGA data suggest there is a high thiol/Au ratio, which is in accord 
with ICP-OES data. ICP-OES and MALDI-TOF-MS are two powerful techniques 
for the quantitative analysis of AuNPs, initial results are certainly of interest, 
however further investigation is required in order to gain useful quantification 
information on the ligand density.
TEM results showed all nanoparticles synthesised have a uniform spherical 
shape, although phosphonium-AuNPs produced from the PPTS zwitterion or 
PPTA salt all yield the same Au-S ligation, the PPTA salt produces slightly 
larger AuNPs in comparison to the corresponding PPTS zwitterion which is 
consistent with slower or incomplete reaction, this is supported by molecular ion 
observed for the PPTA salt in LDI-TOF-MS spectra. PPTS capped AuNPs were 
taken forward to investigate their cytotoxicity and uptake in cells (chapter 4).
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Chapter 4.
Investigation of the cytotoxicity and cellular 
uptake of phosphonium ligands in cells
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4.1 Introduction
Organic phosphonium compounds are an important class of compounds with 
applications in chemistry and biology; triphenylphosphine has been widely used 
as a Wittig reagent in the synthesis of phosphorus ylides (Wittig, 1980). As 
biological reagents, phosphonium compounds of the type of Ph3P+R (in which 
four aryl and/or alkyl groups are appended to a central phosphorus atom) 
belong to the group of lipophilic phosphonium cations (LPCs) which are of 
interest for mitochondria targeted therapeutics because they are preferentially 
taken up by mitochondria (Ross et al., 2005, Weissig, 2005, Weissig, 2011, 
Smith et al., 2011).
Mitochondria have emerged as an important pharmacological target in many 
areas of biomedical science; beside their well-recognised roles in oxidative 
phosphorylation and in mitochondrial biogenesis, it has become evident that 
mitochondrial play a crucial role in cell death, calcium metabolism, the innate 
immune system, neoplasia, oxygen and hypoxia sensing. Since mitochondrial 
dysfunction contributes to a range of human diseases, there has been an 
increase in effort made towards the development of pharmacological strategies 
to address mitochondrial dysfunction (Gupta et al., 2009, Smith et al., 2012, 
Weissig et al., 2004). A common approach has been to conjugate therapeutic 
molecules to a triphenylphosphonium moiety, which have been shown to 
preferentially accumulate inside the mitochondria due to the phenomenon of the 
mitochondrial membrane potential, thereby making them ideal candidates for 
applications in mitochondrial biology including measuring the membrane 
potential, visualising and controlling drug delivery to the mitochondria (Ross et 
al., 2005).
The TPP moiety has been widely used due to their simplicity and ease of 
synthesis and derivatisation. To date, a number of different species have been 
successfully attached to the TPP moiety for mitochondrial biology applications 
including fluorescent reactive oxygen species probes (Dickinson and Chang, 
2008, Shioji et al., 2010), thiol probes (Burns et al., 1995, Coulter et al., 2000), 
spin traps (Murphy et al., 2003), antioxidants (Smith et al., 1999, Murphy and 
Smith, 2007) and anti-cancer agents (Patel eta!., 1994, Manetta etal., 1996).
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As anti-cancer agents, phosphonium cations offer promising potential as they 
are preferentially accumulated in cancerous cells due to elevated membrane 
potential observed in cancer cells compared to their normal cell counterparts. 
This specific accumulation of LPCs has been demonstrated both in vitro and in 
vivo (Patel et al., 1994, Rideout et al., 1989, Manetta et al., 1996), furthermore 
phosphonium compounds also exhibit anti-neoplastic properties (Patel et al., 
1994, Millard eta!., 2010).
MALDI-MS is a widely used analytical tool due to its high-speed analysis, 
simplicity and excellent sensitivity; MALDI is a soft-ionisation technique 
introduced in 1987 primarily for the analysis of proteins (Karas and Hillenkamp, 
1988, Tanaka et al., 1988). Since then MALDI-MS has gained a prominent role 
in the qualitative analysis of various non-volatile and fragile biopolymers 
including proteins, oligosaccharides and oligonucleotides (Aebersold and Mann, 
2003, Burnum et al., 2008, Mechref et al., 2003, Stuhler and Meyer, 2004, 
Pieles etal., 1993).
While MALDI-MS has transformed the analysis of large biomolecules, its 
application to small molecules with molar masses typically below 1,000 Da has 
lagged behind. With escalating demand for high-throughput methods in drug 
discovery and biotechnology this has driven the utilisation of MALDI-MS in small 
molecule analysis (Cohen and Gusev, 2002). A range of biological and organic 
small molecules have been successfully analysed by MALDI-MS, these include 
small peptides (Zhu etal., 1995), carbohydrates (Harvey, 2011), lipids (Fuchs et 
al., 2010), synthetic polymers (Choi et al., 2007), retinoids (Wingerath et al., 
1999), amino acids (Gogichaeva and Alterman, 2012) and pharmaceutical 
compounds such as prazosine and its synthetic analogues (Andal etal., 2001).
Although MALDI-MS has always been regarded as a qualitative technique, 
researchers have been pushing the boundaries for quantitative analysis using 
MALDI-MS (Szajli et al., 2008); to date quantification applications of MALDI-MS 
ranging from small to large molecules including amino acids, drugs, 
oligonucleotides, lipids, peptides and proteins have been published (Duncan et 
al., 2008). While the quantification of small molecules is difficult due to the
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strong interferences from MALDI matrix ions (m/z < 500) (Krutchinsky and Chait, 
2002, Gobey et al., 2005), papers published in this area of research all suggest 
that MALDI-MS can be a powerful tool in the quantitative analysis of small 
compounds.
Various small molecules have been quantified using MALDI-MS, including 
amine biomolecules (Lee et al., 2004), quaternary ammonium salts (Lou et al.,
2009), pharmaceutical drugs (e.g. Quinidine, Nadolol and Danofloxacin) (Sleno 
and Volmer, 2005), antibiotics (e.g. Ampicillin, Imipenem and Meropenem) 
(Sparbier et al., 2012) and anti-viral drug (e.g. tenofovir) (Meesters et al., 2011). 
What is of particular interest is that MALDI-MS has been applied to the 
quantification of tetraphenylphosphonium (TPP) in human hypopharyngeal 
carcinoma cells (Rideout et al., 1993) and more recently MALDI-MS has been 
used to study the ability of phosphonium cations to accumulate in a C6 rat 
glioma cell line (Cheng etal., 2005).
The main experimental work reported in this chapter is the study of the use of 
MALDI-MS for quantifying the uptake and cytotoxicity of phosphonium ligands 
synthesised previously (in chapter 3) in a prostate cancer cell line.
4.2 Materials and Experimental Methods 
4.2.1 Chemicals
Alpha-cyano-4-hydroxycinnamic acid (CHCA), 2,5-dihydroxybenzoic acid (DHB), 
sinapinic acid, trifluoroacetic acid (TFA), tetraphenylphosphonium bromide, 
sodium chloride (NaCI), calcium chloride (CaCh), MgS04, 4-(2- 
hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), dextrose, sodium 
hydroxide pellets, dimethyl sulfoxide (DMSO), toluene, acetone, tetrahydrofuran 
(THF) and p-cyclodextrin were obtained from Sigma (Gillingham, Dorset, UK).
4.2.2 Cell Culture
Human prostate cancer cells (PC3) were obtained from ATTC. PC3 were 
maintained in complete media (cDMEM) which contains Dulbecco’s modified 
Eagle medium with GlutaMAX, 4.5 g/L D-Glucose and sodium puruvate 
(Invitrogen Life Technologies, Paisley, Renfrewshire, UK) containing 10% heat-
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inactivated fetal bovine serum (Biosera, East Sussex, Sussex, UK) and 1% 
penicillin-streptomycin (Invitrogen Life Technologies, Paisley, Renfrewshire, UK) 
at 37°C in 5% CO2 and 95% air. Cells were sub-cultured every 3 days and 
routinely screened for mycoplasma.
PC3 cell line was selected because P-AuNPs synthesised previously in chapter 
3 were gold nanospheres, gold nanospheres has a SPR band that lies in the 
visible region at 520 nm. The strong plasmon absorption and photothermal 
conversion of AuNPs has been widely exploited for cancer therapeutics through 
the selective localization of photothermal heating of cancer cells.
Gold nanorods and nanoshells have SPR band in the near-infrared region (650- 
900nm) and are suited for in vivo therapy of tumours under skin and deeply 
within tissue such as ovarian cancer (Fourkal et al., 2009) and colon cancer 
(Goodrich et al., 2010, Huang et al., 2006). NIR light is required because of its 
deep penetration due to minimal absorption of the hemoglobin and water 
molecules between 650 and 900 nm (Jain et al., 2008). In contrast, gold 
nanospheres has a plamon absorption in the visible region and thus is more 
suitable for localised cancers such as breast (Shao et al., 2013, Li et al., 2009) 
and oral cancer (El-Sayed et al., 2005).
To the best of the author knowledge there has been no publication on the use 
gold nanospheres for the photothermal therapy on prostate cancers, reports 
available includes the use of gold nanorods (Wang et al., 2013, 
Manuchehrabadi et al., 2012), gold coated silica nanoshells (Gobin et al., 2008) 
gold nanoshells (Stern et al., 2008) gold nanocages (Cobley et al., 2010) gold 
nano popcorn(Lu et al., 2010) and magnetic nanoparticles (Kawai et al., 2005), 
thereby in this project, PC3 was selected as a model of prostate cancer cells.
4.2.3 Methods
4.2.3.1 Cytotoxicity Assay
Cytotoxicity was assessed using CellTiter-Glo luminescent cell viability assay kit 
(Promega Corporation, Southampton, Hampshire, UK). CellTiter glo is a 
homogeneous assay based on the direct determination of the intracellular ATP
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level in cells, a high level of ATP in cells indicates the presence of metabolically 
active cells. This method involves mixing the CellTiter-Glo substrate with the 
CellTitre-Glo buffer which is then added directly to cultured cells. Subseuqently 
this induces cell lysis and generates a luminescent signal which is proportional 
to the amount of ATP present in the cells, the luminescent signal is recorded on 
a microplate reader (Promega).
PC3 cells were seeded in opaque-walled 96-well plates at a density of 10,000 
cells/well and allowed to adhere overnight. Cells were subsequently treated with 
the corresponding phosphonium ligand (0-1000 pM) for 24, 48 and 72 hours. 
After each incubation period cell viability was measured according to the 
manufacturer’s instructions. In brief plates were equilibrated at room 
temperature for 30 minutes, 100 pL of assay reagent was added to each well, 
placed on an orbital shaker for 2 minutes, left to stand at room temperature for 
10 minutes and read on a Wallac Victor2 1420 multilabel counter (PerkinElmer, 
Cambridge, Cambridgeshire, UK).
All plates contain control wells and all measurements were performed in 
quadruplicates, 3 independent experiments were conducted (n = 12). All plates 
contained the following control wells; control 1 - cells plus CDMEM only, control 
2 - cells plus CDMEM with 0.1 % DMSO, control 3 -  cells plus CDMEM with 
0.01 % DMSO and control 4 - cells plus CDMEM with 0.001 % DMSO. Data are 
expressed as a percentage of live cells normalised to control, the average, 
standard deviation and IC50 values were plotted and calculated using GraphPad 
Prism (GraphPad software, La Jolla, California, USA).
4.2.3.2 Cellular Uptake Studies of Phosphonium Compounds by MALDI- 
MS
Uptake studies of phosphonium compounds by MALDI were conducted using 
the method reported previously by Cheng and colleagues (Cheng et al., 2005), 
this method has been adapted and optimised with own phosphonium 
compounds and instrumentation.
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4.2.3.2.1 Calibration Curve of Phosphonium Ligands for Semi-
Quantification Analysis by MALDI-MS
PC3 cells were cultured in T75 flasks, after trypsinsation the cells were washed 
twice with PBS (Invitrogen Life Technologies, Paisley, Renfrewshire, UK), re­
suspended to lyse the cells and aliquoted at a density of 3.5 x 106 cells/mL 
(labelled as cell lysate). Phosphonium compounds and internal standards were 
dissolved in methanol and diluted with PC3 cell lysate to make various 
concentrations and stored at 4°C. 10 pL of phosphonium compound and 10 pL 
of internal standard were mixed thoroughly, sequentially 10 pL of this solution 
was mixed with 10 pL of matrix and 0.5 pL of sample was deposited on the 
target MALDI plate.
MALDI matrices were made to a concentration of 10 mg/mL in 70:30 MeCN: 
water with 0.1% TFA. Triplicate standards were prepared and analysed, 
standards collected from 3 independent cell lysates were prepared for each 
study.
4.2.3.2.2 Sample Preparation of Phosphonium Ligands for Semi-
Quantification Analysis by MALDI-MS
PC3 cells were cultured in T75 flasks, after trypsinsation the cells were washed 
with PBS twice, re-suspended in low K+HEPES buffer (NaCI, 135 mM, KCI 5 
mM, CaCb 1.8 mM, MgSCUmM, HEPES 50 mM, dextrose 5.5 mM, pH 7.4) and 
aliquoted at a density of 10 x 106 cells/mL.
For cellular uptake studies, PC3 cells (0.5 x 106 cells/50 pL) were incubated 
with 10 pL of 100 pM stock solution of corresponding phosphonium salt (final 
concentration, 5 pM) and 140 pL of low K+ HEPES buffer and incubated 
between 0-120 minutes at 37°C. Subsequent to each incubation period, cells 
were centrifuged (500 x g, 4 minutes) and washed twice in cold PBS. Cell 
pellets were then lysed with 150 pL of cold DIH2O and placed on dry ice 
(labelled as sample cell lysate).
Prior to MALDI analysis, samples were thawed and centrifuged (12,000 x g, 5
minutes). The sample cell lysate (90 pL) and 10 pM (10 pL) of the internal
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standard were mixed together, subsequently 10 pL of this solution was mixed 
with 10 pL of matrix and 0.5 |jL of sample was deposited on the target MALDI 
plate. Triplicate samples were prepared and analysed, samples collected from 3 
independent cell lysates were prepared for each study.
4.2.3.3 Investigating the Cellular Uptake of Phosphonium Ligands in the 
Mitochondrial Fraction by MALDI-MS
Mitochondria/cytosol fractionation kit was purchased from Abeam (Cambridge, 
Cambridgeshire, UK) and conducted according to the manufacturer’s 
instructions. PC3 cells were plated out in a 6-well plate at a density of 5 x 106 
cells/mL and allowed to adhere overnight. The following day, cells were treated 
with phosphonium ligand for different length of time (0-120 minutes), cells were 
then centrifuged (600 x g, 5 minutes, 4°C), washed in ice-cold PBS, re­
suspended in 1 mL of 1 x cytosol extraction buffer (CEB) mixture and incubated 
on ice for 10 minutes.
Cells were homogenised in an ice-cold Dounce tissue grinder (Sigma, 
Gillingham, Dorset, UK); 10 passes using the large pestle for initial sample 
reduction followed by 30-50 passes using a smaller pestle, the efficiency of 
homogenisation was checked under a light microscope.
The homogenate was transferred to a microcentrifgue tube and centrifuged 
(700 x g, 10 minutes, 4°C), the supernatant was collected and transferred to a 
new microcentrifuge tube and centrifuged (12,000 x g, 30 minutes, 4°C). The 
supernatant (labelled as cytosolic fraction (CF)) was stored at -80°C. The pellet 
(intact mitochondria) was re-suspened in 100 pL mitochondrial extraction buffer 
(MEB) and vortexed for 10 seconds to obtain mitochondrial protein lysate 
(labelled as mitohcondria fraction (MF)) and stored at -80°C.
Prior to MALDI analysis CF and MF were thawed and 10 pL of sample were 
mixed with 10 pL of internal standard, 10 pL of this solution was then mixed with 
10 pL of matrix and 0.5 pL of sample was deposited on the target MALDI plate.
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4.3 Results and Discussion
4.3.1 Solubility Studies of Phosphonium Compounds
Phosphonium compounds PPTS, PPTA and FPTTS are all readily dissolved in 
DCM however when added to aqueous media two distinct layers were observed 
and it is not a suitable solvent for dissolving phosphonium compounds for cell 
biology studies. Thioacetate salts (PPTA and FPPTA) are soluble in DMSO and 
methanol and thus can be further diluted in biological media for biological 
experiments. In contrast the zwitterions (PPTS and FPPTS) are insoluble in 
DMSO and methanol.
A number of different solvents including toluene, THF, methanol, acetone and 
PBS, cell culture media, and p-cyclodextrin, which is widely used in the 
pharmaceutical industry to enhance drug solubility (Loftsson and Brewster, 
1996), have all been investigated. None of these solvents were suitable for 
dissolving the zwitterions for cell biology experiments. The poor solubility of the 
zwitterions in solutions could possibly be due to the molecules being held 
together in the lattice via strong electrostatic interactions. Overall the 
thioacetates are readily soluble compared to the corresponding zwitterions, 
therefore the thioacetates (PPTA and FPPTA) were taken forward for cell 
biology studies.
4.3.2 Cytotoxicity of Phosphonium Ligands
Phosphonium compounds are known to selectively accumulate in the 
mitochondria of cancer cells and their anti-cancer activity have been of interest 
and has been investigated by several groups (Millard et al., 2010, Rideout et al., 
1989, Sehy et al., 1993, Manetta et al., 1996, Bergeron et al., 2009). Cell 
viability results presented below (table 4.1 and Figure 4.1) illustrated that the 
thioacetates described in chapter 3 are toxic towards PC3 cells at high 
concentrations and at prolonged treatment periods.
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Staisitical analysis showed that the treatment of PC3 with PPTA (Figure 4.1a) 
was significantly increased compared to untreated cells: at 24 hrs at 109 pm P 
-  <0.0001, 1090 pm P = <0.0001 and 10900 pm P = <0.0001, At 48 hrs 10.9 
pm P -  0.00292, 109 pm P = <0.0001, 1090 pm P = <0.0001 and 10900 pm P 
= <0.0001. At 72 hrs 10.9 pm P = 0.0031, 109 pm P = <0.0001, 1090 pm P = 
<0.0001 and 10900 pm P = <0.0001.
Staisitical analysis showed that the treatment of PC3 with FPPTA (Figure 4.1b) 
was significantly increased compared to untreated cells: at 24 hrs at 98 pm P =
0.0001, 980 pm P = <0.0001 and 9080 pm P = <0.0001. At 48 hrs at 98 pm P =
0.0008, 980 pm P = <0.0001 and 9080 pm P = <0.0001. At 72 hrs at 98 pm P =
0.0004, 980 pm P = <0.0001 and 9080 pmP= <0.0001.
IC50 values (pM)
24 Hr 48 Hr 72 Hr
PPTA 137.9 127.0 67.1
FPPTA 654.7 367.7 252.6
Table 4.1 IC50 values for thioacetate compounds, IC50 values calculated using 
non-linear regression analysis on GraphPad Prism software.
The IC50 values reported here are considerably higher than those of other TPP- 
containing molecules. Millards and co-workers have determined the cytotoxicity 
of 33 phosphonium compounds (all containing the TPP moiety with different 
side chains) in five different cell lines (Millard et al., 2010). The compounds 
investigated had IC50 values between 0.4 -8.0 pM at 72 hours in PC3 cell lines.
To make the comparison for the IC50 values of TPP analogues reported by 
Millard et al., 2010 with phosphonium ligands synthesised in chapter 3 easier, 
the values are shown below in Table 4.2, for comparison reasons only the 3 
most and least toxic compounds are reported, for the full list of IC50 values of 
TPP analogues please refer to their publication (Millard et al. 2010).
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Compound IC50 values (pM)
TPP 731 0.40
TPP 824 0.42
TPP 726 0.50
TPP 764 8.00
TPP 752, 781,825 5.00
PPTA 67.10
FPPTA 252.60
Table 4.2 IC50 values of different TPP analogues at 72 hours in PC3 cells 
reported by Millard et al., 2010 and IC50 values of phosphonium ligands PPTA 
and FPPTA at 72 hours in PC3 cells.
Millard and co-workers (2010) showed that their most toxic compound (TPP 731) 
(Figure 4.2) was -160 fold more toxic that PPTA while their least toxic 
compound (TPP 764) (Figure 4.2) which was still -8  fold more toxic than PPTA, 
this demonstrated that the phosphonium compounds synthesised in this study 
are comparatively non-toxic towards cells and can therefore be used as a 
transport vector to deliver AuNPs specifically to the cells.
b)
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Figure 4.2 Chemical structures of a) TPP 731 and b) TPP 764 (Millard et al.,
2010).
A further interesting feature is that the two phosphonium compounds exhibit 
different IC50 values PPTA has a lower IC50 value than FPPTA, the difference 
between the two thioacetate compounds is the replacement of hydrogen in the
153
para position with fluorine. This slight modification has a dramatic effect on the 
cytotoxicity of these compounds in cells and a decrease in cytotoxicity by 
approximately 4 fold was observed.
This suggested that the toxicity of these compounds is primarily determined by 
the TPP cation itself rather than the side chain (as the side chains are identical), 
and this observation is in agreement with the work reported by Smith and co­
workers (Smith et al., 2003). They showed that the maximum tolerated acute 
dosage for TPMP, MitoVit E and MitoQ (structures shown in Figure 4.3) in mice 
were generally similar (97 ± 13 pmol, 105 ± 9.2 pmol and 154 ± 4 pmol/kg/day 
respectively), despite their differences in their side chains and hydrophobicities. 
The side chains have shown to have an effect on the rate and extent of uptake; 
in vitro and in vivo experiments have demonstrated that the uptake of LPCs into 
the mitochondria is influenced by the length of the alkyl chain which contributes 
to the increase in hydrophobicity (Porteous etal., 2010, Ross etal., 2008).
OH
OCoH
Figure 4.3 Chemical structures of lipophilic phosphonium cations; a) TPMP 
(Porteous et al., 2010), b) MitoVit E (Ross et al., 2008) and c) MitoQ (Porteous 
et al., 2010).
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The PPTS and FPPTS free ligand themselves are relatively non-toxic to PC3 
cells, when these precursor ligands are used to synthesised P-AuNPs the S-C 
bond cleaves to form S-Au bonds. This slight modification in the side chain, may 
affect the rate and the extent of uptake of these P-AuNPs into cells. It has been 
shown that the uptake of LPCs into the mitochondria is influenced by the length 
of the alkyl chain (Porteous et al., 2010, Ross et al., 2008). However the 
functionalised AuNPs containing the TPP moiety maybe cytotoxic to cells, as 
the toxicity of LPCs is primarily determined by the TPP cation itself rather than 
the side chain (Smith et al., 2003).
4.3.1 Semi-Quantification Studies of Phosphonium Ligands in Cells using 
MALDI-MS
4.3.1.1 Matrix optimisation for the Study of Phosphonium Ligands in Cells 
using MALDI-MS
CHCA was unsuitable for the analysis of PPTA as the molecular ion peak for 
this compound [M]+ is at m/z 379 which also correspond to the CHCA dimer 
peak [2M+H]+ at m/z 379 (Figure 4.4). This would be a problem for 
quantification work, as the peak area would be either under or overestimated 
which will dramatically affect the interpretation and the results will also be 
inaccurate and unreliable. The other common matrix used for the analysis of 
small organic molecules is DHB (Cohen and Gusev, 2002), going forward for 
MALDI-MS experiments, DHB would be the matrix of choice for the analysis of 
PPTA to overcome the problem of the overlapping peaks observed for the 
analyte (PPTA) and the matrix (CHCA).
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Figure 4.4 MALDI-MS spectrum of PPTA, zoomed in at m/z 379 peak. The 
spectrum shows two non-fully resolved peaks around m/z 379. m/z 378.9981 
and 379.1038 corresponding to the molecular ion peak for PPTA and CHCA 
dimer peak respectively. The peaks at around m/z 380 correspond to the 
protonated peaks of 379 ([CHCA+H]+and [PPTA+H]+).
4.3.1.2 Internal Standard Optimisation for the Study of Phosphonium 
Ligands in Cells using MALDI-MS
Due to the fact that MALDI suffers from low “shot-to-shot” reproducibility, for 
quantitation experiments an internal standard (IS) can be employed to 
compensate for signal deviations. The use of an IS has shown to minimise 
deviations of analyte to IS signal ratio therefore improving experimental 
reproducibility. It is also important to take into consideration that peak heights 
for equimolar loadings of different analytes may vary significantly (Cohen and 
Gusev, 2002, Duncan et al., 1993, Duncan et a!., 2008, Sleno and Volmer,
2006).
In this project tetraphenylphosphonium bromide was used as the IS; the PPTA 
signal was significantly greater compared to FPPTA (Figure 4.5), therefore the 
IS to analyte ratio was optimised individually for each thioacetate compound 
before any more experiments were conducted. Ideally, the concentration of the
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IS should be roughly at a 1:1 ratio to the concentration of the highest standard. 
If the intensity of the IS is too high in relation to the analyte signal it will 
suppress the sample signal dramatically, and it would be hard to distinguish if 
the signal was actually a peak or background noise (Hoffmann and Stroobant,
2007).
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Figure 4.5 MALDI-MS spectrum of IS, PPTA and FPPTA at the same 
concentration of 100 pM. Peaks corresponding to IS at m/z 339.12, PPTA [M]+ 
at m/z 379.12 and FPPTA [M]+at m/z 433.09.
MALDI-MS spectrum of varying the ratio of the analyte (PPTA) to the IS ratio 
indicated that using a ratio of 1:10 (Figure 4.6a) was unsuitable because the 
signal of the IS was too high and thereby suppressing the sample signal. Using 
a ratio of 1:1 (Figure 4.6b) was a possibility, considering that both the PPTA and 
IS peaks have similar intensity counts.
However the IS was still greater than the PPTA peak. As mentioned previously, 
the ideal ratio between the peaks should ideally be 1:1 at the highest 
concentration of the standard. Using a ratio of 1:0.1 (Figure 4.6c), the PPTA 
peak was greater compared to the IS peak, therefore a ratio between 1:1 and 
1:0.1 should result in a ratio roughly in the region of 1:1 therefore the optimised 
ratio for PPTA was found to be 1:0.5.
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Figure 4.6 MALDI-MS spectrum of analyte to IS with varying different ratios; a) 
PPTA:IS 1:10, b) PPTA:IS 1:1, c) PPTA:IS 1:0.1, d) FPPTA:IS 1:10, e) 
FPPTA:IS 1:1, f) FPPTA:IS 1:0.1.Peaks corresponding to IS at m/z 339.14, 
PPTA [M]+ at m/z 379.15 and FPPTA [M]+at m/z 433.12.
MALDI-MS spectrum of varying the ratio of the analyte (FPPTA) to the IS ratio 
indicated that using a ratio of 1:10 (Figure 4.6d) was unsuitable because the 
signal of the IS was too high, and thereby suppressing the sample signal 
significantly. Using a ratio of 1:1 (Figure 4.6e) was also unsuitable as the IS 
peak was still considerably high in comparison to the sample peak. Using a ratio 
of 1:0.1 was ideal, since both the IS and FPPTA peaks give a roughly 1:1 ratio 
(Figure 4.6f). As mentioned previously the ideal ratio between the analyte and 
IS is around 1:1 and thus the optimised ratio for FPPTA and IS was found to be 
1:0.1.
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4.3.1.3 Calibration Curve of Phosphonium Ligands for Semi- 
Quantification Analysis by MALDI-MS
The graphs displayed in Figure 4.12 show the ion intensity ratio of the product 
ion m/z 379 and m/z 433 for PPTA and FPPTA respectively against the IS at 
m/z 339. The calibration curves demonstrate that the ion intensity ratio
increases with concentration of PPTA and PPTS.
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Figure 4.7 Standard curve for a) PPTA and b) FPPTA. The graph showed that 
between 0-1,000 nM, PPTA and FPPTA has a linear response of R2 = 0.9949 
and 0.9879 respectively. The insert in each graph shows the expanded region 
between 0-500 nM for each compound.
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4.3.1.4 Semi-Quantification Studies on the Cellular Uptake of 
Phosphonium Compounds in PC3 Cells by MALDI-MS
MALDI-MS spectrum shown below in Figure 4.13 shows a typical MALDI-MS 
spectra for a control and a treated sample.
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Figure 4.8 Typical MALDI-MS spectrum of the uptake of PPTA in PC3 cells for
a) the control sample and b) PC3 cells treated with PPTA. Peaks corresponding 
to matrix CHCA at m/z 136.99 and IS at m/z 339.01 were observed. No analyte 
peak for PPTA was observed at m/z 379 (Figure 4.13a) confirming the absence 
of PPTA in the untreated sample. PPTA peak observed at m/z 379.08 (Figure 
4.13b) confirmed the presence of PPTA in PC3 cells.
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All data obtained showed the presence of PPTA peak at m /z 379 across all 
incubation periods (5-90 minutes). This demonstrated that PPTA is taken-up by 
cells. The data obtained from the instrument were converted to ion intensity 
ratios and plotted in Excel for a visual representation of the uptake of the 
phosphonium compounds in cells. The diagram displayed below in Figure 4.9 
shows the concentration of phosphonium compounds against time.
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Figure 4.9 The uptake of PPTA by PC3 cells; PC3 cells were treated with 5 pM 
PPTA and incubated between 0-90 minutes. Concentrations were determined 
from the calibration curve, each sample was analysed in triplicate from 3 
independent experiments. Graph showed that PPTA is rapidly taken-up within 
10 minutes and plateaus >30 minutes. Using the Kruskal-Wallis test, the p value 
is < 0.0001.
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Figure 4.10 The uptake of FPPTA by PC3 cells; PC3 cells were treated with 5 
pM FPPTA and incubated between 0-90 minutes. Concentrations were 
determined from the calibration curve, each sample was analysed in triplicate 
from 3 independent experiments. Graph showed that FPPTA is rapidly taken- 
up within 10 minutes and drops after 60 minutes. Using the Kruskal-Wallis test 
the p value is < 0.0001.
Figures 4.9 and 4.10 showed that both PPTA and FPPTA are taken-up by PC3 
cells however the compounds exhibit different uptake profiles; PPTA is rapidly 
taken-up by the cells reaching a maximum uptake of 10 minutes, then drops 
slightly and finally plateau off after 30 minutes. This rapid increase in 
concentration of PPTA between 0 and 10 minutes was observed visually from 
the PPTA peak at m/z 379 (Figure 11a), between 30-90 minutes where the 
uptake plateaus off this could also be seen visually by overlaying the peaks at 
these specific time points (Figure 4.11 b).
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Figure 4.11 Overlay of MALDI-MS spectra of the PPTA product ion at m/z 379 
at different time points; a) shows the overlay between 0 and 10 minutes and b) 
shows the overlay between 30-90 minutes. Figure (a) shows the dramatic 
increase of PPTA following the 5 minute treatment. Figure (b) shows that the 
uptake between 30-90 minutes were very similar.
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In contrast, FPPTA reaches a maximum uptake 3 times slower than PPTA and 
drops and potentially reaching a plateau after 90 minutes, further experiments 
would be required to confirm this. Overall PPTA are taken-up to a greater extent 
in comparison to FPPTA with concentrations in the region of 100-200 nM for 
PPTA and 50-120 nM for FPPTA.
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Figure 4.12 Overlay of MALDI-MS spectra of the FPPTA product ion at m/z 433 
at varies different time points between 0-60 minutes.
Phosphonium compounds analysed in this chapter by MALDI-MS have shown 
to be taken-up by PC3 in the nanomolar region which is significantly higher 
compared to those reported in the literature. To the best of the authors 
knowledge to date there are only two reports available on the use of MALDI-MS 
for quantifying the uptake of phosphonium compounds in cells. Rideout and 
colleagues (Rideout et al., 1993) were the first to report the quantitative analysis 
of phosphonium cations by MALDI-MS, they have shown that 
tetraphenylphosphonium were taken up in sub-femtomole amounts in 
carcinoma cell lines. Cheng and co-workers (Cheng et al., 2005) reported the 
uptake of various phosphonium cations in the sub-femtomole region by C6 cells 
using MALDI-MS. Different phosphonium compounds (incorporating the TPP 
moiety with different side chains) exhibit different cellular uptake profiles, which
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indicates that the side chains have an effect on their cellular uptake, this 
observation is consistent with Ross et al. (2006) who have shown that the 
hydrophobicity of the side chains has an effect on the rate and extent of uptake 
of phosphonium compounds in vitro.
4.3.1.5 Investigating the Cellular Uptake of Phosphonium Compounds in 
the Mitochondrial Fraction
Once it had been confirmed that these phosphonium compounds are taken-up 
by cells, the next stage was to determine if these phosphonium compounds are 
taken up by the mitochondria and if so to compare their uptake in the 
mitochondrial fraction versus the cytosolic fraction. A mitochondrial fractionation 
kit was used for this part of the experiment (details of kit refer to chapter 4.2.2.3).
For both the mitochondrial and cytosolic fraction, the intensity counts were 
extremely low, below 100 counts (Figure 4.12). Even when the buffer was 
spiked with PPTA and the internal standard, the intensity signal was still 
extremely low (Figure 4.13). This illustrated that the buffer was not suitable to 
be analysed by MALDI-MS, it appeared that the buffer suppresses the signal, 
as on average the matrix gives an intensity count in the region of 1 - 2 x 105, 
and an intensity count in the region of 100 is extremely poor and thus any 
results obtained would be unreliable.
Despite the low intensity signals given, what was interesting was that in the 
cytosolic fraction (Figure 4.12a) the molecular ion peak for PPTA at m/z 379.17 
was observed, and the corresponding cleaved peak for the sample was 
observed at m/z 289.13, 275.10 and 262.10. These cleave peak observed are 
in agreement with the LDI-MS spectra for PPTA capped AuNPs reported in 
chapter 3(Figure 3.26). This confirmed that the PPTA is present in the cytosolic 
fraction of the cell.
The IS at mlz 339.14, and the cleaved PPTA peak at m/z 303.16 is observed in 
the mitochondrial fraction (Figure 4.12b), there is a small peak at m/z 379 which 
suggested it is the sample peak, along with the present of the cleaved peak for 
PPTA at m/z 303.16 this shows that PPTA is present in the mitochondrial
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fraction of the cell thus demonstrating that PPTA is taken-up in the cell and 
specifically by the mitochondria. This observation is confirmed by TEM analysis 
which is reported in next chapter (chapter 5).
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Figure 4.13 Typical MALDI-MS spectrum of the uptake of TPPA in a) the 
cytosolic fraction and b) mitochondrial fraction. Both spectra exhibited extremely 
low intensity counts below 100 counts, thereby illustrating that the buffer 
suppresses the signal and is not suitable to be analysed by MALDI-MS.
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Figure 4.14 Typical MALDI-MS spectrum of extraction buffer spiked with PPTA 
and IS, even when buffer was spiked, the intensity counts were still below 100, 
thereby confirming that the buffer results in supression when analysed by 
MALDI-MS.
4.4 Conclusion
The first aim of this chapter was to evaluate the cytotoxicity of PPTA and 
FPPTA in PC3 cells; the results showed that both compounds were cytotoxic 
towards cells at very high concentrations and at long incubation times of 72 
hours. Rather than synthesising compounds containing the TPP moiety that are 
cytotoxic towards cells for therapeutic effects like many other research groups 
(Millard et al., 2010, Rideout etal., 1989, Patel et al., 1994, Manetta etal., 1996) 
the aim of this project was to exploit relatively non-cytotoxic phosphonium 
compound as described previously in chapter 3 to act as transport vector to 
delivery AuNPs into the cells for photothermal therapy applications.
The IC50 value for PPTA at 72 hours is approximately 16 times lower than the 
least cytotoxic phosphonium salt reported by Millard et al. (2010), this 
demonstrates that these compounds are relatively non-toxic to the cells and it
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would be feasible to these compounds to the surface of nanoparticles to 
produce functionalised AuNPs for targeted drug delivery to the site of 
mitochondria for other therapeutic effects such as PTT (this will be investigated 
in the next chapter).
The second aim of the work reported in this chapter is the semi-quantification 
studies of phosphonium compounds in cells by MALDI-TOF-MS; cellular uptake 
studies provided evidence that both thioacetate compounds are rapidly taken up 
by cells in the nanomolar region. The use of MALDI-MS for quantitative 
applications is very complicated and challenging due to the irreproducible 
analyte signal arises from non-homogenous co-crystallisation of the sample with 
the matrix. CHCA is routinely used in the analysis of small molecules as it 
produces uniform crystallisation (Sleno and Volmer, 2006). DHB was employed 
in this study to compensate for the isobaric interference with the CHCA dimer 
peak ([2M+H]+) at m/z 379, an IS was also used to improve overall experimental 
reproducibility.
The uptake of phosphonium compounds in the mitochondrial fractions have 
been attempted, however the buffers in the mitochondrial isolation kit appeared 
to suppress sample signals and gave extremely low intensity counts (< 100). In 
future, in order to obtain useful information on the uptake of phosphonium 
compounds in the mitochondria fraction, it is critical to find alternative 
approaches to isolate the mitochondria fraction and use buffers that do not 
suppress the intensity count in the MS.
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Chapter 5.
Investigation of the use of phosphonium- 
functionalised gold nanoparticles in vitro for 
photothermal therapy applications
174
5.1 Introduction
AuNPs are known to passively target tumour cells due to their inherent small 
size and the chaotic nature of tumour blood vessels. It has been demonstrated 
that "naked" AuNPs with no functionalisation do not target all cell types (Patra et 
al., 2007). AuNPs can be directed to specific sites by attaching ligands to the 
surface of the nanoparticles for targeted delivery, examples include antibodies 
to target a specific tumour marker that is usually overexpressed on tumour cells 
of interest (El-Sayed et al., 2006, Sokolov et al., 2003, Kirui et al., 2010) and 
ligands to target specific receptors overexpressed on the surface of tumour cells 
(Dixit et al., 2006, Chen et al., 2007).
Chemotherapeutic drugs have also been attached to the surface of AuNPs to 
enhance the cellular uptake and improve the bioavailability of the drug (Gibson 
et al., 2007, Nadeau et al., 2010, Hwu et al., 2009). Targeting can be improved 
further to target specific sub-cellular organelles such as the mitochondria; 
AuNPs have been functionalised with a pro-apoptotic peptide which has shown 
to amplify apoptotic cell death in HeLa cells by inducing mitochondrial 
membrane swelling and bursting the membrane (Chen et al., 2013).
The concept of using heat to treat cancer is not new (Field and Bleehen, 1979); 
both hyperthermia and thermal ablation use heat to kill pathophysiological 
tissues, the difference is based on the range of heating temperatures. Thermal 
ablation involves raising the temperature above 50°C and induces cell death by 
necrosis, whereas hyperthermia is associated with mild increase in temperature 
between 41-46°C and causes cell death via the apoptotic pathway (Vauthier et 
al., 2011, Lepock, 2003, Rivera Gil etal., 2010).
The current model of apoptotic hyperthermic cell death indicates that an 
increase in temperature will result in the activation of pro-caspase-2; caspase-2 
can act as an initiator caspase which engages in the mitochondria-dependent 
apoptotic pathway by inducing the release of cytochrome c and other apoptotic 
proteins (e.g. Bak and Bax) into the cell cytoplasm, subsequently activating 
other apoptotic proteins leading to mitochondrial membrane damage which is 
critical for hyperthermic induced apoptotic cell death (Milleron and Bratton, 2007,
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Aksenova et al., 2013, Guo et al., 2002). Furthermore Caspase-2 has also 
been suggested to be able to act as an effector caspase (Delgado et al., 2013, 
He et al., 2004).
The application of thermotherapy in a clinical setting has been limited to 
unresectable malignant hepatic leison, pelvic, prostate cancer, head and neck 
tumours (Cherukuri et al., 2010, Baronzio et al., 2009, El-Sayed, 2010). At 
present the lack of tissue specificity is the primary obstacle in the development 
of thermotherapy, in addition to killing cancer cells, the heat also spreads to 
neighbouring healthy tissues causing collateral damage (Cherukuri and Curley, 
2010, Diagaradjane et al., 2008, Feng et al., 2009). This lack of specificity has 
been overcome by using gold based nanomaterials; the use of AuNPs for 
photothermal therapy (PTT) was first demonstrated by Pistillides and co­
workers in 2003 (Pitsillides et al., 2003).
AuNPs have the unique ability of converting absorbed light into heat on a 
picosecond time domain by electron-phonon and phonon-phonon processes 
(Link and El-Sayed, 2000). This highly efficient conversion of heat energy from 
absorbed light led to their investigation for cancer therapeutics (Huang et al., 
2008, Huang et al., 2007, Vauthier et al., 2011, Everts, 2007). Several groups 
have demonstrated elective PTT in cancer cells in vitro; Pitsillides and 
colleagues (Pitsillides et al., 2003) treated lymphocytes with spherical AuNPs (d 
= 30 nm) conjugated to anti-CD8-R-phycoerythrin and irradiated with short laser 
pulses (20 ns) at 532 nm. CD8+ T lymphocytes showed an increase in 
percentage cell death with the increase in number of AuNPs per cell with lowest 
cell death > 50%, whereas CD8- T lymphocytes exhibited good cell viability 
greater than 90% under the same conditions. Li and co-workers (Li et al., 2009) 
treated breast cancer cells (Ks578T) with spherical AuNPs (d = 23 nm) 
conjugated with transferrin and irradiated with a nanosecond laser at 530 nm. 
When cells were treated with conjugated AuNPs cell damage were observed at 
a significant lower laser power of 7 W/cm2 in comparison to 1600 cm2 in the 
absence of AuNPs.
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El-Sayed’s group (El-Sayed et al., 2006, Huang et al., 2006) treated oral 
squamous carcinoma cells lines (HOC 3 Clone 8 and HSC 313) and a benign 
epithelial cell line (HaCaT) with spherical AuNPs (d = 40 nm) conjugated to anti- 
EGFR antibody and irradiated with a continuous wave (CW) argon laser at 514 
nm. The selectivity of this method is demonstrated by the results that carcinoma 
cells required less than half the laser energy to be killed in comparison to 
benign cells; 19 W/cm2 for HOC, 25 W/cm2for HSC and 57 W/cm2for HaCaT. 
In addition, no photothermal damage were observed for any of the cell types 
without AuNP labeling, even at four times the energy required to kill cancer cells 
labelled with antibody conjugated AuNPs.
The main aim of this chapter was to investigate if AuNPs functionalised with 
lipophilic phosphonium ligands synthesised previously in chapter 3 can lead to 
mitochondria specific accumulation and to selectively induce apoptosis of cells 
by photothermal therapy.
5.2 Materials and Experimental Methods
5.2.1 Reagents
Propidium iodide (PI) Hoechst 33342, gold nanoparticles 5 nm, glutaraldehyde, 
sodium phosphate dibasic (Na2HP0 4), sodium phosphate dibasic, 
dodecahydrate (Na2HP04.12H20) and 1,2-epoxypropane were purchased from 
Sigma (Gillingham, Dorset, UK). Phenol red free Dulbecco’s Modified Eagle 
Medium (PRF DMEM) was obtained from Invitrogen Life Technologies (Paisley, 
Renfrewshire, UK) and Caspase-3 activity assay was acquired from Cambridge 
Bioscience (Bar Hill, Cambridge, UK). Agar low viscosity (LV) resin, agar low 
viscosity hardener (VH1 & VH2), low viscosity accelerator and 2% osmimum 
tetraoxide were purchased from Agar Scientific (Stansted, Essex, UK).
5.2.2 Investigating the use of Phosphonium-Functionalised Gold 
Nanoparticles for Photothermal Therapy
PC3 cells were seeded in a 96 well plate at a density of 10,000 cells/ well and 
allowed to adhere overnight. Cells were then treated with different 
concentrations of AuNPs (0-100 mg/mL) and incubated for several hours. For 
preliminary irradiation experiments, an Olympus 1X81 motorised inverted
177
microscope (Olympus, Southend-on-Sea, UK) with a 100 watt bulb, with varying 
different wavelength cubes for different length of time (0-30 minutes) was used, 
after irradiation cells were returned to the incubator and visualised on the 
following day.
5 nm diameter gold nanoparticles was chosen as a control for experiments, 
because it has been reported in the literature that AuNPs sizes > 3 nm was able 
to enter the mitochondria intermembrane space whereas 6 nm AuNPs were not 
(Salnikov et al., 2007). Thus the cut off point for AuNPs not able to pass through 
the mitochondrial membrane is somewhere between > 3 and 6 nm. 5 nm were 
chosen because P-AuNPs synthesised previously in chapter 3 are between 3.0 
and 4.9 nm depending on the precursor ligand. If the control of 5 nm were 
taken-up by the mitochondria, in theory PPTA capped AuNPs (4.9 nm) would 
also be taken-up by the mitochondria.
For experiments irradiated using a Zeiss Axiovert 200M inverted microscope, 
laser LSM 510 laser module (Zeiss, Cambridge, UK), PC3 cells were seeded in 
fluorodish cell culture dish 35 mm (World Precision Instruments, Hitchin, 
Hertfordshire, UK) at a density of 500,000 cells/dish. Cells were then treated 
with different concentrations of AuNPs (0-10 pg/mL), incubated for several 
hours and irradiated, after irradiation cells were returned to the incubator and 
visualised the next day.
To visualise the cells, the cells were first stained with Hoechst (20pg/mL) and 
incubated for 30 minutes, prior to analysis PI (10pg/mL) was added. Cells were 
visualised using an Olympus 1X81 motorised inverted microscope (Olympus, 
Southend-on-Sea, UK). The number of viable, apoptotic and necrotic cells were 
counted, a total umber of 200 cells were counted from each field of view from 3 
independent repeats. The number of viable, apoptotic and necrotic cells are 
expressed as a percentage of the total number of cells counted. Staistical 
analyses were then conducted using the method described previously in 
chapter 2.16.
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5.2.3 Investigating the Cellular Uptake of Phosphonium-Functionalised 
Gold Nanoparticles by Transmission Electron Microscopy
PC3 cells were plated in a 6 well plate at a density of 500,000 cells/ well and 
allowed to adhere overnight. Cells were then treated with varied concentrations 
of P-AuNPs (12.5, 25.0, 50.0 mg/mL) and incubated overnight. After incubation, 
cells were trypsinised and transferred to a microcentrifuge tube and washed 
with phosphate buffer 0.1 M pH 7.2 for 10 minutes x 2. 0.1 M phosphate buffer
7.2 was prepared by mixing 36 mL of phosphate solution A (0.2 M of 
Na2HP0 4 .1 2 H2 0 ) with 14 mL phosphate solution B (0.2 M of Na2HP0 4 ). Cell 
pellet were then fixed in 2% glutaraldehyde in phosphate buffer for 1 hour, 
washed in phosphate buffer 0.1 M pH 7.2 for 10 minutes x 2.
Cells were then fixed in 2% aqueous osmium tetroxide for 1 hour, washed in 
DIH2O for 15 minutes x 2 and embedded in 2% agar in DIH2O at 50°C. Agar 
pellets were cut into pieces approximately 1 x1  mm, dehydrated in a series of 
ethanol and water (25, 50, 70, 90 and 100% x 2, 30 minutes each), ethanol was 
then replaced with 1,2-epoxypropane for 1 hour, after an hour 1,2- 
epoxypropane was replaced with 50:50 1,2-epoxypropane: resin overnight. 
Sample was then transferred to a BEEM capsules and fresh 100% resin was 
added and incubated overnight at 65°C with caps off. Resin was prepared by 
mixing 48 mL Agar LV resin, 10 mL VH1, 42 mL VH2 and 2.5 mL accelerator. 
For a schematic illustration see Figure 5.1.
Samples were taken to Brunei University for sectioning and TEM analysis; 
samples were sectioned at 100 nm thickness using a PowerTome XL 
Ultramicrotome (Boeckeler, Tuscon, Arizona, USA). TEM micrographs of 
AuNPs in cells were obtained on a Jeol JEM-21 OOF TEM (ETC, Brunei 
University, Middlesex, UK), set at 100 kV.
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5.2.4 Quantification of the Uptake of Phosphonium-Functionalised Gold 
Nanoparticles in cells by ICP-MS
PC3 cells were plated in a 6 well plate at a density of 500,000 cells/well and 
allowed to adhere overnight. Cells were treated with different concentrations of 
P-AuNPs (12.5, 25.0, 50.0 mg/mL) and incubated overnight. On the subsequent 
day cells were trypsinised, washed in PBS, fixed in 100% EtOH and sent to 
MEDAC (Chobham, Surrey, UK) for ICP-MS analysis.
5.3 Results and Discussion
5.3.1 Solubility of Phosphonium-Functionalised Gold Nanoparticles in 
Biological Media
The biological activity of AuNPs is influenced by many parameters including the 
particle size, shape, concentration, surface charge and agglomeration state 
(Pan et al., 2007, Yen et al., 2009). The investigation of the biological effects of 
AuNPs and their applications in biomedical research is ongoing (Sperling et al., 
2008, Arnida et al., 2010, Cobley et al., 2011, Kanaras et al., 2011, Kumar et al., 
2013). The size of commercial standard AuNPs (60 nm, National Institute of 
Standards and Technology reference material 8013) has been shown to 
increase in size from 61 to 70 nm in the presence of human plasma, indicating 
that the addition of proteins modifies the surface of the nanoparticles in some 
way (Montes-Burgos et al., 2010). This alteration may induce changes of the 
AuNPs properties and thus affect their biological activity in cells.
The freeze-dried P-AuNPs can be re-suspended in water, methanol, ethanol or 
DMSO. The UV-vis spectra of the solutions after re-suspension in DIH2O are 
similar to that of a freshly prepared solution (Figure 3. 9), indicating that the 
freeze-drying process does not significantly alter the particle size or shape. In 
contrast when dissolved in complete Dulbecco’s modified Eagle’s medium 
(CDMEM), a significant shift in the SPR band from 520 nm to -560 nm was 
observed, this suggest that the particle size has been modified. This shift in 
SPR band was also observed for purchase AuNPs of similar size (5 nm) (Figure 
5.4), which indicate that the CDMEM has an effect on AuNPs in general and not 
just P-AuNPs.
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Different cell culture media have been used to investigate the dispersibility of 
AuNPs; in pure RPMI, strong agglomeration was observed, where as in RPMI 
containing up to 10% foetal calf serum (FCS) or bovine serum albumin showed 
the AuNPs remained well dispersed above 1% w/v protein concentration (Mahl 
et al., 2010).
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Figure 5.2 Visible spectra of nanoparticles re-suspended in DIH20  and 
CDMEM for a) commercial 5nm AuNPs and b) P-AuNPs.
Both nanoparticles exhibited their characteristic SPR band at -520 nm when 
dissolved in deionised-water, however when dissolved in CDMEM, their 
characteristic SPR band shifts to above -550 nm. It is known that the SPR band 
of spherical gold nanoparticles shifts from -  520 nm to -  600 nm as you 
increase the size from 5 nm to 99 nm (Jain et al., 2007). Therefore the shift in 
peak observed from 520 nm to 550 nm suggested that the AuNPs has 
aggregated.
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Visible spectra shown in Figure 5.2 suggested that there might be a possible 
peak at around 400 nm, the origin of this peak has been investigated (Figure 
5.3). Studies showed that this peak is due to FCS and does not interfere with 
the SPR band of the AuNPs.
Figure 5.3 Visable spectra of P-AuNPs re-suspended in different solutions, and 
with different concentration of FCS. The peak at around 400 nm correlates to 
FCS as the absorbance of this peak increases dramatically as the concentration 
of FCS increase from 10% to 100%.
•  a) PRF DMEM + 10% FCS
•  b) PBS+10% FCS
•  c) DIH20
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Figure 5.4 Visable spectra of P-AuNPs re-suspended in different biological 
media; a) phosphate buffered saline plus 10% foetal calf serum, b) phenol red 
free Dulbecco’s modified Eagle medium plus 10% foetal calf serum and c) 
deionised water.
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Visible spectra illustrated that P-AuNPs can be dissolved in phenol red free 
DMEM, as its gives a very similar SPR band profile as observed in deionised 
water. When P-AuNPs was dissolved in either PBS or phenol red free DMEM it 
gave very similar SPR profiles as observed in DIH20. This indicated that these 
biological media do not alter the particle size or shape of the AuNPs and are 
both suitable for re-suspending AuNPs for cell culture studies. Since cells are 
best cultured in DMEM, it was decided that phenol red free DMEM would be 
used as the cell culture medium rather than PBS plus 10% FCS for experiments 
involving AuNPs and cells.
5.3.2 Investigating the Potential of Phosphonium-Functionalised Gold 
Nanoparticles for Photothermal Therapy Applications
5.3.2.1 Investigating Different Excitation Wavelength of Light
AuNPs tuneable optical properties are due to the phenomenon of SPR, and are 
sensitive to the size, shape, composition and the dielectric environment 
(Dreaden et al., 2011, Jain et al., 2008, Kelly et al., 2003, Liz-Marzan, 2004). 
Theoretically the SPR effect should only occur when a frequency overlaps the 
SPR band of the AuNPs which subsequently result in local heating of the 
surrounding environment.
To test this theory, cells have been treated with P-AuNPs and irradiated for the 
same amount of time with different wavelengths of light by using different filter 
cubes including yellow filter cube (U-MWIY, 545-580 nm), blue filter cube (U- 
MWIB, 460-490 nm), narrow green filter cube (U-MNG, 530-550 nm) and wide 
green filter cube (U-MWG, 510-550 nm) (Figure 5.6). After irradiating the cells 
with the light they were returned to the incubator for 24 hours prior to analysis 
by fluorescent microscopy.
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Figure 5.5 Diagram to illustrate different filter block cubes used in the 
experiment; yellow filter cube (U-MWIY, 545-580 nm), blue filter cube (U-MWB, 
460-495 nm), narrow green filter cube (U-MNG, 530-550 nm) and wide green 
filter cube (U-MWG, 510-550 nm). Only the latter filter cube overlaps the SPR 
band of P-AuNPs, when cells were irradiated with this filter cube it induces a 
response in cells.
The result showed that when PC3 cells were treated with P-AuNPs at a 
concentration non-toxic to cells and irradiated with a light source that does not 
overlap the SPR band of the AuNPs, the cells have no effect and were alive. 
When cells were treated with the same dose of P-AuNPs and irradiated with a 
light source that overlaps the SPR band of the AuNPs (510-550 nm) cells were 
killed either by apoptosis or necrosis depending on the radiation length of time
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(Figure 5.6). After 5 minutes irradiation, cells died by apoptosis as shown by 
typical apoptotic morphology (cell shrinkage and nuclear material condensation), 
and after 10 minutes irradiation cells died from necrosis as confirmed by the 
positive staining of PI.
_____________ 5 minutes
Apoptotic
10 minutes
All cells 
Late apoptotic or necrotic
100 pm
Figure 5.6 Fluorescent microscope images of PC3 cells treated with P-AuNPs 
25 mg/ml_ for 4 hours and irradiated with wide green filter cube (U-MWG, 510- 
550 nm) for 5 and 10 minutes. At 5 minutes, cells exhibited typical apoptotic 
morphology, whereas at 10 minuntes, all cells were dead (late apoptosis or 
necrosis) and the membranes were permeabilised which was confirmed by the 
positive staining of PI. Images were taken on an 20x objective lens.
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These results illustrated that P-AuNPs are specific to green light excitation (510- 
550 nm); when cells which were irradiated with yellow (U-MWIY, 545-580 nm), 
blue (U-MWB, 460-490 nm) and narrow green filter cube (U-MNG, 530-550 nm) 
cells remain viable. However when irradiated with a light source that overlaps 
the SPR of the P-AuNPs at 520 nm, cells undergo photothermal effect and 
result in cell death. Therefore the wide green (U-MWG, 510-550 nm) filter cube 
was used for future PTT experiments.
5.3.2.2 Preliminary Investigation of the use of Phosphonium- 
Functionalised Gold Nanoparticles as Photothermal Therapy 
Agents
Once it had been established that P-AuNPs are specifically activated by green 
light excitation (U-MWG, 510-550 nm), experiments were conducted to explore 
the effect of different concentrations of P-AuNPs on cells. PC3 cells were 
treated with different concentration of P-AuNPs and irradiated with the same 
wavelength (U-MWG, 510-550 nm) and length of time (5 minutes). The result 
(Figure 5.8) showed that an increasing in concentration of P-AuNPs resulted in 
an increase number of dead cells.
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Figure 5.8 Fluorescent microscope images of cells treated with varying 
concentrations of P-AuPs (0-10 mg/mL) and irradiated with U-MWG, 510-550 
nm light for 10 minutes. The number of PI positive cells increases with 
concentration of P-AuNPs. Cells stained with Hoechst and PI, images were 
taken on a 10x objective lens.
To confirm that cells undergo apoptosis when treated with P-AuNPs (25 mg/mL) 
and irradiated for 5 minutes with U-MWG, 510-550 nm light source, caspase-3 
activity assay was used. With the addition of P-AuNPs to cells, the percentage 
of caspase-3 positive cells increased from 6 % (prior to treatment) to -70% 
(Figure 5.10). Cells that were caspase 3 positive indicated that they were 
actively undergoing apoptosis and the results (Figure 5.9) showed that there 
was an increase in the number of cells that were actively undergoing apoptosis 
followed by 5 minutes irradiation. Statisitcal analysis (figure 5.10) showed that 
there is a significant increase of caspase-3 positive cells after the treatment of 
25 mg/mL of P-AuNPs followed by 5 minutes irradiation with green light U-MWG 
510-550 nm excitation (P = 0.0213).
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Figure 5.9 Fluorescent microscope images of cells treated with P-AuNPs and 
irradiated with U-MWG, 510-550 nm light for 5 minutes. Cells were stained with 
caspase-3 assay; the number of caspase-3 positive cells increases 
considerably when cells were treated and irradiated. Images were taken on a 
10x objective lens.
190
120-1
100
75
0o
4-o0)U)ro4-*c
G)ya>en­
viable Cells
Caspase-3 Positive Cells
Concentration of P-AuNPs 
Figure 5.10 Quantitation of PC3 cells treated with 25 mg/mL P-AuNPs and 
irradiated with U-MWG 510-550 nm light for 5 minutes. Cells were stained with 
caspase-3 assay. Data is expressed as a percentage of cells (200 cells were 
count for each reading), for each sample 3 readings were recorded from each 
triplicate repeats (n=9). * Statisitcal significance between the number of 
Caspase-3 positive cells P < 0.05.
In a subsequent experiment, instead of irradiating each well individually, two 
sample wells were irradiated at the same time in an attempt to increase sample 
throughput. Interestingly, the result showed a dramatic difference in caspase-3 
positive cells within the irradiated area vs non-irradiated area (Figure 5.11). 
When cells were treated with P-AuNPs at a concentration of 25 mg/mL and 
irradiated with U-MWG, 510-550 nm light for 5 minutes, cells responded to PTT 
and apoptosis was observed, furthermore death by apoptosis was confirmed by 
caspase 3 assay.
191
500 Mm
Figure 5.11 Fluorescent microscope images of cells treated with P-AuPs (25 
mg/mL) and irradiated with U-MWG, 510-550 nm light for 5 minutes, cells 
stained with caspase-3 assay. As shown in the Figure, there are substantial 
number of cells that are caspase-3 positive within the irradiated area compared 
to the non-irradiated area. Images were taken on a 4x objective lens.
Preliminary PTT experiments demonstrated that P-AuNPs synthesised 
responded specifically to an excitation wavelength that overlaps with the SPR 
band at 520 nm and no PTT effect was observed when cells were irradiated 
with a light source that did not overlap the SPR band (Figure 5.5). The PTT 
effect on cells is dependent on the concentration of P-AuNPs; at a 
concentration of 25 mg/mL cells were alive, with some apoptotic cell death 
whereas concentrations above 50 mg/mL majority of cells were dead by 
necrosis. Apoptotic death were observed at a concentration 25 mg/mL P-AuNPs, 
this was confirmed by caspase 3 assay, which showed that after 5 minutes 
irradiation, cells were actively undergoing apoptosis.
To confirm the preliminary PTT results, it was important to conduct the 
experiments using a more controlled system particularly the intensity of the
excitation source and the irradiation area, which had to be consistent and 
regulated across experiments. These parameters were not controllable using 
the Olympus fluorescent microscope; the Zeiss confocal microscope has the 
ability to control the laser power and scan size, thereby PTT experiments were 
investigated using the confocal microscope.
5.3.2.3 Investigating the use of Phosphonium-Functionalised Gold 
Nanoparticles as Photothermal Therapy Agents by Confocal 
Microscopy
Before irradiating PC3 cells treated with P-AuNPs, it was crucial to determine 
the non-toxic dosage of P-AuNPs, to ensure that cell death is a result of 
hyperthermia rather than from the cytotoxicity of the P-AuNPs. PC3 cells were 
treated with P-AuNPs at different concentrations for 24 hours, typical images 
are shown in Figure 5.13. To provide useful quantification data 200 cells were 
counted and the values of viable, apoptotic and necrotic cells were expressed 
as a percentage (Figure 5.12).
Late Apoptotic/Necrotic
Apoptotic
Live
P-AuNP Concentration (mg/mL)
Figure 5.12 PC3 cells were treated with varying different concentrations of P- 
AuNPs (0-10 mg/mL) for 24 hours. Cells were stained with Hoechst and PI and 
viewed by fluorescent microscopy. Data is expressed as percentages of cells 
(200 cells were counted for each reading), for each sample 3 readings were 
recorded for each of the triplicate repeats (n=9). *Statisitcal significance 
between the levels of apoptotic cells P < 0.05.
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Staisitical analysis showed that the levels of apoptotic cells in PC3 treated with 
different concentrations of P-AuNPs increased significantly compared to control: 
0.25 mg/mL (P = 0.0017), 0.50 mg/mL (P = 0.0002), 0.75 mg/mL (P = 0.00021), 
1.0 mg/mL (P = < 0.0001), 1.25 mg/mL (P = < 0.0001), 2.5 mg/mL (P = < 
0.0001), 5.0 mg/mL (P= < 0.0001), 7.5 mg/mL (P = < 0.0001), 10.0 mg/mL (P = 
<0.00291).
Results presented above in Figure 5.12 showed that P-AuNPs with a 
concentration of up to 5.0 mg/mL are relatively non-toxic to cells, with cell 
viability above 90% and at a P-AuNPs concentration above 5.0 mg/mL the 
majority of dead cells were necrotic. This observation could also be seen 
visually as shown below in Figure 5.13, with the number of of PI positive cells 
increasing with the increase in concentration of P-AuNPs.
P-AuNPs concentration of 1.25 and 2.50 mg/mL were chosen for follow up PTT 
experiments to determine if the cells would selectively induce apoptosis 
following green light excitation (U-MWG, 510-550 nm). As a positive control, P- 
AuNPs concentration of 5.0 mg/mL was used as the toxic dose for comparison 
purposes.
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In subsequent PTT experiments, P-AuNPs concentration at 1.25 and 2.50 
mg/mL were investigated to determine if the cells would selectively induce 
apoptosis following green light excitation (U-MWG, 510-550 nm). In addition to 
treating the cells with P-AuNPs for 24 hours, a 6 hour time point was also 
selected as it has been reported that the cellular uptake of AuNPs reached a 
plateau after 6 hours incubation with cells (Chithrani et al., 2006).
Overall the results suggested that irradiating PC3 cells followed by a 6 hour 
treatment of P-AuNPs with varying concentrations between 0-5.0 mg/mL have 
negligible effect on cells. As shown in Figure 5.14-5.16 when PC3 cells were 
treated with P-AuNPs (0-5.0 mg/mL) for 6 hours and irradiated between 0-20 
minutes, ca 90% of cells remained viable.
In contrast when PC3 wells were treated with P-AuNPs for 24 hours and 
irradiated for different lengths of time (between 0-20 minutes), the effect of cell 
death is dependent upon the concentration of P-AuNPs. As the concentration of 
P-AuNPs increase from 1.25 mg/mL to 5.0 mg/mL the percentage of dead cells 
also increases (Figure 5.17-5.19). At the highest concentration of 5.0 mg/mL ca 
80% of cells were dead, even when not irradiated. This result is in agreement 
with results obtained previously in Figure 5.12, and this confirmed that P-AuNPs 
at a concentration of 5.0 mg/mL is cytotoxic to cells after 24 hours incubation. 
However this dosage is not cytotoxic to cells at a shorter incubation time of 6 
hours (Figure 5.16).
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Figure 5.14 Percentage of viable, apoptotic and necrotic cells following a 6 hour 
treatment with P-AuNPs at a concentration of 1.25 mg/mL and irradiated with a 
523 nm laser for varied length of time (0-20 minutes). For each sample 3 
repeats were conducted, for each repeat 3 readings were obtained by counting 
200 cells per sample (n=9), data expressed as percentage of cells.
Results showed that treating cells with P-AuNPs at a concentration of 1.25 
mg/mL for 6 hours is non-cytotoxic to cells (control at 0 min), when irradiated 
with a laser at 523 nm at the maximum time point of 20 minutes, cells remained 
unaffected with cell viability above 95%. Statistical analysis showed that when 
PC3 cells were treated with P-AuNPs at a concentration at 1.25 mg/mL for 6 
hours and irradiated for up to 20 minutes with a 532 nm laser has no significant 
effect on the number of apoptotic cells compared to control (P = > 0.05).
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Figure 5.15 Percentage of viable, apoptotic and necrotic cells following a 6 hour 
treatment with P-AuNPs at a concentration of 2.50 mg/mL and irradiated with a 
523 nm laser for varied length of time (0-20 minutes). For each sample 3 
repeats were conducted, for each repeat 3 readings were obtained by counting 
200 cells per sample, data expressed as a percentage of cells (n=9).
Results showed that treating cells with P-AuNPs at a concentration of 2.50 
mg/mL for 6 hours is non-cytotoxic to cells (control at 0 min), when irradiated 
with a laser at 523 nm at the maximum time point of 20 minutes, cells remained 
unaffected with cell viability above 95%. Statistical analysis showed that when 
PC3 cells were treated with P-AuNPs at a concentration of 2.50 mg/mL for 6 
hours and irradiated for 20 minutes with a 532 nm laser has no significant effect 
on the number of apoptotic cells compared to control (P = > 0.05).
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Figure 5.16 Percentage of viable, apoptotic and necrotic cells following a 6 hour 
treatment with P-AuNPs at a concentration of 5.00 mg/mL and irradiated with a 
523 nm laser for varied length of time (0-20 minutes). For each sample 3 
repeats were conducted, for each repeat 3 readings were obtained by counting 
200 cells per sample, data expressed as percentage of cells (n=9). * Statisitcal 
significance between the levels of apoptotic cells P < 0.05.
Results showed that treating cells with P-AuNPs at a concentration of 5.00 
mg/mL for 6 hours is non-cytotoxic to cells (control at 0 min), this confirmed that 
the death of cells following irradiation were due to the effect from the irradiation 
of cells and not by the cytotoxicity of P-AuNPs. Statistical analysis showed that 
when PC3 cells were treated at a concentration of 5.00 mg/mL for 6 hours and 
irradiated for 5, 10 and 20 minutes with a 532 nm laser has an significant effect 
on the number of apoptotic cells compared to control (P = > 0.0001, P = > 
0.0002 and P = > 0.0031 respectively).
199
120n
100
tj)
o  80Mn-0
o> 6 01  c1
o  4 0<DCL
20 -I
<3
"n r
■ I  Late apoptotic/ necrotic
■ 1  Apoptotic
□  Live
o f
+1.25 mg/mL P-AuNPs
Figure 5.17 Percentage of viable, apoptotic and necrotic cells following a 24 
hour treatment with P-AuNPs at a concentration of 1.25 mg/mL and irradiated 
with a 523 nm laser for varied length of time (0-20 minutes). For each sample 3 
repeats were conducted, for each repeat 3 readings were obtained by counting 
200 cells per sample, data expressed as percentage of cells (n=9). * Statisitcal 
significance between the levels of apoptotic cells P < 0.05.
Results showed that treating cells with P-AuNPs at a concentration of 1.25 
mg/mL for 24 hours has negligible effect on cells (control at 0 min), this 
confirmed that the death of cells following irradiation were due to effect from the 
irradiation of cells and not by the cytotoxicity of P-AuNPs. When cells were 
irradiated with a laser at 523 nm approximately 10% of cells were dead. 
Statistical analysis showed that PC3 cells treated at a concentration of 1.25 
mg/mL for 24 hours and irradiated for 10 minutes with a 532 nm laser has an 
significant effect on the number of apoptotic cells compared to control (P = < 
0.0005).
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Figure 5.18 Percentage of viable, apoptotic and necrotic cells following a 24 
hour treatment with P-AuNPs at a concentration of 2.50 mg/mL and irradiated 
with a 523 nm laser for varied length of time (0-20 minutes). For each sample 3 
repeats were conducted, for each repeat 3 readings were obtained by counting 
200 cells per sample, data expressed as percentage of cells (n=9). * Statisitcal 
significance between the levels of apoptotic cells P < 0.05.
Results showed that treating cells with P-AuNPs at a concentration of 2.50 
mg/mL for 24 hours has negligible effect on cells (control at 0 min) this 
confirmed that the death of cells following irradiation was due to the effect from 
the irradiation of cells and not the cytotoxicity of P-AuNPs. Statistical analysis 
showed that PC3 cells treated at a concentration of 2.50 mg/mL for 24 hours 
and irradiated for 5, 10 and 20 minutes with a 532 nm laser has an significant 
effect on the number of apoptotic cells compared to control (P = < 0.0001, P = < 
0.0001 and P = < 0.0021 respectively).
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The main type of cell death observed was by necrosis, with the number of 
necrotic cells being dependent on the length of irradiation time. As shown on 
the graph, the percentage of both apoptotic and necrotic cells increases with 
irradiation time from 1 to 20 minutes.
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Figure 5.19 Percentage of viable, apoptotic and necrotic cells following a 24 
hour treatment with P-AuNPs at a concentration of 5.00 mg/mL and irradiated 
with a 523 nm laser for varied length of time (0-20 minutes). For each sample 3 
repeats were conducted, for each repeat 3 readings were obtained by counting 
200 cells per sample, data expressed as percentage of cells (n=9). * Statisitcal 
significance between the levels of apoptotic cells P < 0.05.
Results showed that treating cells with P-AuNPs at a concentration of 5.00 
mg/mL for 24 hours are cytotoxic to cells (control at 0 min). Following irradiation 
the percentage of necrotic cells increases from -60% to 80%. This dosage of P- 
AuNPs is cytotoxic to cells with and without irradiation. Statistical analysis 
showed that PC3 cells treated at a concentration of 5.00 mg/mL for 24 hours 
and irradiated for 20 minutes with a 532 nm laser has an significant effect on 
the number of apoptotic cells compared to control (P = 0.0429).
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In subsequent experiments, PC3 cells were treated with the same 
concentrations of P-AuNPs (0-5.00 mg/mL) with an additional step of removing 
excess P-AuNPs following the treatment. This was done by replacing the media 
with fresh media, and the results showed that number of necrotic cells 
decreased significantly (Figure 5.20 and 5.21).
What was particularly interesting was when PC3 cells were treated with P- 
AuNPs at a concentration of 5.00 mg/mL for 24 hours with excess P-AuNPs 
removed, there was an increase in the proportion of apoptotic cells as the 
irradiation time increases from 0 to 20 minutes (Figure 5.21). In addition, there 
is a significant difference between treating the cells with same concentration of 
P-AuNPs for same period of time, with no replacement in media. By replacing 
the media, the percentage of necrotic cells decreases drastically from -80% 
(Figure 5.19) to -10% (Figure 5.21).
The removal of excess P-AuNPs prior to irradiation could explain the increase in 
cell viability observed as only cells taken-up the P-AuNPs would exhibit an 
effect upon irradiation. Higher percentage of necrotic cells were observed in 
samples without the change of media, this was not surprising since excess P- 
AuNPs not taken-up by the cells would still respond when irradiated and 
produce heat and effectively heating cells in the entire well.
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Figure 5.20 Percentage of viable, apoptotic and necrotic cells following a 24 
hour treatment with P-AuNPs at a concentration of 2.50 mg/mL, media was 
removed and replaced with fresh media prior to irradiation with a 523 nm laser 
for varied length of time (0-20 minutes). For each sample 3 repeats were 
conducted, for each repeat 3 readings were obtained by counting 200 cells per 
sample, data expressed as percentage of cells (n=9). *Statisitcal significance 
between the levels of apoptotic cells P < 0.05.
Results showed that treating cells with P-AuNPs at a concentration of 2.50 
mg/mL for 24 hours, replacing media prior to irradiation has an effect on cells 
(control at 0 min) with a decrease in cell viability by approximately 10%. 
Following irradiation even at the longest period of 20 minutes, the percentage of 
apoptotic cells remained very similar, this suggested that increasing the 
irradiation time does not have much effect compared to cells with no irradiation. 
Statistical analysis showed that PC3 cells treated at a concentration of 2.50 
mg/mL for 24 hours, replaced with fresh media and irradiated for 1, 5, 10 and 20 
minutes with a 532 nm laser has an significant effect on the number of apoptotic 
cells compared to control (P = 0.014, P = < 0.0001, P = < 0.0001 and P = < 
0.0001 respectively).
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Figure 5.21 Percentage of viable, apoptotic and necrotic cells following a 24 
hour treatment with P-AuNPs at a concentration of 5.00 mg/mL, media was 
removed and replaced with fresh media prior to irradiation with a 523 nm laser 
for varied length of time (0-20 minutes). For each sample 3 repeats were 
conducted, and for each repeat 3 readings were obtained by counting 200 cells 
per sample, data expressed as percentage of cells (n=9). *Statisitcal 
significance between the levels of apoptotic cells P < 0.05.
Results showed that treating cells with P-AuNPs at a concentration of 5.00 
mg/mL for 24 hours, replacing media prior to irradiation has an effect on cells 
(control at 0 min) with a decrease in cell viability by approximately 10%. The 
results showed that the percentage of apoptotic cells increases with irradiation 
time, as shown above in Figure 5.21. Statistical analysis showed that PC3 cells 
treated at a concentration of 5.00 mg/mL for 24 hours, replaced with fresh 
media and irradiated for 1, 5, 10 and 20 minutes with a 532 nm laser has an 
significant effect on the number of apoptotic cells compared to control (P = < 
0.0001, P = < 0.0001, P = 0.0008 and P = < 0.0001 respectively).
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5.3.3 Investigating the Cellular Uptake of Phosphonium-Functionalised 
Gold Nanoparticles by Transmission Electron Microscopy
Studying the uptake of nanoparticles in cellular systems is of utmost importance 
for understanding their biological effects. Detecting their uptake inside cells is 
challenging owing to their small size and quantity. Electron microscopy is 
commonly used in nanoparticle research, despite lengthy and complex sample 
preparation (Mayhew et al., 2009). TEM has been the preferred method for 
studying the cellular uptake of nanoparticles, and reports have been published 
for both in vitro and in vivo accumulation (Nativo et a/., 2008, Rothen- 
Rutishauser etal., 2007, Muhlfeld et al., 2007a, Muhlfeld etal., 2007b, Arnida et 
al., 2010). Due to the high resolution of electron microscopy TEM analysis can 
provide invaluable details of the interaction of nanoparticles with cell structures, 
as well as images of organelles, membrane invaginations and vesicle formation, 
thus making it feasible to study the mode of uptake of nanoparticles inside cells 
(Motskin etal., 2009, Nativo et al., 2008, Chithrani, 2010, Chithrani etal., 2006).
To determine whether P-AuNPs are taken-up by cells, PC3 cells have been 
treated with P-AuNPs (1.25, 2.50 and 5.00 mg/mL) for 24 hours and analysed 
using TEM. For each sample two 100 nm sections were imaged; one section 
was analysed as prepared in the department, the other section was stained with 
saturated solutions of uranyl acetate and lead citrate at Brunei University. In 
addition to visualising the samples by electron microscopy, elemental analysis 
was conducted by using energy-dispersive X-ray spectroscopy (EDX).
TEM images confirmed that P-AuNPs are taken-up by PC3 cells; at the lowest 
concentration of 1.25 mg/mL, P-AuNPs can be seen to be located in vesicles or 
organelles as shown in Figure 5.24. The P-AuNPs are clearly encapsulated by 
a membrane with image 5.24 a and c showing a double membrane. Zoomed-in 
images of Figure 5.24 a, b and c are shown in Figure 5.25, 5.26 and 5.27, 
respectively along with their corresponding EDX spectrum which confirmed the 
particles to be gold and thereby confirming the presence of P-AuNPs in the 
encapsulated vesicle/organelle.
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Without any staining, TEM images obtained were clear with dense regions of P- 
AuNPs easily identified. The dense regions of suspected P-AuNPs were 
confirmed by EDX analysis which confirmed the presence of gold (AuLA) and 
thus confirming the presence of P-AuNPs in cells. In an attempt to obtain better 
images, with greater sub-cellular structure details particularly the mitochondrion, 
a section from the same sample was prepared by staining with uranyl acetate 
and lead citrate, which are routinely used for TEM staining of biological samples 
(McNeil, 2011).
Staining improved the image contrast significantly, as shown in Figure 5.28 
when viewing the cell as a whole more detail could be observed compared to 
un-stained sample (Figure 5.24). With staining a beautiful TEM image of P- 
AuNPs inside the mitochondrion was observed, as shown in Figure 5.29, the 
outer double membrane and cristae can be clearly seen. Several darker, dense 
black rounded shaped spots inside the cell (Figure 5.28) were originally thought 
to be the gold nanoparticles, EDX analysis (data not shown) confirmed they 
were Au negative and osmium positive indicating they are lipid dense 
organelles and are likely to be peroxisome.
EDX spot analyses were conducted to confirm the presence of P-AuNPs inside 
the cells (Figure 5.29, 5.31, 5.35, 5.38, 5.41 and 5.43). EDX mapping analyses 
were conducted on samples to obtain a visual image of the location of Au inside 
the cell. Unfortunately, when the maps are exported from the software the 
images are automatically converted to black, the maps are not as clear in black 
and white as they are in colour. However, what was fascinating with the results 
was that the density of the map of Au correlates to the overall shape of the 
AuNPs cluster inside the cell (Figure 5.36 and 5.42).
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Figure 5.23 TEM images and EDX spectrum of the areas shown Figure 5.21a-c.
Figure 5.23a showed that P-AuNPs are encapsulated around a double 
membrane, which may not be a mitochondrion as the folded inner membrane 
was not observed. Figure 5.23b showed that P-AuNPs are encapsulated around 
a single membrane, which could be a vesicle. Figure 5.23c showed that the P- 
AuNPs are encapsulated around a double membrane, which could potentially 
be a mitochondrion, however the folded inner membrane was not identified.
The yellow spots (labelled 1) in Figure 5.23a-c indicated the area analysed by 
EDX and the corresponding spectrum is shown next to the TEN image. EDX 
spectrum of unstained sample of PC3 cells treated with P-AuNPs 1.25 mg/mL 
for 24 hours confirmed the uptake of P-AuNPs inside the cells.
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Figure 5.24 TEM image of PC3 cells treated with P-AuNPs 1.25 mg/mL for 24 
hours. Sample stained with uranyl acetate and lead citrate. The yellow spot 
(labelled 1) indicated the area analysed by EDX and the spectrum obtained is 
shown next to the zoomed-in image.
With staining the mitochondria were readily identified compared to unstained 
samples. The zoomed-in TEM image showed that P-AuNPs are taken-up by the 
mitochondrion, as shown by the double membrane and the clear 
intermembrane. EDX spectrum of stained sample of PC3 cells treated with P- 
AuNPs 1.25 mg/mL for 24 hours confirmed the presence of P-AuNPs inside the 
mitochondrion.
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Figure 5.5.25 TEM image of PC3 cells treated with P-AuNPs 1.25 mg/mL for 24 
hours, sample stained with uranyl acetate and lead citrate. The blue spots 
(labelled 2) indicated the area analysed by EDX and the spectrum obtained is 
shown next to the zoomed-in image.
TEM image showed that P-AuNPs are taken-up by the cells (as shown by 
electron dense region) in the image and the outline of mitochondria could be 
observed from the staining. The blue spots (labelled 2 & 3) indicated the area 
analysed by EDX and the spectrum obtained is shown next to the zoomed-in 
image.
The image showed two mitochondria have been stained uranyl acetate and lead 
citrate, with clear inner membrane which can be observed. What was interesting 
about this particular image was that one mitochondria (red arrow) was sliced
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vertically across the mitochondrion whereas the other mitochondrion (blue 
arrow) the mitochondrion is sectioned on the horizontal plane with the double 
membrane and cristae clearly identifiable. EDX spectrum of stained sample of 
PC3 cells treated with P-AuNPs 1.25 mg/mL for 24 hours confirmed the 
presence of P-AuNPs inside the mitochondrion.r
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Figure 5.26 TEM image of PC3 cells treated with P-AuNPs 2.50 mg/mL for 24 
hours, sample stained with uranyl acetate and lead citrate. The yellow spot 
(labelled 1) indicated the area analysed by EDX and the spectrum obtained is 
shown next the TEM image.
TEM image showed that P-AuNPs are encapsulated in vesicle of some form 
most likely to be endocytosis as vesicle is towards the edge of the cell. The 
zoomed-in imaged illustrated that P-AuNPs are taken-up by vesicle or organelle 
of some form as shown by the singe membrane. EDX spectrum confirmed the 
electron dense particles inside the vesicle/organelle are P-AuNPs.
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Endocytosis is one of the main pathways for the cellular uptake of nanoparticles; 
the internalisation mechanism of AuNPs is generally considered to be receptor- 
mediated endocytosis also called clathrin-dependent endocytosis (Kirchhausen, 
2000, Chithrani et al., 2006, Harush-Frenkel et al., 2007). Receptor-mediated 
endocytosis of nanoparticles occurs through the interactions between ligands 
on the surface of the nanoparticles and cell membrane receptors and this 
ligand-receptor property has been exploited to improve the targeting of AuNPs, 
For example human transferrin has been coated onto the surface of PEGylated 
AuNPs to target cancer cells that over express transferrin receptors to enhance 
intracellular delivery of therapeutic agents to the site of solid tumours (Choi et 
al., 2010).
Figure 5.26 showed that the P-AuNPs are taken-up in cells by vesicles, the size 
of the diameter of vesicle is approximately 400 nm, this observation is in 
agreement with Chithrani and colleagues (Chithrani et al., 2009). The authors 
reported that AuNPs were localized in vesicles with an average diameter of 
300-500 nm, and no AuNPs were found in the cytoplasm or nucleus of the cells. 
To confirm that P-AuNPs are only taken-up in the mitochondria and not in the 
cytoplasm or nucleus, cell fractionation can be used; one method is to use 
mitochondria isolation kit as used in chapter 4.3.1.5. This would isolate the 
mitochondria fraction only, which can subsequently be analysed by TEM.
Furthermore, P-AuNPs were shown to be encapsulated in a vesicle near the 
edge of the cell which suggested that the P-AuNPs are taken-up by clathrin- 
dependent endocytosis. Harush-Frenkel and colleagues (Harush-Frenkel et al.,
2007) have investigated the endocytosis pathways of negatively- and positively- 
charged nanoparticles in HeLa cells; the results showed that negatively charged 
nanoparticles exhibited a lower rate of endocytosis and are not involved in the 
clathrin-mediated endocytosis pathway, whereas positively charged 
nanoparticles are internalised rapidly via the clathrin-mediated pathway.
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Figure 5.28 TEM image of PC3 cells treated with P-AuNPs 2.50 mg/mL for 24 
hours, unstained sample. The yellow spot (labelled 1) indicated the area 
analysed by EDX and the spectrum obtained is shown next to the TEM image.
TEM image showed that P-AuNPs are taken-up by the mitochondrion, even with 
no staining the double layer membrane can be identified. EDX spectrum of 
unstained sample of PC3 cells treated with P-AuNPs 2.5 mg/mL for 24 hours 
confirmed the electron dense particles inside the vesicle/organelle are P-AuNPs.
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Figure 5.29 TEM image of PC3 cells treated with P-AuNPs 2.50 mg/mL for 24 
hours, sample stained with uranyl acetate and lead citrate. The yellow spot 
(labelled 1) indicated the area analysed by EDX and the spectrum obtained is 
shown next to the TEM image.
Following staining, the organelles within the cell could be readily identified by 
the increase in contrast of TEM images. TEM image showws that P-AuNPs are 
taken-up by the mitochondria, as can be observed from the double membrane 
in the stained sample. EDX spectrum of the stained sample of PC3 cells treated 
with P-AuNPs 2.5 mg/mL for 24 hours confirmed the electron dense particles 
inside the mitochondrion are P-AuNPs.
TEM data confirmed that P-AuNPs are taken-up by the mitochondrion; staining 
the sample with uranyl acetate and lead citrate provided stronger contrast in the 
TEM images and enable the organelles and membrane to be readily identified 
compared to unstained sample. As shown in Figure 5.29 in the sainted sample, 
the double membrane of the mitochondrion can easily be identified which also 
support the TEM image obtained previously in Figure 5.28 in the unstained 
sample, confirming the structure of the mitochondrion.
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Mitochondria have emerged as an attractive pharmacological target for cancer 
therapeutics (Gupta et al., 2009, Weissig, 2005), several research groups have 
investigated the use of nanocarriers for mitochondria-specific delivery, these 
include DQAsomes (D'Souza et al., 2003), liposomes (Boddapati et al., 2010) 
and solid nanoparticles (Weissig et al., 2007). The most challenging aspect of 
targeting therapeutic agents to the mitochondrial is that the therapeutic agents 
must be able to cross the mitochondrial membranes, it has been determined 
that permeability of the outer mitochondrial membrane to be > 3 and < 6 nm 
(Salnikov et al., 2007).
TEM images (Figure 5. 28and 5.29) showed that P-AuNPs (mean diameter of 3 
nm) were taken-up by the mitochondria these observations are in agreement 
with the data reported by Salnikov et al. 2007 who have illustrated that the outer 
mitochondrial membrane are not permeable to nanoparticles greater than 6 nm 
in diameter.
Figure 5.31 TEM image of PC3 cells treated with P-AuNPs 5.0 mg/mL for 24 
hours, sample stained with uranyl acetate and lead citrate. SEM image shows 
the expansion region in boxed area in the TEM image. The yellow spot (labelled 
1) indicated the area analysed by EDX, EDX analysis confirmed the presence of 
P-AuNPs inside the cell.
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At the highest concentration of P-AuNPs at 5.0 mg/mL, the TEM image (Figure 
5.31) showed the shrinkage of the cells and cell contents spilling outside the cell. 
P-AuNPs are contained in several distinct vesicles which appeared to be an 
apoptotic body, this illustrated that P-AuNPs are cytotoxic to cells at this 
concentration. This observation is in accord with the results obtained by 
fluorescent microscopy (Figure 5.15 and Figure 5.21).
Figure 5.31 showed that P-AuNPs have aggregated inside the cells, it has been 
reported that nanoparticles can aggregate in cell culture media due to the 
presence of ions and proteins which may cause unexpected results (Maiorano 
et al., 2010, Rausch et al., 2010). Aggregation occurs when the van der Waals 
forces between particles are greater than the electrostatic repulsive forces on 
the nano surface (Derjaguin and Landau, 1993, Lundqvist et al., 2008). It is 
important to study/understand the aggregation of nanomaterials, as the 
aggregation of nanoparticles can have an effect on their cellular uptake and 
cytotoxicity; Albanese and co-workers (Albanese and Chan, 2011) have 
reported a 25% decrease in uptake of aggregated nanoparticles compared to 
single and monodisperse nanoparticles in HeLa and A549 cells.
In general, TEM images recorded display 3 trends: 1) the number of 
nanoaprticles present in cells increases with the concentration of P-AuNPs, 2) 
P-AuNPs are taken-up by cells, however they are not distributed equally in all 
the organelles. Zhu and colleagues (Zhu et al., 2008) reported similar 
observation; within a cell, AuNPs were only observed to be taken-up as one big 
cluster in one endosome and not the other endosomes. 3) P-AuNPs are taken- 
up in clusters, this observation has been reported by other research groups 
(Arnida etal., 2010, Nativo et al., 2008, Liu et al., 2010).
Uptake of single nanoparticles has been observed; Chithrani and colleagues 
(Chithrani and Chan, 2007) reported single 50 nm transferrin-coated AuNPs are 
able to enter the cells, while 14 nm transferrin-coated AuNPs were only taken 
up when clustered in groups with a minimum of 6 particles, indicating that the 
uptake of nanoparticles (single or clusters) is influenced by the particle size.
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5.3.4 Quantification of the Uptake of Phosphonium-Functionalised Gold 
Nanoparticles in cells by ICP-MS
Quantification of AuNPs in the pure form has been achieved successfully using 
ICP-MS (Allabashi et al., 2009, Elzey et al., 2012, Helfrich and Bettmer, 2011). 
The use of ICP-MS for quantifying the uptake of AuNPs in cells has also been 
investigated (Zhu et al., 2012, Chithrani et al., 2006). In this chapter, ICP-MS 
has been used to determine the amount of AuNPs in cells, and the results 
showed that both P-AuNPs and commercial AuNPs (stabilised suspension in 
citrate buffer) with good uptake (> 70%) observed across all concentrations 
(Figure 5.32).
P-AuNPs
Sigma AuNP 5 nm
Concentration of AuNPs (%w/v)
Figure 5.32 ICP-MS data showing the percentage uptake of P-AuNPs and 
commerical AuNPs in PC3 (n=3). *Statisitcal significance between the levels of 
apoptotic cells P < 0.05.
Staisitical analysis showed that the treatment of PC3 treated with P-AuNPs and 
commercial available AuNPs 5 nm has significantly increased compared to 
control, assuming there are no uptake at 0 mg/mL. The P value for P-AuNPs 
and Sigma AuNPs for all 3 concentrations (12.5, 25.0 and 5.0 mg/MI) is 
calculated to be P = 0.0213,
220
The uptake of “naked” AuNPs is consistent for all concentrations, this 
observation is in agreement with Arnida and co-workers (Arnida et al., 2010) 
who have reported the uptake of plan spherical AuNPs (d = 30 nm) is steady 
across all concentration tested (0-40 nM) and this saturated uptake may be due 
to the limited cationic sites available on the cell surface (Wilhelm et al., 2003).
It is difficult to compare data obtained with published studies, due to variations 
in reporting the data, as reviewed by Levy and colleagues (Levy et al., 2010). 
For example the units of size vary between groups thereby making comparison 
a tricky and complicated task; Zhu et al. (2012) reported the uptake of AuNPs 
by ICP-MS in terms of pmol, while Arnida et al. (2010) reported the uptake of 
AuNPs by number per cell and Chithrani et al. (2006) reported the uptake by 
number of AuNPs per cell (103). The cellular uptake of AuNPs as a function of 
size have been reported by the number of particles per cell (Chithrani et al., 
2006) and pg/cell (Lu et al., 2009). What was interesting was that when Levy et 
al. expressed Chithrani et al results in pg/cell instead of the number of particles 
per cell, the results changes significantly with a plateau observed around 100 
nm rather than the reported 50 nm.
Chithrani et al. 2006 have used the following equations (equation 1 and 2) to 
convert the number of gold atoms obtained from ICP-AES measurements to the 
number of gold nanoparticles. The number of atoms (U) in each volume of gold 
nanoparticles can be calculated, where D is the diameter of a nanosphere, a 
refers to the edge of a unit cells which has a vlue of 4.0786 A on the edge, there 
are 4 gold atoms per unit cells, M is the measured number of gold atoms from 
ICP-AES.
U = -  it  (equation 1)
N = ^  (equation 2)
For a sphere nanoparticle, the diameter (D), the number of atoms (U) in each 
volume of gold nanoparticles can be calculated. Based on these equations, the 
diameter of PPTS capped AuNPs (3.0 nm) can be substituted in the equation
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and the number of gold atoms calculated to be 27,328 gold nanoparticles per 
cell.
2 /3' 3980u - r { a ) = ° -
11000 N = — - — = 27638 0.3980
Arnida et al. 2010 investigated the uptake of plain and PEGylated gold 
nanospheres of different sizes (30, 50 and 90 nm) in PC3 cells, PEGylated 
nanoparticles showed very little uptake compared to pain AuNPs. The authors 
reported the uptake of plain 30 nm AuNPs to be between 10,000 to 45,000 gold 
nanoparticles per cell depending on concentration (1 nM -  10 nM). The results 
showed that the uptake of AuNPs is concentration dependent: at the lowest 
concentration at 1 nM the uptake is around 11,000 particles per cell and at the 
highest concentration at 10 nM the uptake is around 45,000 particles per cell.
ICP-MS data obtained was converted to AuNPs per cell using the equations 
described above (equation 1 and 2). The number of AuNPs per cell has been 
calculated to be 27,638, 47,738 and 128,643 for cells treated with P-AuNPs at a 
concentration of 12.0 mg/mL, 25.0 mg/mL and 50.0 mg/mL respectively. 
Comparing results obtained in this chapter with results reported by Arnida and 
colleagues (Arnida et al., 2010) the data showed that plain 30 nm AuNPs 
(nanomolar concentration) has a higher uptake compared to 3 nm P-AuNPs 
(millimolar concentration). The ease of synthesis of AuNPs with variety of 
surface ligands has been exploited by many research groups to enhance their 
cellular uptake for biomedical applications (described previously in chapter 
1.1.3.). It is evident that functionalised AuNPs have better cellular uptake 
compared to plain AuNPs (Chou et al., 2011, Wang and Thanou, 2010, Wang et 
al., 2012). The higher uptake observed for 30 nm AuNPs could be due to the 
different size: Chithrani et al. 2006 have investigated the cellular uptake of plain 
spherical AuNPs of different sizes (10 nm -  100 nm): the results showed that 
with an increase in size from 10 nm to 50 nm the uptake increases with size, 
where as increase size from 50 nm to 100 nm the uptake decreases. This 
demonstrated that the size plays an important role in the cellular uptake of 
AuNPs in cells.
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5.4 Conclusion
Results reported in this chapter demonstrated that P-AuNPs are soluble in 
biological media which is of great importance for cell biology studies. Initial PTT 
studies illustrated that P-AuNPs are specific and respond specifically to a wide 
green excitation source (510-550 nm) which overlaps the SPR band of the P- 
AuNPs at -525 nm. Preliminary qualitative data showed promising results that 
P-AuNPs can selectively induce apoptosis in cells followed by PTT; under the 
same irradiation conditions cells with a higher concentration of P-AuNPs 
undergo cell death by necrosis, whereas cells with a lower concentration of P- 
AuNPs undergo apoptosis. Quantitative analysis of PTT indicated that the 
percentage of apoptosis cell is actually around a third which is not as high as 
originally hypothesised.
TEM images showed that P-AuNPs are clustered inside the cells and are not 
distributed equally amongst all mitochondria, which could explain the small 
population of apoptotic cells observed from PTT experiments. TEM images 
suggested that the uptake mode of P-AuNPs is by endocytosis, which is in 
agreement with other research groups (Chithrani et al., 2006, Nativo et al.,
2008).
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6.1 Conclusion and Future Work
The work presented in this thesis demonstrated that
triarylphosphoniopropylthiosulfate zwitterions and cd-thioacetylpropyl(triphenyl)- 
phosphonium salts can be used to prepare cationic, water-soluble AuNPs with 
mean core sizes in the range of 2.5-5 nm. A number of techniques have been 
employed to characterise the P-AuNPs including NMR, LDI MS, SIMS, XPS, 
TGA, ICP-MS, MALDI-MS and TEM. The presence of phosphoniopropylthiolate 
ligands on the surface of the AuNPs have been supported by NMR, LDI, SIMS 
and XPS.
Quantitative analysis of P-AuNPs has also been investigated; TGA data indicate 
there is a high thiol/Au ratio which is in line with ICP-MS data, ICP-MS has been 
successfully used to quantify the thiol ligand density of AuNPs (Hinterwirth et a/., 
2013), additional ICP-MS analysis are required in order to obtain more 
quantitative data regarding the thiol ligand density. To-date the characterisation 
of intact AuNPs by MALDI-MS has only been reported for Au core sizes of up to 
2 nm (Chaki et at., 2008, Yu and Andriola, 2010). The use of MALDI-MS as an 
additional tool to characterise AuNPs has been challenging and further 
experiments are required.
TEM results showed all nanoparticles synthesised have a uniform spherical 
shape, however the PPTA salt produces slightly larger AuNPs and greater 
particle size distribution in comparison to the corresponding PPTS zwitterion, 
despite both protecting ligands produces the same Au-S ligation. This 
observation is consistent with slower or incomplete reaction and is supported by 
LDI-MS results.
In general the thioacetate salts (PPTA and FPPTA) are more soluble than the 
corresponding zwitterion, this poor solubility of the zwitterions is possibly due to 
their structural packing in their lattice obtained from crystallography study. Since 
thioacetate salts are readily soluble in a range of solvents, they were taken 
forward for cell culture experiments.
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Cell viability assay demonstrated that thioacetates are toxic towards PC3 cells 
at high concentrations and at prolonged incubation time. However, thioacetate 
salts synthesised in this project are not as cytotoxic compared to other 
phosphonium compounds reported by Millard et al (2010). The authors 
investigated the cytotoxicity of numerous phosphonium compounds in several 
cancer cell lines including PC3 cells utilised in this study. Their most toxic 
compound has an IC50 value of 0.4 pM at 72 hours in PC3 which is 
approximately -150 fold more toxic than PPTA.
In contrast in synthesising compounds containing the TPP moiety that are 
cytotoxic towards the cells like other research groups (Millard et al., 2010, 
Rideout et al., 1989, Patel et al., 1994, Manetta et al., 1996), thioacetates 
ligands synthesised in this project are comparatively non-toxic towards cells and 
can be used as transport vector to deliver AuNPs into the cell for other 
therapeutic applications such as PTT.
The work presented in chapter 4 demonstrated the successful application of 
MALDI-MS for the semi-quantification of phosphonium compounds in PC3 cells, 
follow on work from this could include treating tissues with ligands and 
analysing by MALDI-MS imaging to obtain useful information regarding the 
distribution of phosphonium ligands in tissues as well obtaining useful 
quantification data. The success uses of MALDI-MS imaging of tissues has 
been reported and reviewed by several groups (Koeniger et al., 2011, Pol et al., 
2010, Norris and Caprioli, 2013).
MALDI-MS results also showed that phosphonium ligands (PPTA and FPPTA) 
are rapidly taken-up by PC3 cells within minutes, an attempt has been made to 
analyse the uptake of PPTA in the mitochondrial fraction, to compare to uptake 
of phosphonium ligands inside the mitochondrial versus in the cytosol however 
the signal from the instruments were extremely weak, future studies in this area 
could be to isolate the mitochondria fraction by an alternative method such as 
the protocol published by Wieckowski and colleagues (Wieckowski et al., 2009).
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Results from chapter 5 illustrated that P-AuNPs synthesised are soluble in 
biological media which is of great importance for cell biology studies. Initial PTT 
studies demonstrated that P-AuNPs are specific and respond only to wide 
green excitation source (510-550 nm) which overlaps the SPR band of the P- 
AuNPs at -525 nm. TEM results confirmed that P-AuNPs synthesised are 
indeed taken-up in the mitochondria as hypothesised, this observation agrees 
with the report by Salnikov and colleagues (Salnikov et al., 2007) who have 
demonstrated that the outer mitochondrial membrane is not permeable to 
nanoparticles greater than 6 nm in diameter. Due to the nature of the small size 
of P-AuNPs (< 6 nm) they are able to accumulate inside the mitochondria thus 
making them feasible for mitochondria targeting applications.
TEM results also showed that P-AuNPs are not taken-up by all mitochondria in 
cells, which may explain the PTT results why apoptosis death is only around 
25% which is lower than originally hypothesised. P-AuNPs are taken-up by 
small fraction of mitochondria in cells, when exposed with a light source only the 
cells containing P-AuNPs will result in mitochondrial damage and releasing 
cytochrome c into the cytosol and triggering the caspase cascade, since only a 
small fraction of mitochondria membrane will burst open, the cells can tolerate 
minor damages to the mitochondria and thus the results will not be as 
catastrophic if all P-AuNPs are taken-up by all mitochondria, upon irradiation all 
mitochondria membranes will burst open, triggering the caspase cascade and 
inducing apoptosis throughout the entire cell.
In addition, TEM images showed that P-AuNPs awere taken-up in cells in 
clusters rather than single nanoparticles as originally hypothesised, this might 
explain the percentage of apoptotic cells from photothermal therapy 
experiments were lower than hypothesised.. The results suggested that P- 
AuNPs are taken-up in clusters by the cells and thus only mitochondria 
containing P-AuNPs will respond to irradiation. Since a small proportion of 
mitochondria contain P-AuNPs would be affected, the death of small 
percentage of mitochondria are not enough to be a catastrophic event for the 
entire cell and may just induce localized autophagy.
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The idea that cells can commit suicide by other mechanisms besides apoptosis 
has gained momentum over the past few years; non-apoptotic forms of 
programmed cell death include necrosis and autophagy (Lockshin and Zakeri, 
2004, Proskuryakov et al., 2003, Edinger and Thompson, 2004). The term 
autophagy is derived from Greek meaning “eating of self, is credited to de 
Duve and colleague (Deter and De Duve, 1967), it is a cellular catabolic 
degradation process which respond to starvation or stress by engulfing 
damaged proteins and organelles which are then recycled to maintain cellular 
metabolism (Mathew et al., 2007).
Furthermore autophagy is also the mechanism for the engulfment of apoptosis 
cells (Qu et al., 2007), which may be feasible explanation to why the percentage 
of apoptosis observed from PTT studies were lower than expected, as when 
cells were stained with caspase-3, majority of cells were caspase-3 positive 
thereby suggesting that cells are actively undergoing apoptosis, however when 
stained with Hoechst, only minority of cells exhibited apoptotic morphology. If 
the apoptotic cells were engulfed by autophagy the number of apoptotic cells 
will thereby decrease which agree with the observations for PTT experiments. 
To determine if cells are dying through autophagy rather than apoptosis, for 
future experiments could be to test for autophagy.
The measurement of autophagy has been a topic of intense discussion, with 
reviews, methods and guidelines available in the literature (Mizushima, 2004, 
Klionsky et al., 2008, Mizushima et al., 2010). Conventionally, electron 
microscopy has been the standard approach to detect autophagy by the 
studying the morphological structures of autophagosomes, however it can be 
difficult to distinguish autophagic vacuoles from other structures just by 
examining the morphology. Although TEM is well established method, the main 
downfalls are that it is quite costly and not readily accessible (Kimmelman, 2011, 
Mizushima, 2004).
Several newer essays have been based on LC3 (ATG8) which is a general 
marker for autophagic membranes, this protein cleaved by ATG4 to generate 
LC3-I, subsequently it is lapidated to give LC3-II (Ichimura et al., 2000), which
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can be detected as a faster migrating band by immunoblotting (Mizushima and 
Yoshimori, 2007). Since LC3-II is incorporated into the inner and outer surfaces 
of autophagosomes, this localisation can easily be examined by fusing LC3 with 
green fluorescent protein (GFP) which can be visualised by fluorescent 
microscopy (Mizushima, 2004). In order to test for autophagy, future analysis 
could include the detection and confirmation of autophagy using a range of 
methods including Western-blot analysis, fluorescence microscopy to gain both 
qualitative and quantitative data and TEM to obtain high resolution images. 
Confocal microscopy can be used to image autophagy markers, which can be 
used to visualise ATG/LC3-1, confocal microscopy enables real-time cross 
section viewing of autophagy forming, and can take Z-stacks of cell to provide a 
3 dimensional image of the cell.
In recent years, autophagy has emerged as a mechanism of nanomaterials 
toxicity (Stern et al., 2012, Li et al., 2010), what is particularly interesting is that 
iron core and gold shell nanoparticles have been shown to inhibit cell 
proliferation of oral cancer through mitochondria-mediated autophagy (Wu et al., 
2011). With the finding that nanomaterials can cause cell death by autophagy, 
future work will focus on investigating whether P-AuNPs causes autophagy in 
cells.
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7.4 Appendices
Appendix 1 Crystal data and structure refinement for FPPTS.
Compound
Empirical formula
Formula weight
Crystal system
Space group
a / A
b / A
c / A
p / °
Volume / A3 
Z
Dcaic/ Mg m3
Absorption coefficient / mm-1 
F(000)
Crystal
Crystal size / mm3 
6 range for data collection / ° 
Reflections collected 
Independent reflections 
Completeness to d -  27.48° 
Max. and min. transmission 
Data / restraints / parameters 
Goodness-of-fit on F2 
Final R indices [F2 > 2o(F2)\ 
R indices (all data)
Largest diff. peak and hole
FPPTS (7)
C21H18F3O3PS2 
470.44 
Triclinic 
P- 1
9.4169(13)
15.279(3)
16.090(3)
77.619(10)
2099.2(6)
4
1.489
0.377
968
Slab; colourless 
0.20 x 0.20 x 0.04 
2.98 -  27.48 
40825
9403 [Rint = 0.1243]
97.7 %
0.9851 and 0.9284 
9403 / 9 / 554
1.035
R1 = 0.0830, wR2 = 0.1670 
R1 = 0.1834, wR2 = 0.2039 
0.464 and -0.456 e A-3
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Appendix 2 Crystal data and structure refinement for FPPTA
Compound
Empirical formula
Formula weight
Crystal system
Space group
a /A
b / A
c / A
J3 /0
Volume / A3 
Z
Dcaic/Mg m3
Absorption coefficient / mm-1 
F(000)
Crystal
Crystal size / mm3 
Grange for data collection / ° 
Reflections collected 
Independent reflections 
Completeness to 6 -  25.00° 
Max. and min. transmission 
Data / restraints / parameters 
Goodness-of-fit on F2 
Final R indices [F2 > 2o{F2)] 
R indices (all data)
Largest diff. peak and hole
FPPTA (8)
C23H23BrF302PS
531.35
Monoclinic
P21/c
14.8827(3)
31.9320(5)
10.6385(2)
108.9170(10)
4782.71(15)
8
1.476
1.914
2160
Block; Colourless 
0.20x0.17x0.17 
2.91 -25.00°
73742
[Rint = 0.1243)
99.8 %
0.7368 and 0.7008 
8401 / 8 / 573 
1.029
R1 = 0.0760, wR2 = 0.1978 
R1 = 0.0933, wR2 = 0.2113 
1.824 and -2.589 e A"3
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